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ABSTRACT 
 
In the UK, oesophago-gastric (OG) cancer remains a disease with poor patient outcomes and 
only 35% of patients are suitable for potentially curative treatment at first presentation. Early 
detection of these cancers is necessary with Volatile Organic Compound (VOC) analysis being 
a promising area to explore for new endogenous biomarkers. 
In this research, the application of Selected-Ion Flow Tube Mass Spectrometry (SIFT-
MS), a real-time technique, for the analysis of VOCs in biofluids and exhaled breath has been 
investigated. The primary aim of this research was to identify potential VOC biomarkers in 
oesophago-gastric cancer; the long-term application being the translational development of 
VOCs as non-invasive diagnostic tests. A total of 13 VOCs emitted from gastric content were 
investigated in the first study; acetone, formaldehyde, acetaldehyde, hexanoic acid, hydrogen 
sulphide, acetic acid, hydrogen cyanide and methyl phenol were found to be significantly 
different between oesophago-gastric cancer and healthy groups. In a study on the headspace of 
urine, acetaldehyde, acetone, acetic acid, hexanoic acid, hydrogen sulphide, methanol and 
phenol were found to be at significantly different concentrations between oesophago-gastric 
cancer, positive control and healthy groups. Methodology experiments including the 
optimisation of VOC sampling techniques with evaluation of exogenous contamination and 
variability measures have also been conducted. 
Investigation of reference ranges for C3-C10 aldehydes in healthy subjects using SIFT-
MS have been undertaken for the first time; C4-C10 aldehydes were present in the exhaled 
breath of healthy persons at concentrations < 3 ppbv. In a study on 210 consecutive patients, 
increased concentrations of fatty acids, phenols and aldehydes were observed in the exhaled 
breath of patients with oesophageal and gastric adenocarcinoma. The potential effects of 
clinical confounding factors have been also assessed and possible explanations for the observed 
differences have been discussed. The results of the pilot study on acute infection demonstrated 
minimal influence on the cancer-linked VOCs in OG cancer, except for butanal. The analysis 
of gastric content, urine and exhaled breath have proven that trace compounds are more 
influential than abundant metabolites in upper gastro-intestinal malignancy. It is also 
demonstrated that VOC profiles rather than individual compounds are more accurate in the 
molecular-orientated diagnosis of oesophago-gastric cancer. 
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OESOPHAGEAL AND GASTRIC CANCER 
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1.1 Introduction 
Cancer remains the leading cause of death worldwide: it accounted for 7.6 million deaths in 
20081. Despite an increasing incidence, mortality from cancer has been decreasing over the last 
four decades2. Between 1979 and 2008, the European age-standardised mortality rates for all 
malignant neoplasms fell by 20% from 219 to 176 per 100,000 population3. Screening 
programmes and disease awareness coupled with treatment advances have contributed to this 
decrease in cancer mortality rates. However, it is estimated that a further 30-40% of these 
deaths can be prevented1. Early disease detection remains one of the most important aspects in 
further improving cancer-related outcomes and survival rates. The majority of screening 
processes involve invasive procedures to appropriately diagnose those with cancer and suitably 
confirm the true negative cohort. Although these screening procedures are invariably 
necessary, there always remains a small but non-negligible morbidity risk associated with 
invasive procedures. Moreover, one of the main factors in deciding whether to institute a 
screening programme (population-based or selective) for a specific cancer is dependent on the 
prevalence of that cancer within the target population4; although this is justifiable in terms of 
healthcare costs and resource allocation, this results in the less common cancers being detected 
in their earliest stages and hence these cancers tend to have poor outcomes.    
 
1.2 Oesophageal and Gastric Cancer Trends 
1.2.1 Incidence 
Oesophageal cancer is the currently the sixth leading cause of cancer death worldwide; in 2008, 
there were 482,000 new cases of oesophageal cancer diagnosed and 407,000 oesophageal 
cancer deaths recorded globally5. There is also significant geographical variation in the 
prevalence of the different histological subtypes of oesophageal cancer, with squamous cell 
carcinoma far more common in south-central Asia and south-eastern Africa5,6,. There has been 
a steady decrease in the oesophageal squamous cell carcinoma incidence in the West, with one 
of the main factors being the associated decline in smoking rates. However, the incidence of 
adenocarcinoma of the gastro-oesophageal junction has significantly increased in Europe and 
the USA in the past thirty years5,7; the evidence shows that both reflux oesophagitis and obesity 
are primary risk factors contributing this increase7,8,9,10,11,12. A significant decline in the 
incidence of gastric cancer has been observed over the past seventy years, which has been 
attributed to the control of H.pylori infection and dietary changes13. Nonetheless, it remains the 
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second leading cause of cancer-related death worldwide5,14. In 2008, there were 989,000 new 
cases of gastric cancer diagnosed and 738,000 gastric cancer deaths recorded globally5. The 
highest incidence of gastric cancer is seen in East Asia, Eastern Europe and South 
America15,16,17. Although the survival rates are slightly better in comparison to oesophageal 
cancer (with age standardised 5 year relative survival of 27.7% in the USA), the incidence-
mortality ratio is higher than for the more common cancers such as breast, prostate and 
colorectal5,15. 
 
1.2.2 Survival 
Oesophageal and gastric malignancies account for 15% of cancer-related deaths globally15. The 
poor prognosis of these cancers is all too evident with age-standardised 5-year relative survival 
rates, from 2005-2009, in the UK of 13% and 17.6% for oesophageal and gastric cancer, 
respectively18. The statistics are similar in North America, where the five-year survival rates, 
from 2002-2008, were 20% and 3% for regional oesophageal cancer and distant oesophageal 
cancer, respectively19. 
 
1.2.3 Diagnosis and National Guidelines 
Oesophago-gastric (OG) cancers often present to clinicians with a spectra of non-specific 
symptoms/signs. These can include nausea, vomiting, abdominal pain, dysphagia, odynophagia 
and/or weight loss amongst others. The variable nature of the early signs of OG cancer and 
lack of ‘alarm’ symptoms until the disease is at a more advanced stage contribute to the 
aforementioned poor survival statistics. However, the guidance from the National Institute of 
Clinical Excellence (NICE) for suspected OG Cancer focusses on late symptoms in its referral 
criteria for investigation20. The guidelines state that ‘An urgent referral for endoscopy or to a 
specialist with expertise in upper gastrointestinal cancer should be made for patients of any age 
with dyspepsia who present with any of the following’:  
 chronic gastrointestinal bleeding 
 dysphagia 
 progressive unintentional weight loss 
 persistent vomiting 
 iron deficiency anaemia 
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 epigastric mass 
 suspicious barium meal result. 
The guidance also states that for patients less than 55 years old, endoscopic investigation of 
dyspepsia is not necessary in the absence of alarm symptoms. The Health department of the 
Scottish executive has also published guidelines for urgent referral in suspected cases of upper 
GI cancer21; their recommendations are similar to NICE and include the following:  
 
 Dysphagia – food sticking on swallowing (any age)  
 Dyspepsia at any age combined with one or more of the following ‘alarm’ symptoms:  
- weight loss 
- proven anaemia 
- vomiting  
 Dyspepsia in a patient aged 55 years or more with at least one of the following ‘high 
risk’ features:  
- onset of dyspepsia less than one year ago  
- continuous symptoms since onset  
 Dyspepsia combined with at least one of the following known risk factors:  
- family history of Upper GI cancer in more than 2 first degree relatives  
- family history of colorectal cancer (familial adenomatous polyposis, 
hereditary non-polyposis colorectal cancer)  
- Barrett’s oesophagus  
- pernicious anaemia  
- peptic ulcer surgery over 20 years ago  
- known dysplasia, atrophic gastritis, intestinal metaplasia  
 Jaundice  
 Upper abdominal mass  
 Back pain and weight loss  
 
Due to the expansile nature of the oesophageal and gastric muscular layers, there is often a 
masking effect of a growing tumour. When patients do present to a doctor with alarm 
symptoms, the tumour has often invaded deep into the muscularis propria and spread to the 
surrounding lymph nodes or distant sites; this results in only one-third of patients diagnosed 
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with OG cancer being considered suitable for treatment with curative intent22. However, 
diagnosis of these cancers at a treatable stage is associated with a significant survival benefit. 
Treatment of early oesophageal adenocarcinoma, either endoscopically or surgically, has a 
reported overall 5-year survival rate of 83-96%23. There are currently no established screening 
programmes for oesophageal or gastric cancer in Western countries. Only Japan and South 
Korea have population-based screening programmes targeting gastric cancer24,25. However, in 
Western countries, these endoscopy-based screening approaches are not justified given the low 
incidence of significant pathology and associated healthcare costs (estimated at ~£55,000 for 
detecting each upper gastro-intestinal malignancy)26. 
Alarm symptoms such as dysphagia and weight loss have also been shown to have low 
predictive value for underlying malignancy, despite forming a major part of the 2-week wait 
primary care referral guidance for suspected upper gastro-intestinal cancer27. A recent study on 
inequality in oesophago-gastric cancer outcomes reported that OG cancer patients belonging 
to general practices with low rates of gastroscopy referral are at increased risk of poor 
outcomes28. However, a retrospective analysis of 2000 patients undergoing endoscopy for 
upper gastrointestinal symptoms demonstrated that no abnormal findings were identified in 
53% of patients and only 1% of patients undergoing endoscopy were diagnosed with cancer29. 
This creates a diagnostic dilemma for general practitioners; they have no objective methods 
other than endoscopy for identifying those at highest risk of an upper gastrointestinal 
malignancy whilst they cannot refer every patient with non-specific upper gastrointestinal 
symptoms for an Oesophago-Gastro-Duodenoscopy (OGD). Thus, there remains an important 
clinical need to develop novel diagnostic techniques for early disease detection in both 
oesophageal and gastric cancer.  
 
1.2.4 Diagnostic Biomarkers in Oesophageal and Gastric Cancer 
Research investigating potential non-endoscopic diagnostic biomarkers in oesophageal and 
gastric cancer has primarily concentrated on molecular targets. In a study on cell-free DNA 
(cfDNA), increased levels of cfDNA95 were observed in patients with oesophageal 
adenocarcinoma compared with healthy controls30. Mutations in chromatin-remodelling genes 
including ARID1A and SMARCA4 have been reported in 25% of patients with oesophageal 
adenocarcinoma31,32; dysfunction of chromatin regulatory mechanisms appear to be crucial in 
oesophageal adenocarcinoma tumourigenesis33,34,35. Jin et al. observed AKAP12 promoter 
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hypermethylation in 53% of patients with oesophageal adenocarcinoma and dysplastic 
Barrett’s oesophagus however the same mutation was absent in patients with a normal 
oesophagus36. Reprimo and TAC1 promoter hypermethylation have also been shown to be 
increased in patients with oesophageal adenocarcinoma compared to control subjects37,38. 
However, these studies have also confirmed the marked heterogeneity that exists between 
oesophageal adenocarcinomas; TP53 is the only identified tumour suppressor gene to be 
mutated in more than half of oesophageal cancers31.  
Serum biomarker panels including a combination of Epidermal Growth Factor Receptor 
(EGFR), transthyretin (TTR), regulated upon activation, normally T-expressed and presumably 
secreted (RANTES) and vitronectin (VN) demonstrated a diagnostic accuracy of 88% for 
gastric adenocarcinoma39. RUNX3 methylation was observed in the serum of 65% of patients 
with gastric carcinoma compared with 8.1% of patients with chronic gastritis40; RUNX3 
methylation was also higher in gastric cancer tissue than in healthy gastric mucosa41.  
RASSF1A methylation and CDKN2A methylation has been observed in 34% and 44% of 
patients with gastric adenocarcinoma whilst being absent in healthy controls42,43. Several non-
invasive technologies have also been trialled in the diagnosis of oesophageal and gastric cancer. 
A non-invasive occult blood detector was tested in 200,000 asymptomatic individuals however 
the sensitivity for oesophageal and gastric cancer was only 3.4%44. Cytological techniques 
utilising balloon and sponge capture devices have also been developed for oesophageal 
cancer45. However, these cytological methods have demonstrated poor sensitivity for 
diagnosing both dysplasia and cancer (24-47%)45. Hence, alternative diagnostic strategies for 
oesophageal and gastric cancer need to be investigated.        
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2.1 Introduction 
Halitosis and systemic disease states have been associated since the days of Hippocrates. 
Physical breath analysis during examination of a patient has often provided the clinician with 
important clues in reaching the correct diagnosis. Foetor oris associated with appendicitis, 
foetor hepaticus linked to chronic liver failure and the fruity odour associated with diabetic 
ketoacidosis have all been described over the years. However, the roots of modern breath gas 
analysis can be traced back to the Nobel Prize winner Linus Pauling. In 1971, he demonstrated 
by gas liquid partition chromatography that human breath is a complex mixture containing over 
250 volatile organic compounds (VOCs)46; he also demonstrated that there were over 280 
VOCs within urine vapour46.  The term volatile organic compound (VOC) encompasses 
organic chemicals that have a high vapour pressure at room temperature. VOCs have routinely 
been measured in the assessment of environmental gases and within the flavour & fragrance 
industry for many years; Gas Chromatography-Mass Spectrometry, GC-MS, is considered a 
‘gold-standard’ method for forensic substance identification and has been extensively 
employed for this purpose. However, many of the biochemical pathways relating to the origin 
of these VOCs within humans are as yet unknown; it is postulated that these endogenous VOCs 
potentially hold the key to identification of new biomarkers for underlying disease processes. 
Since the original discovery of Pauling, research in this field has focussed on identifying VOCs 
associated with certain disease states; the ultimate translational application for this research 
being the quantification of VOCs as a non-invasive diagnostic and therapeutic monitoring tool 
in medicine. In 1983, Manolis published a seminal review on the diagnostic potential of breath 
analysis, including identifying disease-specific VOCs47. Although the potential of such non-
invasive techniques is readily acknowledged, there remain limited applications of human 
breath analysis. The most well-known example of exhaled breath analysis remains the 
quantification of blood alcohol levels; this test is almost exclusively employed by law 
enforcement agencies for the purposes of roadside breathalyser testing. In the field of medicine, 
the 13C urea breath testing for H. pylori bacterium, hydrogen breath test for small bowel 
bacterial overgrowth and the measurement of exhaled nitric oxide as a biomarker of airways 
inflammation in asthma represent the few routinely employed clinical breath tests48,49,50. Hence, 
there remains much opportunity to develop VOCs as non-invasive diagnostic tools.  
The detection of VOCs in cancer has been investigated using both innovative and conventional 
methods. Sonoda et al. made global headlines after they trained a Labrador retriever dog in 
scent detection of colorectal cancer51. After completion of 4 years of training using a reward-
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based approach, the sniffer dog was then expected to identify those with colorectal cancer from 
breath and watery stool samples. On each occasion, a cancer sample was placed in a room with 
4 control samples51. Detection of colorectal cancer in exhaled breath using this method had a 
sensitivity of 91% and a specificity of 99%51. The sensitivity of canine scent detection for 
watery stools was 97% with a specificity of 99%51. The study demonstrated that canine 
olfaction of VOCs could discriminate patients with colorectal cancer from controls with good 
diagnostic accuracy. Ehmann et al. wanted to investigate the robustness of a ‘so far unknown’ 
VOC fingerprint within the exhaled breath of lung cancer patients52. To test this hypothesis, 
they trained four dogs (two German shepherd dogs, one Australian shepherd dog and one 
Labrador retriever) of both sexes (two females, two males) aged 2.5–3 yrs in scent detection 
for lung cancer52. They collected breath samples from 220 participants; lung cancer was 
identified by the dogs with a sensitivity of 71% and a specificity of 93%52. Lung cancer 
detection was independent of Chronic Obstructive Pulmonary Disease (COPD) status, smoking 
and food odours52. Although the results of both studies are clearly impressive, it is impractical 
to implement canine olfaction for clinical screening purposes; the cost and length of time 
required in dog training as well as the practicalities of maintaining an appropriate dog facility 
do not make it justifiable. More importantly, both studies further support the theory that cancer-
specific VOCs exist, which could potentially be identified through chemical analytical 
techniques.   
However, the identification, characterisation and accurate quantification of VOCs associated 
with certain diseases continue to pose a major scientific challenge. In recent years, there have 
been technological advances in gas phase analytical techniques, allowing one to measure VOCs 
emitted from exhaled breath, headspace of bodily fluids and histological specimens with 
accuracy at levels of parts-per-billion by volume (ppbv), and even down to parts-per-trillion by 
volume (pptv)53. The mass spectrometry tools available have increased the analytical chemist’s 
capabilities in detecting the smallest differences between biological samples and several 
encouraging VOC-disease associations have been described. However, the use of the 
technology remains confined to the laboratory and robust scientific protocols are essential as 
both dilution and contamination of gaseous samples remain a source of potential error. There 
has been no methodology standardization thus far and it has been postulated that sampling 
errors may be one of the major factors contributing to variation in VOC concentrations between 
studies54. Since Pauling’s original study on VOCs in exhaled breath and urine vapour, there 
has been much research on VOCs and disease; the literature pertaining to cancer has been 
assessed in the form of a systematic review.  
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2.2 Objective 
The aim of this systematic review was to identify volatile organic compounds (VOCs) linked 
to cancer disease states.  
 
2.3 Methods  
2.3.1 Search Strategy 
Methodology for this review was adapted from that for compiling systematic reviews of clinical 
studies of healthcare interventions55. Bibliographic searches using PubMed (1951–2011), 
EMBASE (1947–2011), Web of Science (1900-2011) and Google Scholar (1980–2011) 
electronic databases were conducted up to and including 19th November 2011 for studies on 
Volatile Organic Compounds and Cancer. Search strategy incorporated 2 different domains of 
MeSH-terms and key words combined by “AND”. The first domain contained terms on volatile 
organic compounds/volatile compounds and the second had terms on 
cancer/malignancy/neoplasm. Selection was not restricted by language. Two reviewers (S 
Kumar and J Cushnir) independently screened titles and abstracts of studies identified through 
the searches. For those fulfilling inclusion criteria, full texts of potentially relevant articles were 
retrieved and assessed for eligibility in final review. Further potentially relevant articles were 
identified through the searching of reference lists of included studies. Inclusion criteria were 
studies employing mass spectrometry or VOC sensor technology and investigating human 
biological samples or cell lines only. Exclusion criteria encompassed all reviews, method 
papers, letters, comments, perspectives and papers without original experimental data. Studies 
that reported the same patient population were also excluded, except for the most recent 
publication. Both reviewers independently extracted data from the selected studies including 
primary author; year of publication; number and types of specimen; mass spectrometry 
platform; and identified cancer-related VOCs. The primary outcome measure was the 
identification of VOCs observed at varying concentrations within cancer samples.  
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2.3.2 Study Quality Assessment 
The QUADAS-2 tool was used to assess the quality of the studies which involved recruitment 
of patients or analysed patient samples56; this quality evaluation tool consists of 4 domains 
including patient selection, index test, reference standard, and flow of patients through the 
study56. The reference standard is defined as the best available method to establish the presence 
or absence of the target condition57. In this review, the reference standard was histological 
confirmation of the cancer diagnosis. Each domain is assessed in terms of the risk of bias and 
the first three are also assessed in terms of concerns regarding applicability.  
 
2.4 Results 
2.4.1 Search Strategy Results and Selected Studies 
In total, 5764 potential articles were identified from the literature search (Figure 2.1 - Google 
Scholar 2907, PubMed 1171, Web of Science 1169, EMBASE 517). Ninety-two studies 
potentially fulfilled the inclusion criteria. A total of 45 studies (Exhaled breath - 30, Tissue - 
4, Blood - 2, Urine - 3, Cell lines - 9) were included. The tables in Appendix A include the 
primary author, year of publication, number and types of specimen and mass spectrometry 
platform employed for all the relevant studies included in the review. 
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Figure 2.1: Systematic Review Search Strategy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
5764 reports identified that 
potentially fulfil inclusion 
criteria 
92 papers retrieved and 
assessed 
45 papers included in the 
final review 
Exhaled breath 
30* studies 
Tissue 
4* studies 
Blood 
2* studies 
Cell lines 
9* studies 
5672 reports excluded after 
screening of titles and abstracts 
47 papers excluded as 
reviews, method papers or 
duplicate data sets.  
1 study (Deng 
2004) analysed 
blood & exhaled 
breath  
Urine 
3 studies 
1 study (Chen 
2007) analysed 
tissue & exhaled 
breath  
1 study (Barash 
2009) analysed cell 
lines & exhaled 
breath  
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2.4.2 Quality assessment of Studies 
The QUADAS-2 study quality assessment results are shown in Figures 2.2A & 2.2B.  There 
was an unclear risk of bias for patient selection in the majority of studies due to the lack of 
clarity regarding patient recruitment. In particular, it was unclear whether consecutive patient 
data had been included. The risk of bias for the index test and reference standard were unclear 
in most studies, due to a lack of information regarding blinding of assessors. Forty-five percent 
of the studies had an unclear risk of applicability for the reference standard, mostly due to the 
limited information regarding histological assessment of control samples. 
 
Figure 2.2: QUADAS-2 Assessments of Study Quality (A) Bar chart demonstrating an 
assessment of risk of bias and (B) assessment of applicability concerns  
(A) 
 
 
 
(B) 
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2.5 Discussion 
The results of this review demonstrated that Gas Chromatography Mass-Spectrometry (GC-
MS) is the most frequently employed mass spectrometry platform. GC-MS coupled with 
sample collection and pre-concentration techniques, in particular solid-phase microextraction 
(SPME), have further enhanced the isolation and identification of VOCs from mixed samples. 
Pawlisyzn et al. originally developed the SPME technique, which is simple to use, relatively 
inexpensive and negates the need for solvents58. It allows the collected sample to undergo pre-
concentration prior to GC-MS analysis. SPME uses fibres that are coated with different 
materials to allow for optimal adsorption of compounds of interest. Deng et al. investigated 5 
different fibre coatings to optimise recovery of VOCs from the headspace of blood in patients 
with lung cancer59. This study highlighted the significant method development necessary when 
employing the GC-MS technique for analysis of VOCs emitted by biological samples.   
 
2.5.1 Exhaled Breath VOCs and Cancer 
One of the earliest studies on exhaled breath VOCs by Phillips et al. investigated 108 patients 
with abnormal radiographs (of which 60 patients had histologically confirmed cancer)60. They 
trapped a range of volatile organic compounds from samples from patients with and without 
lung cancer on a sorbent trap. These VOCs were later desorbed, concentrated by 2-stage cryo-
focusing and analysed using GC-MS. Twenty two breath VOCs, including alkanes, alkane 
derivatives and benzene derivatives were used to distinguish between patients with and without 
lung cancer (100% sensitivity, 81.3% specificity for stage 1 lung cancer) 60. Poli et al. employed 
SPME/GC-MS to analyse the VOCs in the breath of patients with non-small cell lung cancer 
(NSCLC), patients with COPD, smokers and healthy controls61. The VOC profile in the 
NSCLC group was also analysed 3 weeks after these patients had undergone pulmonary 
surgery. None of the VOCs alone allowed for discrimination between the study groups. 
However, it was observed that both isoprene (2-methyl-1,3-butadiene) and decane levels 
significantly decreased after surgery61. More recently, Poli et al. used an on-fiber-derivatisation 
SPME sampling technique with GC-MS to investigate C3-C9 aldehydes in the exhaled breath 
of 40 NSCLC lung cancer patients and 38 healthy controls62. In this study, they employed a 
PDMS/DVB fibre (Supelco, Bellefonte, BA, USA) specifically for extraction of the aldehydes; 
they excluded formaldehyde and acetaldehyde from analysis due to the presence of these 
compounds in both indoor and outdoor environments as well as being combustion products of 
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tobacco smoke. The concentrations of all the C3-C9 aldehydes were significantly increased in 
the patients with NSCLC in comparison with controls62. Their results also demonstrated that 
the selected aldehydes had good discriminatory power in being able to distinguish between 
asymptomatic non-smokers and patients with NSCLC (92.1% of controls vs. 90% of NSCLC 
were correctly classified).  
Fuchs et al. investigated volatile aldehydes in the exhaled breath of 12 lung cancer 
patients (8 NSCLC, 4 small cell lung cancer), 12 smokers and 12 healthy volunteers63. In this 
study, the reactive aldehydes were derivatised to their corresponding stable oximes using on-
fibre derivatisation (SPME-OFD) and subsequently analysed with GC-MS63. Exhaled pentanal, 
hexanal, octanal and nonanal concentrations were found to be significantly higher in lung 
cancer patients than in smokers and healthy controls. However, there were no statistically 
significant differences in the concentrations of acetaldehyde, propanal, butanal, heptanal and 
decanal between the three groups. Fuchs et al. also reported that the sensitivity and specificity 
of their identified exhaled breath VOCs for cancer discrimination were comparable to 
conventional serum markers and CT imaging; however it is noted that their study was pilot in 
nature and had a relatively small sample size63. Song et al. employed SPME/GC-MS to assess 
mixed expiratory samples from 43 patients with NSCLC and 41 healthy volunteers64. Their 
study reported that the peak areas (indication of concentration) of 1-butanol (sensitivity of 
95.3% and a specificity of 85.4%) and 3-hydroxy-2-butanone (a sensitivity of 93.0% and a 
specificity of 92.7%) were significantly higher in the exhaled breath of patients with NSCLC 
than those in the control subjects64.   
De Gennaro et al. designed a cross-sectional, case control study in which they recruited 
39 patients, divided equally into 3 groups65. They analysed exhaled breath VOCs from patients 
with histologically confirmed malignant pleural mesothelioma (MPM), those with similar 
occupational asbestos exposure and healthy controls. The exhaled breath VOCs were adsorbed 
on sorbent cartridges, then thermally desorbed and analysed by GC-MS. Through univariate 
statistical analysis, it was found that cyclohexane was the only compound that could distinguish 
between MPM and the other 2 groups65. Cyclopentane was reported as the dominant compound 
to discriminate between the occupational asbestos exposure group from the mesothelioma 
patients and healthy controls; it was proposed by De Gennaro et al. that cyclopentane could 
potentially be a good indicator of long term asbestos exposure.  
The studies in this review indicate that it is highly unlikely that a single VOC biomarker would 
be able to distinguish cancer patients from controls. This has led to several authors exploring 
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the concept of VOC profiling and discriminative analysis of the resultant VOC patterns from 
biological samples. Phillips et al. collected exhaled breath samples from 51 women with 
abnormal mammograms & biopsy-proven breast cancer as well as 42 age-matched controls66. 
After analysis with GC-MS, the results were analysed using fuzzy logic software. The women 
were randomly assigned to either the training or prediction set in a 2:1 ratio. Five breath 
biomarkers of breast cancer were identified – 2-propanol, 2,3 dihydo-1phenyl-4(1H)-
quinazolinone, 1-phenyl-ethanone, heptanal and isopropyl myristate66. The fuzzy logic model 
incorporating the aforementioned breath biomarkers predicted breast cancer with a 93.8% 
sensitivity and 84.6% specificity66. Phillips et al. also applied a similar predictive model to a 
cohort of lung cancer patients67; 66% of patients were randomly assigned to the training set 
and the remaining 33% of patients were put in the prediction set. Thirty five candidate VOCs 
were identified in the training set and 16 of these VOCs were selected for inclusion for fuzzy 
logic analysis. In this study, the model predicted primary lung cancer with 84.6% sensitivity 
and 80.0% specificity67. Qin et al. investigated exhaled breath VOCs in hepatocellular 
carcinoma (HCC)68. In this study, they recruited 30 patients with histologically confirmed 
HCC, 27 patients with hepatitis B-induced cirrhosis and 36 healthy volunteers68. They 
employed a SPME/GC-MS method to analysis the collected breath samples. 3-hydroxy-2-
butanone was only compound found to be statistically significant between all three groups. 3-
Hydroxy-2-butanone had a sensitivity of 83.3% and specificity of 91.7% to discriminate 
healthy volunteers and HCC patients; there was a sensitivity of 70.0% and a specificity of 
70.4% between hepatitis B-induced cirrhosis group and patients with HCC68.  
2.5.2 Urine VOCs and Cancer 
Guadagni et al. employed SPME/GC-MS to investigate hexanal and heptanal urinary excretion 
in 10 patients with lung cancer and 25 healthy subjects69. Hexanal levels were slightly higher 
in the cancer cohort; there were no differences observed in urinary heptanal concentrations 
between the 2 groups69. Silva et al. investigated urinary volatile metabolites as potential cancer 
biomarkers using urine samples from 33 cancer patients (14 leukaemia, 12 colorectal and 7 
lymphoma) and 21 healthy controls70. Through analysis with SPME/GC-MS, benzene 
derivatives, terpenoids and phenols were the most common compounds observed in the cancer 
patients; ketones and sulphur compounds were the main classes that were isolated from the 
urine headspace of the healthy controls. Significant increases were observed in the peak area 
of 2-methyl-3-phenyl-2-propenal, p-cymene, anisole, 4-methyl-phenol and 1,2-dihydro-1,1,6-
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trimethyl-naphthalene in the cancer cohort, whereas statistically significantly lower 
abundances of dimethyl disulphide were noted70. 
 
2.5.3 Sensor Technologies 
Electronic nose technology using an array of VOCs has also been applied in the prediction of 
cancer. The majority of electronic nose studies employed an array of composite nano-sensors; 
the data generated from the electronic nose is analysed with learning algorithms such as 
artificial neural networks which characterise ‘patterns of VOCs’ rather than allow for formal 
identification of individual VOCs. Dragonieri et al. investigated electronic nose technology to 
distinguish VOC-patterns in the exhaled breath of lung cancer patients from those with COPD 
and healthy controls71. Canonical discrimination analysis with the optimal number of vectors 
showed the cross-validation results were 85% accurate for distinguishing lung cancer vs. 
COPD and 90% accurate for distinguishing lung cancer vs. healthy controls71. A potential 
limitation in this study was the small sample size (n=10 for each group); there was also no 
discrimination possible between different stages of lung cancer. Peng et al. used a combination 
of gold nanoparticles (GNP) sensor arrays and GC-MS to analyse exhaled breath samples from 
96 subjects with a variety of cancers (lung, colon, breast and prostate) and 81 healthy 
volunteers72. The nanosensors were able to suitably discriminate between patients with lung, 
colon and breast cancer and healthy controls72. There was a slight overlap between the data for 
the prostate cancer and healthy controls; it was hypothesised that this overlap was due to a 
higher proportion of the prostate cancer patients having stage 1 disease compared to the other 
cancer patients. By combining all the cancers together, it was possible to distinguish between 
all four cancer groups and healthy controls, with minimal overlap between the prostate cancer 
and healthy controls72. The same breath samples were also analysed using SPME/GC-MS. A 
specific SPME fibre cannot extract all VOCs in a sample and hence it was not possible to 
identify all the cancer-specific VOCs to which the nanosensor array responded to. The results 
demonstrated that it was possible to achieve reasonable discrimination between healthy 
controls and patients with a specific type of cancer. Mazzone et al. analysed exhaled breath 
from 143 individuals (49 with non-small cell lung cancer, 18 with chronic obstructive 
pulmonary disease 15 with idiopathic pulmonary fibrosis, 20 with pulmonary hypertension, 20 
with sarcoidosis and 21 controls) using a colorimetric sensor array73. The colorimetric sensor 
array contained 36 spots, each with different sensitivities to a range of VOCs, which changed 
colour depending on the analytes they come into contact with73. In this study, they reported 
colometric spots to be generally responsive to different VOCs but not specific. Applying data 
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from the colometric spots, a predictive model for lung cancer was created which demonstrated 
a sensitivity of 73.3% and specificity of 72.4% for lung cancer73.  
 
2.5.4 Blood VOCs and Cancer 
Deng et al. investigated exhaled breath and blood samples from 10 patients with NSCLC and 
10 healthy controls59. They reported a range of VOCs including aromatic and aliphatic 
alcohols, ketones and aldehydes from both bio-samples. Specifically, hexanal and heptanal 
were found to be at significantly higher concentrations in the blood of lung cancer patients 
compared to healthy controls. These 2 compounds were also detected in the exhaled breath of 
lung cancer patients but not in the controls, these results being consistent with a previous study 
on VOCs in lung cancer60. Xue et al. employed SPME/GC-MS to investigate the VOCs within 
the blood of liver cancer patients74. Comparative analysis of the liver cancer blood group 
(n=19) and the controls (n=18) revealed 19 VOCs to be significantly different between the 2 
groups74. Of the compounds that were statistically significant, 3 peaks were observed at 
increased concentrations in liver cancer blood – hexanal (sensitivity 94.7%, specificity 100%), 
1-octen-3-ol (sensitivity 84.2%, specificity 100%) and octane (sensitivity 89.5%, specificity 
100%)74.  
 
2.5.5 VOCs and Cancer Cell lines 
The majority of the studies on cell lines have primarily investigated lung cancer. Filipiak et al. 
conducted VOC analysis on the non-small cell lung cancer (NSCLC) cell line CALU-1 (which 
expresses the mutant K-ras gene)75. The cultivated cell lines were incubated and 200mL of the 
headspace gas was retrieved for analysis by thermal desorption GC-MS. The results 
demonstrated 2,3,3-trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-
methyloctane were released from the headspace of the cell line CALU-175. Sponring et al. 
investigated the headspace of NCI-H2087 lung cancer cell line using GC-MS76; there was a 
significant increase in 2-ethyl-1-hexanol and 2-methylpentane in the headspace of NCI-H2087 
lung cancer cells and statistically significant lower concentrations of acetaldehyde were present 
when compared to medium only76. Filipiak et al. employed the same analytical methodology 
to investigate the VOCs released by the lung cancer cell line A549 and used primary human 
bronchial epithelial cells (HBEpC) & human fibroblasts (hFB) as controls77. The compounds 
2-pentanone and 2,4-dimethyl-1-heptene were significantly elevated within the headspace of 
the A549 cell line77. However, several aldehydes (including 2-ethylacrolein and 2-methyl-2-
butenal) were found exclusively in the headspace of the medium controls and not within the 
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headspace of the cell lines; it was postulated that the cancer cell lines may be consuming these 
aldehydes77. Sponring et al. conducted one further study of volatile gas analysis in the 
headspace of NCI-H1666 lung cancer cells, but in contrast to the aforementioned studies, no 
unequivocal release of VOCs was observed78.  
 
2.5.6 SIFT-MS and PTR-MS 
GC-MS has been the most frequently employed analytical method in the investigation of VOCs 
to date. However, there are several important technical considerations for GC-MS analysis of 
biological samples; it remains an offline technique requiring appropriate GC-column selection 
and pre-analysis sample preparation. Analysis processing times are lengthy and VOCs with 
low molecular weight (some of which have been proposed as potential biomarkers) can be 
difficult to accurately quantify with GC-MS. The advent of newer ionization techniques such 
as atmospheric pressure chemical ionization (APCI), proton transfer reaction mass 
spectrometry (PTR-MS), and selected ion flow tube mass spectrometry (SIFT-MS) have 
allowed one to perform real-time, online sample analysis79,80,81. In comparison to GC-MS 
techniques, SIFT-MS has the advantage of real-time VOC quantification without the need for 
any pre-concentration steps. SIFT-MS has been employed to detect and quantify VOCs in 
several disease states within the headspace of cancer cell lines and biofluids as well as exhaled 
breath. Smith et al. employed SIFT-MS to investigate acetaldehyde in the non-small cell lung 
cancer cell lines - SK-MES and CALU-182. Acetaldehyde was produced by both lung cancer 
cell lines and its concentration was found to be proportional to the number of cancer cells in 
the medium82. Španěl et al. investigated formaldehyde within the headspace of urine using 
SIFT-MS83. Fourteen patients with bladder cancer, 24 patients with prostate cancer and 14 
healthy volunteers were recruited into this seminal study. Formaldehyde was clearly increased 
in the headspace of the urine from the cancer patients compared with the healthy controls; it 
was proposed that the analysis of the headspace of urine could be a valuable non-invasive 
diagnostic tool for the future83.  
Proton transfer reaction mass spectrometry (PTR-MS) is another online analytical method 
which has been employed in the analysis of VOCs. Wehinger et al. assessed exhaled breath 
VOCs in 17 patients with primary lung cancer and 170 healthy individuals84. The results of this 
study indicated that VOC-31 a product ion of mass-to-charge ratio, m/z, of 31 (tentatively 
protonated formaldehyde) and VOC-43 a product ion of m/z 43 (tentatively a fragment of 
protonated iso-propanol) were present at significantly higher concentrations in the exhaled 
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breath of lung cancer patients compared to controls84. A disadvantage of PTR-MS is that one 
can only tentatively identify the compounds; the authors did propose that PTR-MS should be 
used in conjunction with GC-MS to confirm the identity of peaks of interest84. Brunner et al. 
employed PTR-MS to investigate the VOCs in the headspace of cultured human cells (2 
cancerous and 2 non-cancerous human cell lines)85. The cell lines used were (i) lung epithelial 
tumour cells A-549 and retinal pigment epithelium cells hTERT-RPE1 and (ii) squamous lung 
carcinoma cells EPLC and immortalised human bronchial epithelial cells BEAS2B. A 
compound with a mass-to-charge ratio (m/z) of 45 was significantly consumed by the 
cancerous cell lines A-549 and EPLC but not by the controls85. They tentatively assigned the 
VOC detected at m/z=45 to be acetaldehyde and indicated its potential as a cancer biomarker; 
however, the authors stated that the reasons for the variation in acetaldehyde metabolism 
remain unclear. 
 
2.6 Conclusions 
The results of this review demonstrate that VOC analysis for cancer diagnostics is a promising 
area for further development. However, in terms of the phases of screening biomarker 
development, VOC analysis for cancer remains in phase 1 (pre-clinical exploratory studies) 
and there remains much research to be done before VOC biomarkers can be utilised in routine 
clinical practice86. GC-MS has been the most widely employed technique for the analysis of 
VOCs and it can be considered as a ‘gold standard’ analytical method, although there is much 
sample preparation necessary when analysing biological samples with this platform. SPME has 
been a critically important tool in VOC extraction from a variety of biological matrices. 
However, it is accepted that a SPME filter is unlikely to extract all the VOCs in a biological 
sample to the same degree as a real-time, online mass spectrometric technique could87. The 
constitution of a biological sample is also altered with the use of necessary solvents and this 
may affect adsorption/desorption efficiencies of VOCs. This is an important limitation to 
consider for VOC analysis in cancer with GC-MS and there remains a need to develop real-
time, online technologies such as PTR-MS & SIFT-MS.  
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2.6.1 Aldehydes 
The majority of the studies performed global VOC analyses of their biological samples and it 
was evident that aldehydes were repeatedly linked with several cancer types. An aldehyde is 
defined as an organic compound containing a carbonyl centre (-CHO) bonded to a hydrogen 
and an R group. Aldehydes have multiple industrial and commercial applications, in particular 
formaldehyde (e.g. textile resins, automobile manufacturing) and acetaldehyde (e.g. chemical 
intermediate for acetic acid and ester production). Aldehydes are produced within the human 
body but they are not common in the natural building blocks such as amino acids, nucleic acids 
and lipids. The catalytic dehydrogenation of alcohols results in the production of aldehydes 
and ketones. When these aldehydes are produced within the human body, they are most 
commonly oxidised to carboxylic acids by aldehyde dehydrogenase enzymes. In recent years, 
there has been much epidemiological and laboratory research examining the potential 
mutagenic and carcinogenic properties of aldehydes. Zhang et al. performed a meta-analysis 
of epidemiological studies based on the hypothesis that high formaldehyde exposure can induce 
leukaemia88. Their results suggested that formaldehyde exposure can increase the risk of 
leukaemia by 54%. Teng et al. studied the effects of formaldehyde in rat hepatocytes and found 
that there was a marked increase in formaldehyde cytotoxicity when either alcohol 
dehydrogenase or aldehyde dehydrogenase were inhibited89. Wang et al. investigated the 
genotoxic mechanisms of formaldehyde and their group showed that formaldehyde induces 
both DNA damage via DNA adducts and DNA protein cross-links formation as well as through 
chromosomal abberations in exposed rats90. Rager et al. studied formaldehyde exposure in 
human lung cells and found that formaldehyde alters miRNA patterns that regulate gene 
expression91. The evolving evidence regarding formaldehyde has meant that as of June 10th 
2011, the US National Toxicology Programme described formaldehyde as ‘known to be a 
human carcinogen’.  
Significant evidence linking acetaldehyde and carcinogenesis has also been reported. 
Acetaldehyde is the first metabolite of ethanol oxidation and there is a known increased risk of 
liver and aerodigestive cancers in those with heavy alcohol consumption92. Several 
epidemiological studies have demonstrated that the risk of upper digestive tract cancers, 
specifically squamous cell oesophageal cancer, is markedly increased among ALDH2-deficient 
alcohol users compared to those with the normal enzyme93,94,95. Fanelli et al. examined the 
effects of acetaldehyde accumulation in rat mammary tissue and concluded that this may be a 
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critical event in the development of breast cancer96. The World Health Organization (WHO) 
has concluded that acetaldehyde derived from alcohol is a Group 1 carcinogen to humans97. 
The mutagenic potential of several other aldehydes, including malondialdehyde, acrolein and 
glyceraldehyde, have also been implicated in oxidative stress/lipid peroxidation pathways98. 
However, VOCs in oesophageal or gastric cancer have not been thus far investigated. 
 
2.6.2 VOCs as potential diagnostic tools 
Several published papers have suggested that the VOCs linked to a particular type of cancer 
could be used as biomarkers. However, any diagnostic test for cancer screening needs to have 
an acceptable level of sensitivity (i.e., true positive rate) and specificity (i.e., true negative rate). 
In the UK, the incidence of oesophageal and gastric cancer is 13.6 per 100,000 persons and 
11.7 per 100,000 persons, respectively99; this incidence is relatively low when compared to 
other cancers. For example, breast cancer and prostate cancer have an incidence of 156.8 per 
100,000 women and 133.7 per 100,000 men, respectively99. Hence, a screening tool for a 
disease with a low incidence must have excellent sensitivity and an acceptable specificity. The 
sensitivity needs to be sufficiently high for the test to pick up the persons with cancers. 
However, the specificity cannot be too low otherwise this can lead to healthy individuals 
unnecessarily being subjected to invasive investigations and undue stress. Many of the studies 
identified in the review provide sensitivity and specificity metrics for their reported ‘VOC 
biomarkers’; however, the majority have relatively small samples sizes, minimal evaluation of 
exogenous contributions and negligible assessment of confounding factors, all of which are 
important in the development of new diagnostic tests. There is also a need to develop 
standardized VOC sampling protocols and address the concerns regarding contamination and 
degradation of biological samples. Future VOC research should also consider the effects of 
confounding factors, employ rigorous protocols for recruitment of patients and controls and 
investigate sampling of multiple biological surrogates (e.g. urine and breath).  
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2.6.3 Thesis Aims 
The primary aim of this thesis is to identify potential VOC biomarkers in oesophago-gastric 
cancer; the long-term aim of this research being the translational development of VOCs as non-
invasive diagnostic tests. For this investigation, Selected-Ion Flow Tube Mass Spectrometry 
(SIFT-MS) has been employed in the analysis of VOCs from gastric content, urine and exhaled 
breath of patients with oesophageal and gastric cancer (Figure 3). Method experiments include 
the optimisation of VOC sampling techniques with evaluation of exogenous contamination and 
variability measures.   
 
Figure 2.3: Bio-samples analysis strategy in oesophageal and gastric cancer 
 
 
 
 
 
 
 
 
 
 
 
Gastric Content – 
Endoscopically retrieved 
    Urine           Exhaled Breath 
Patient selected for VOC 
gas-phase analysis 
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3.1 The Selected Ion Flow Tube Mass Spectrometry Technique 
Adams & Smith originally conceptualised and developed the Selected Ion Flow Tube (SIFT) 
in 1976 to study ion-molecule reactions at thermal energies100,101; it has been fundamental to 
the advancement of interstellar ion chemistry and the understanding of reactions that occur in 
the ionized terrestrial atmosphere102,103,104. The SIFT-MS analytical method is borne out of the 
SIFT and represents a direct mass spectrometric analysis by chemical ionization of the volatile 
compounds in the air/vapour samples53. Precursor ions are formed in a microwave discharge 
source and are selected according to their mass-to-charge ratio (m/z) by an upstream 
quadrupole mass filter; they are injected into flowing helium carrier gas (at a pressure of ~100 
Pa and a flow rate of typically 400 mL/min at standard temperature & pressure) through a 
Venturi-type inlet (diameter of 1 mm) where they are convected as a thermalized swarm along 
a flow tube (typically at a velocity of 100m/s)53. The selected precursor ions (H3O
+, NO+ and 
O2
+) are used to ionize the trace gases in air/vapour samples. These precursor ions are injected 
into flowing helium carrier gas, and the gas/vapour to be analysed is introduced at a specified 
flow rate (20 mL/min in the present experiments) via the heated sample inlet port; the capillary 
within the inlet port is heated to a temperature of 80oC to prevent condensation of water vapour 
and/or metabolites. The flow speed of the helium carrier gas transporting the ion swarm and 
the length of the flow tube determines the reaction time of the precursor ions with the analyte 
molecules. Bimolecular and termolecular reactions occur when a specific precursor ion reacts 
with the trace compounds in the sample gas/vapour, leading to conversion of a small fraction 
of the reagent ions to the product ions that are characteristic of the analytes53. The remaining 
(large fraction) of the reagent ions together with the characteristic product ions are sampled 
from the flowing swarm via a pinhole orifice (~0.3 mm diameter) located at the downstream 
quadrupole mass spectrometer. After mass analysis, absolute quantification of the volatile 
organic compounds is achieved by detection and counting at the channeltron multiplier/pulse 
counting system53.   
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3.2 Ion Chemistry in SIFT-MS 
Chemical ionisation (soft ionisation) in combination with mass spectrometry was developed 
with the specific objective of minimising the fragmentation of complex analyte molecules, 
resulting in simpler characteristic product ions and thus aiding analyte molecule identification 
and quantification. However, there are few precursor ions suitable for ambient gas analysis as 
these ions must be relatively unreactive with the major constituents of air (i.e. N2, O2, H2O, 
CO2, Ar) but very reactive with the trace gases being quantified. The study of ion-molecule 
reactions at thermal energies identified those ions appropriate for this purpose104. At present, 
the only suitable reagent ions species for SIFT-MS are H3O
+, NO+ & O2
+; these ions do not 
undergo bimolecular reactions with the major components of air and react only very slowly via 
slow termolecular association105,106,107,108. The availability of three reagent ions in SIFT-MS 
provides improved accuracy for compound identification, which is particularly important when 
isobaric product ions are formed. The ability to rapidly switch between the H3O
+, NO+ & O2
+ 
reagent ions within milliseconds also allows one to obtain analytical data for each reagent ion 
without delay, which is advantageous in the analysis of transient gaseous samples. Moreover, 
these precursor ion species are generated efficiently in simple discharge ion sources109. The 
potential use of anions as precursor ions for SIFT-MS analyses has previously been explored. 
The reactivity of OH- was found to be far less in comparison to H3O
+ and there was difficulty 
in obtaining a large enough current of OH- ions; using negative ions would thus restrict the 
level of analytical sensitivity of SIFT-MS110.  
 
3.3 The development of the Profile 3 SIFT-MS instrument 
In 1997, the drive to develop a transportable SIFT-MS instrument resulted in the creation of 
the transportable Mk.1 instrument, which weighed 350kg. The new-found mobility of the 
SIFT-MS allowed it to be employed for the first time outside the setting of the analytical 
chemistry laboratory. Online gas analysis was conducted of exhaled breath samples from 
patients pre- and post-haemodialysis in a hospital111. The Mk1 instrument was also employed 
to study exhaust gas emissions from a diesel engine in a health and safety laboratory112. In 
2001, the Mk.2 instrument became the first commercial version of SIFT-MS and consisted of 
the latest components (pumps and quadrupole mass spectrometers) and improved 
specifications113. This allowed for a relaxation in critical parameters such as orifice diameters 
and improved the detection limit for exhaled breath samples to 2 ppbv for a 1 sec integration 
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time113. The Mk.2 instrument was essential in the study of important abundant exhaled breath 
metabolites in healthy subjects including acetone, ammonia, methanol, acetaldehyde, propanol 
and isoprene114,115,116,117. The considerable thinking and continued efforts of Professors Smith 
and Španěl regarding the flow dynamics, Venturi design, pumping systems, vacuum housings 
and the underlying ion chemistry of SIFT-MS led to the production of the Profile 3  instrument 
(Instrument Science Ltd, Crewe, UK), which was launched in 2006 in the UK. In particular, 
the replacement of the large pumps that were utilized in the Mk.1 and Mk.2 instruments with 
rotary backing pumps, led to a significant reduction in weight and size of the Profile 3 
instrument (weight ~120kg), resulting in a more easily transported instrument. 
There have been several important principles that have guided the desire to increase the 
sensitivities of the SIFT-MS instruments113. As the reagent ions are convected along the flow 
tube by the carrier gas, their number density (n1) near to the upstream ion injection orifice is 
continuously reduced by diffusive loss to the flow tube walls. This results in a lower number 
density (n2) near the downstream ion sampling orifice. After being transported through the ion 
sampling orifice and subsequent detection at the downstream mass spectrometer, the count rate 
of the precursor ions at the ion detector is designated I1. The ion diffusive loss is decreased by 
increasing the carrier gas pressure; however, the upper limit of this pressure is dictated by the 
gas flow that can be tolerated through both orifices to ensure appropriately low pressures within 
the quadrupole chambers. A reduction in the length of the flowtube (l) and increasing the flow 
velocity of the carrier gas and therefore the ions (vi) also reduces diffusive loss. Once a gaseous 
sample is introduced into the instrument, the precursor ions react with the trace gases within 
the sample (rate coefficient k) producing characteristic product ions. The equation below 
expresses the fundamental scientific principles that underpin the design of SIFT-MS, in 
particular the need for a suitably high enough I1 and reaction time (l/vi)
113:   
   
                                          I2 = I1k[M] 1 
                                                   vi 
 
(N.B. [M] = number density of the trace gas) 
 
There is a need for balance between all the variable parameters including the diameters of the 
upstream ion injection and ion sampling orifices diameters, carrier gas pressure, length of flow 
tube and flow velocity of ions to ensure optimal sensitivity of the SIFT-MS instrument. The 
flowtube within a Profile 3 instrument is 5 cm long and 1 cm diameter. The operating helium 
28 
 
carrier gas pressure is ~1.0 Torr and the reaction time is about 0.5msec113. The combination of 
the shorter flow tube and the higher pressure than in the Mk.1 and Mk.2 instruments has led to 
a decrease in the diffusive loss of precursor ions to the walls of the flow tube, resulting in I1 
values more than 106/sec113. A Profile 3 instrument was employed for all the experiments 
described in this thesis (see Figure 3.1) 
 
3.4 Modes of acquisition of SIFT-MS data 
SIFT-MS can be operated in two different modes. In the full-scan mode (FS), the ambient 
air/breath or liquid headspace vapours are introduced at known flow rates into the carrier gas, 
and the downstream analytical mass spectrometer system is scanned over predetermined m/z 
ranges for a chosen time period53. The count rates of the ions are then calculated from the actual 
numbers of counts and the total sampling time for each ion. The count rates are stored, and 
then displayed on a linear or semi-logarithmic scale. The mass spectra are interpreted by 
relating the product ion peaks to the trace gases present in the sample. The concentrations of 
VOCs and trace gases are calculated from the count rates of the precursor ions and their 
characteristic product ions and the appropriate k values (using the standardized kinetics library) 
and the flow rates of the helium carrier gas and of the air/breath/headspace sample. In the multi-
ion monitoring mode (MIM), the downstream analytical mass spectrometer is rapidly switched 
between selected m/z values to target selected trace gas species53. From the data obtained, 
together with the rate coefficients of the reactions as included in the kinetics library, 
specifically targeted volatile compounds are quantified in real-time. This real-time monitoring 
is possible because of the instantaneous response of SIFT-MS, which is typically less than 20 
ms; the fast response time is dictated by the fast flow rates of the carrier gas along the flow 
tube and the sample gas along the inlet tube. In addition to the count rates of the characteristic 
product ions, those of the precursor ions (e.g., H3O
+ and H3O
+(H2O)n) are also continuously 
recorded, because they continually change with the humidity of the sample gas. 
 
3.5 Sensitivity and limit of detection of the Profile 3 SIFT-MS instrument 
The functionality of the ion sources employed in SIFT-MS are essential in determining the 
sensitivities and detection limits of the instrument. Španěl et al. conducted a study on the ion 
chemistry occurring within the microwave discharge plasma ion sources that are currently used 
for the production of currents of the three precursor ions118. They demonstrated that the most 
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suitable ion source gas composition is a mixture comprising maximal water vapour and 
minimal air at the lowest total pressure at which the discharge is sustained and stable118. It was 
also reported that rapid switching between the H3O
+, NO+ and O2
+ precursor ions is only 
possible because the SIFT-MS source constantly produces these three reagent ions in similar 
concentration when the partial pressures of air and water vapour in the discharge are optimised. 
The continual improvements in the performance of the microwave discharge ion sources have 
led to count rates of several million per second for the reagent ions and, in turn, superior count 
rates for the characteristic analytical product ions, which have a first order influence over the 
sensitivity of SIFT-MS. Most importantly, this has the overall effect of delivering better quality 
mass spectra. The limit of detection for any trace gas can be evaluated in terms of the reagent 
ion count rate, the sample flow rate, the reaction rate coefficient and the data acquisition 
time119. The reagent ion count rate of the Profile-3 SIFT-MS instrument under optimal 
conditions is in excess of 106
 
s-1, which results in a detection limit of ~0.1 ppbv for 1 sec of 
integration113.  
 
3.6 Direct analysis of ambient gaseous samples 
A major advantage of the SIFT-MS technique is that the sample and its analytes are not 
modified by any pre-analysis preparation and remain undisturbed throughout the analytical 
process. Several approaches for ambient analyses using SIFT-MS have previously been 
described: 
 
1) Through presentation of the sample to the sampling capillary of the instrument when the 
ambient air is also sampled simultaneously;  
2) By collecting the gaseous sample in either a collapsible bag in which atmospheric pressure 
is automatically maintained or in a fixed volume vessel;  
3)  Liquid samples have been placed in a fixed volume container closed by a septum, which 
is subsequently punctured by a needle connected directly to the sample inlet of the 
instrument.  
Real time analysis of a gaseous sample can be performed by directly connecting it to the 
sampling inlet, whilst the downstream mass spectrometer allows for data acquisition in either 
the FS or MIM mode. This is made possible as the sample input pressure remains atmospheric, 
thereby making the analysis relatively simple. Another valuable feature of the SIFT-MS 
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method is that the humidity of an air and breath sample can be obtained routinely from the 
distribution of the hydrated hydronium ions. The humidity measurement is based on the idea 
that the injected H3O
+ precursor ions react with H2O molecules in the sample producing the 
hydrates H3O
+(H2O)1,2,3, and it is the fraction of the H3O
+ that is converted to its hydrates that 
provides a determination of the H2O number density in the helium carrier gas and hence the 
sample humidity. This determination is possible, because the three-body rate coefficient (k3) 
for the conversion of H3O
+ to H3O
+(H2O) is known. Since the humidity of exhaled breath in 
humans (6% at a body temperature of 37oC) is known, this serves as an internal validation for 
the analytical process119. Prior to any sample being analysed, the operator performs a 
calibration procedure using exhaled breath acetone (H3O
+). The flow rate settings of the 
instrument are standardized to ensure the water content of the operator’s exhaled breath 
measures 6 +/- 0.1%; these checks act as an important quality control step prior to performing 
any SIFT-MS analysis120.  
Another unique feature of the SIFT-MS method is that one can analyse several 
compounds simultaneously from the headspace above a liquid, a Nalophan®/Tedlar® collected 
exhaled breath sample or even from a single exhalation directly into the instrument. These 
compounds can range from water vapour and CO2 present at percentage levels to trace 
compounds that are present at ppbv concentrations. Figure 3.2a illustrates the online 
capabilities of SIFT-MS; it includes data obtained for the detection and quantification of water 
vapour, CO2 and acetone using a Profile 3 instrument in MIM mode from six sequential single 
breath exhalations121. In Figure 3.2b, the simultaneous analysis of ammonia, acetone and 
hydrogen cyanide within single exhalations is shown - the rapid time response of the SIFT-MS 
allows instantaneous measurement of trace compounds and abundant compounds 
simultaneously and spans a concentration range of 107.  
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Figure 3.1: A schematic diagram of the Profile 3 SIFT-MS instrument showing the microwave discharge ion source, injection mass filter and the 
three metal discs to which ion current can be measured and which support the orifices through which (left to right) ions pass from the ion source 
into the injection mass filter, mass selected ions enter the flow tube, and ions pass from the carrier gas into the analytical quadrupole mass 
spectrometer121.  
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Figure 3.2: Plots of the derived concentrations of water vapour and  acetone (in ppbv) obtained 
using the Profile 3 SIFT-MS instrument in the multi ion monitoring mode for six sequential 
breath exhalations by one volunteer over the time indicated in seconds. This data illustrates the 
consistency in the derived levels of these compounds in the alveolar regions of the exhalations 
(as indicated within the shaded regions) The mean values (with standard deviations): are water 
vapour, 6.1 (+/-0.1)%, CO2 3.8 (+/-0.1)% and acetone 428 (+/-14) ppbv. Also indicated are the 
laboratory air levels of these compounds. b: Simultaneous absolute quantification of water 
vapour, ammonia, acetone and hydrogen cyanide in three sequential breath exhalations. The 
water vapour is ~6% of the exhaled breath and that the concentration of the trace compound 
hydrogen cyanide obtained in the same breath exhalations has a mean value of 10 ppbv121. 
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3.7 The SIFT-MS Kinetics Library 
SIFT-MS quantification of VOC concentrations is calculated using the laws of chemical 
kinetics and the measured physical quantities. The concentrations are automatically calculated 
instantaneously using the on-board Profile 3 SIFT-MS software. There are general equations 
applying to all compounds which are coded within the algorithms of the SIFT-MS software. 
Separately, there is a kinetics library of numerical constants which are characteristic and 
specific to individual compounds. The number densities of analytes diluted by the sample air 
and by the carrier gas in the flow tube, [M], are calculated using the known rate coefficients 
for their reactions with the reagent ions, k1, the reaction time, tr, and the ratio of the sum of the 
count rates of all the product ions to the sum of the count rates of the precursor ions and their 
hydrates122. These count rates are divided by factors that account for differential diffusion (De) 
and can be optionally modified by factors (f) when specific additional kinetic processes must 
be accounted for.  
To allow for immediate calculation of VOCs, each compound is assigned a corresponding set 
of reagent ions and characteristic product (analyte) ions together with the rate coefficients and 
factors (f). This data are stored within the SIFT-MS kinetics library. Examples of the kinetics 
library entries used for the analysis of acetone by H3O
+, NO+ and O2
+ are given in Table 3.1: 
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Compound(ion) Acetone (H3O
+) Acetone (NO+) Acetone (O2
+) 
 
Number of precursors 
(m/z k fi) 
 
4 precursors 
19 3.9e-9 1.0 
37 3.3e-9 1.0 
55 2.5e-9 1.0 
73 2.4e-9 1.0 
 
1 precursor 
30 1.8e-9 1.0 
 
1 precursor 
32 3.1e-9 1.0 
 
Number of products 
(m/z k fp) 
 
3 products 
59 1.0 
77 1.0 
95 1.0 
 
1 product 
88 1.0 
 
2 products 
43 1.0 
58 1.0 
Table 3.1: Sample Kinetics Library entries for acetone using all three precursor ions. 
The format of each entry within the kinetics library is as follows - after the name of the 
compound and the symbol of the injected ion, the number of reagent ions is given followed by 
their m/z values with the rate coefficients in units of cm3s-1. The fi are simply used to multiply 
the acquired raw count rate of the ion, with its m/z given at the beginning of the row. Normally, 
fi values of 1.0 are used, as indicated in example of acetone. However, such simple calculations 
do not always provide valid results in the cases when additional ion chemistry occurs (e.g. the 
removal of the product ions by reactions with H2O molecules in reverse proton transfer or 
switching reactions) or when product ions overlap with other ions present122. Values other than 
1.0 can therefore be incorporated to account for the influence of humidity or to optimise 
calculations that do not sum all product ions122.  
 
3.8 Headspace of Biofluids and Exhaled Breath Sampling 
The sampling methodologies and individual experimental protocols employed for SIFT-MS 
analysis of gastric content, urine and exhaled breath are described in subsequent chapters. The 
reproducibility of these methods is also evaluated. 
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Chapter 4  
 
 VOCs in the headspace of gastric content 
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4.1 VOCs within gastric content in OG Cancer  
4.1.1 Objective  
To evaluate whether the VOCs within gastric content retrieved from patients with oesophago-
gastric cancer differs from patients with benign upper gastro-intestinal conditions and those 
with healthy upper gastro-intestinal tracts. 
 
4.1.2 Introduction 
Gastric content is a complex biofluid within the human stomach, which has an important role 
in digestive processes and is a combination of gastric acid, saliva and bile reflux. Gastric acid 
forms a major component of gastric content, being secreted by the gastric parietal cells and is 
a combination of HCl, NaCl and KCl; this results in gastric content most commonly being at 
the strongly acidic end of the pH range. Gastric content hypoacidity has been implicated in the 
development of upper gastrointestinal (GI) diseases. Lu et al. investigated the pH of fasting 
gastric content samples from patients with upper GI diseases and healthy controls and observed 
gastric cancer and gastric ulcer patients have a significantly higher pH than healthy controls123. 
Gastric content has also been proposed as a potential source of upper GI disease biomarkers. 
Inada et al. found that cobalamin-binding protein was present in the gastric content of all 
patients with early gastric cancer124. Hsu et al. reported that gastric content α1-antitrypsin 
concentrations in gastric cancer patients are markedly increased compared to healthy subjects 
and patients with benign gastrointestinal diseases125. Deng et al. have investigated aromatic 
amino acids in gastric content samples from patients with early-stage gastric cancer, advanced 
gastric cancer and non-neoplastic gastric diseases using high performance liquid 
chromatography mass spectrometry (HPLC-MS)126. They reported significantly higher 
concentrations of tyrosine, phenylalanine, tryptophan and total protein in the gastric content of 
patients with gastric malignancies126. 
Biofluids obtained from organ-specific cavities have much potential in assisting in the 
identification of disease biomarkers. VOCs have previously been investigated in urine, serum, 
plasma, saliva, sweat and bronchoalveolar lavage59,70, 127,128.  Gastric content has been proposed 
as a contributory factor in the pathogenesis of upper gastro-intestinal diseases and represents 
the only biofluid to comes into direct contact with oesophageal and gastric cancer cells.  Hence, 
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it represents a promising medium to investigate VOCs of interest in oesophago-gastric cancer. 
In the present study, headspace analysis of gastric content in upper gastro-intestinal diseases 
was investigated for the first time.  
 
4.1.3 Methods 
4.1.3.1 Patient selection  
Patients for this study were recruited through St. Mary’s Hospital, Paddington (Imperial 
College NHS Trust, London) and via the North West Thames regional oesophago-gastric 
cancer network (UK). Patients referred with upper gastro-intestinal symptoms are commonly 
sent for an Oesophago-Gastro-Duodenoscopy (OGD) by their clinician. An OGD is a routinely 
performed camera test in which the upper gastro-intestinal tract is visualized (a description of 
the procedure and sample retrieval process is provided in the section below). An OGD referral 
form contains information explaining the indication for the procedure and the patient’s known 
medical history. These referral forms were screened to identify suitable patients for 
recruitment. The exclusion criteria for this study included patients with: 
 Barrett’s oesophagus  
 Liver disease  
 Small bowel or colonic pathology 
 A history or presence of another type of cancer 
 Presence of acute infection 
Local ethics committee approval was obtained for this study. Patients eligible for the study 
were given information sheets pertaining to the study and informed consent was obtained prior 
to enrolment in the study. All patients provided a comprehensive medical history, including 
past medical history, medications as well as smoking status and alcohol intake. Demographic 
and clinical data for each patient were archived in a linked, anonymized database. Only patients 
who had requested sedation for their OGD procedure and agreed not to have Xylocaine® 
(lidocaine hydrochloride) throat spray were included in the study. Patients with a biopsy-
confirmed invasive gastric or oesophageal cancer were included in the cancer cohort. Patients 
with any non-cancer conditions of the upper gastrointestinal tract (e.g. oesophagitis, gastritis 
and peptic ulcer disease) were included in the positive control cohort. Patients with a normal 
OGD examination and confirmed H. pylori negative were included in a normal Upper GI cohort 
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group. The comparative analysis of gastric content vapour metabolites was conducted with an 
oesophago-gastric cancer cohort of 25 patients, a positive control group of 20 patients and a 
‘Normal Upper GI’ group of 18 patients.   
 
4.1.3.2 Gastric content sampling 
All patients were fasted for a minimum of 6 hours, which is standard protocol for an OGD 
procedure. All gastric content samples were taken from patients undergoing an OGD. A 
gastroscope (Olympus, Essex, UK) is introduced through the mouth, into the oesophagus and 
then into the stomach. During this procedure, biopsies can be taken for histological examination 
and fluid can also be retrieved through a suction channel within the gastroscope. The gastric 
content was retrieved during the first pass of the gastroscope and captured in a disposable 
suction jar (see Figure 4.1). This suction jar was then taken to the SIFT-MS instrument located 
in the hospital and all samples were analysed within 1 hour. The pH of gastric content samples 
was measured immediately after SIFT-MS analysis using a Hanna Piccolo® pH meter (Sigma-
Aldrich, Missouri, USA). 
 
Figure 4.1: Suction Trap for the collection of gastric content
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4.1.3.3 SIFT-MS analysis  
In the first phase of this study, the FS mode (please refer to section 3.4) of SIFT-MS was 
initially operated to reveal which groups of compounds were present in the headspace vapour 
of the gastric content. However, the MIM mode (please refer to section 3.4) was mainly 
employed for this study as it is more sensitive and reproducible than the FS mode and allows 
targeted compound analysis. Prior to MIM headspace analysis of a sample, the calibration 
procedure using the water content of the operator’s exhaled breath (6 +/- 0.1%) was carried out 
to check the sample flow rate into the instrument. For each measurement, a total of 10mL of 
gastric content from the original sample jar was aliquoted into a standard 60 mL specimen jar, 
which was then sealed with parafilm and placed in an incubator at 37 ̊C for five minutes prior 
to analysis. A 21g Luer-lock sterile hypodermic needle was connected to a 200cm Vygon 
extension tube, which was directly connected to the SIFT-MS sampling port. The sterile needle 
end punctured the parafilm layer of the specimen jar to sample the headspace above the gastric 
content liquid. The headspace vapour automatically flowed into the helium carrier gas at a fixed 
rate of 20mLs/min through the sampling line which was held at a temperature of 80 ̊C and the 
analysis was conducted. Throughout the analysis, the specimen jar, needle and extension tubing 
were all kept in the incubator at 37 ̊C. All experiments in the study were conducted using only 
the 200cm version of the tubing, after assessment of 50cm versus 200cm Vygon extension 
tubes for headspace sampling of gastric content was conducted. The 50cm extension tubing 
was suitable for headspace analysis for a short period of analysis; however, after ~20minutes a 
droplet of condensation would reach the sample inlet and if this entered the instrument, the 
analysis would be ruined. For the FS mode, two serials of 9 x 60 seconds repeated scans were 
performed using H3O
+ and NO+ precursor ions. The O2
+ precursor ion was not used for the FS 
analysis as it is more energetic than the others precursor ions resulting in busy spectra that are 
more difficult to interpret129. For the MIM mode, the selected VOCs from the vapour samples 
were analysed for a total of 60 seconds and the measured concentrations were averaged over 
the analysis time for each VOC.  
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4.1.3.4 Statistical analysis 
Statistical analysis was performed using IBM SPSS statistics 19 (SPSS Inc., Chicago, IL). 
Mann-Whitney U test was used to compare the measured concentrations of VOCs between 
oesophago-gastric cancer patients and healthy controls. A p-value ≤ 0.05 was taken as the level 
to indicate statistical significance. In medicine, a Receiver Operating Characteristic curve 
(ROC) is a fundamental test used to assess the accuracy of a diagnostic test to discriminate 
between a diseased group and healthy group. ROC curves were originally developed in the 
field of statistical decision theory and used by radar operators in World War II to distinguish 
between enemy targets or ships belonging to the Allied Powers130. In a ROC curve for clinical 
assessment, the sensitivity is plotted against (1-specificity) using the variation to differentiate 
between the two groups. The cut-off points on the ROC curve indicate when a discrimination 
threshold is reached with a paired sensitivity and specificity. The area under the curve (AUC) 
measures the discrimination power of the test, which is the ability of the test to correctly 
classify subjects into the correct group131. The higher the AUC value, the better the ability of 
the test to positively identify those persons with the disease and correctly rule out those persons 
without the disease. A diagnostic test is considered highly accurate when the AUC is > 0.964. 
The statistically significant VOCs (identified through Mann Whitney U analysis) that showed 
a difference between the cancer and the healthy cohort were used as included variables to 
construct the ROC curve. The disease conditions were used as the dependent variable and the 
statistically significant VOCs were used as the independent variable. A binary logistic 
regression method was conducted to test different combinations of selected VOCs as the 
variables to find the model with the highest R2 value and AUC value for the ROC curve. 
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4.1.4 Results 
4.1.4.1 Analysis of full scan spectra  
 
 
Figure 4.2: Full scan spectra of SIFT-MS analysis of the headspace of gastric content using 
(a) H3O
+ precursor ion; (b) NO+ precursor ion. The individual characteristic product ions and 
their hydrates were assigned to the analysed molecules. In (a), m/z 19, 37, 55, 73 are 
H3O
+(H2O)0,1,2,3; m/z 59, 77, acetone; m/z 33, 51, 69, methanol; m/z 47, 65, 83, ethanol; m/z 45, 
81, 83, acetaldehyde; m/z 31, formaldehyde; m/z 35, hydrogen sulphide; m/z 28, hydrogen 
cyanide; m/z 95, phenol; m/z 18, 36, 54, ammonia. In (b), m/z 19, 37, 55, 73 are 
H3O
+(H2O)0,1,2,3; m/z 30, 48, 66, 84 are NO
+(H2O)0,1,2,3; m/z 90 is acetic acid.  
 
Full scan (FS) spectra were obtained from analysis of the headspace vapour of gastric content. 
Representative spectra using H3O
+ and NO+ precursor ions are shown in Figure 4.2. A variety 
of VOCs was detected and several compounds were identified from their characteristic product 
ions. From full scan spectra, those VOCs that led to characteristic product ions of nominally 
the same m/z values (overlapping ions) were not selected for MIM mode analysis. For instance, 
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in the carboxylic acid group, propanoic acid and butanoic acid were not selected for further 
MIM investigation as their product ions shared overlapping m/z values and these would be 
difficult to quantify accurately. GC-MS is often not capable of detecting low molecular mass 
trace volatile organic compounds such as hydrogen sulphide and hydrogen cyanide, but both 
H2S and HCN were unambiguously identified from their product ions using SIFT-MS.  
 
4.1.4.2 Reproducibility and validity of the sampling method 
The reproducibility of headspace analysis of gastric content was assessed. A total of ten gastric 
content samples were analysed and with each sample three MIM measurements for selected 
VOCs were taken. The coefficient of variation (CV) were calculated for the spread of measured 
concentrations of the VOCs in the gastric content headspace. These CV values in percent are: 
acetaldehyde, 6.7%; formaldehyde, 11%; acetone, 6.8%; hexanoic acid, 10.7%; methanol, 
15.9%; ethanol, 6.2%; phenol, 22.6%; methyl phenol, 13.4%; hydrogen sulphide, 44.7%; 
hydrogen cyanide, 22.7%; ammonia, 6.8%; nitric oxide, 14.8%. These coefficients of variation 
demonstrate the reproducibility of the MIM measurement. In contrast to the major metabolites 
(e.g. acetone, acetaldehyde) the higher CV for hydrogen sulphide and hydrogen cyanide is 
expected given their extremely low concentrations in gastric content and hence the lower count 
rates of their characteristic product ions119.  
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4.1.4.3 MIM analysis of selected VOCs in the headspace of gastric content 
 
Compounds Molecular 
formula 
Precursor 
Ions 
m/z Characteristic product ions REF 
Methanol CH4O H3O
+ 33,51,
69 
CH5O
+,CH5O
+(H2O), 
CH5O
+(H2O)2 
132 
Ethanol 
 
C2H6O H3O
+ 47,65,
83 
C2H7O
+,C2H7O
+(H2O), 
C2H7O
+(H2O)2 
132 
Acetic acid C2H4O2 NO
+ 90, 
108 
NO+·CH3COOH, 
NO+·H2OCH3COOH 
133 
Hexanoic acid C6H12O2 H3O
+ 117, 
135 
C6H12O2H
+,C6H12O2H
+(H2O) 132 
Acetaldehyde 
 
C2H4O H3O
+ 45, 81 CH3CHOH
+, 
CH3CHOH
+(H2O)2 
134 
Formaldehyde CH2O H3O
+ 31 CH2OH
+ 134 
Acetone C3H6O H3O
+ 59, 77 C3H6OH
+, C3H6OH
+(H2O) 134 
Acetone C3H6O O2
+ 43, 58 C3H6O
+, C2H3O
+ 134 
Hydrogen 
sulphide 
H2S H3O
+ 35, 53 H3S
+, H3S
+(H2O) 129 
Phenol C6H6O H3O
+ 95, 
113 
C6H6OH
+, C6H6OH
+(H2O) 135 
Methyl phenol C7H8O O2
+ 108, 
126 
C7H8O
+, C7H8O
+(H2O) 135 
Ammonia NH3 O2
+ 17 NH3
+  83 
Hydrogen 
cyanide 
HCN H3O
+ 28 H2CN
+ 136 
Nitric oxide NO O2
+ 30 NO+ 83 
Table 4.1: A summary of analytical information of VOCs analysed by the MIM mode of SIFT-
MS using variously H3O
+, NO+ and O2
+ precursor ions and the m/z of characteristic product 
ions. 
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A total of 13 volatile compounds released from the headspace of gastric content were analysed 
using the MIM mode of the SIFT-MS. The analytical information, including chemical formula, 
precursor ions used, and the characteristic product ions and their m/z ratio are given in Table 
4.1. H3O
+ is the most used precursor ion as it readily protonates most VOCs. However, NO+ 
and O2
+ have also been employed for specific molecules, when they produce unambiguous 
characteristic product ion and the overlapping ions that sometimes occur when using H3O
+ 
precursor ions, e.g. propanol and acetic acid. 
 
 
 
Table 4.2: A summary of median concentrations and interquartile ranges (IQR) for those 
VOCs that were significantly different between cancer and healthy groups. (The results of 
positive control group are included for comparison). 1(The concentrations are measured in part-
per-billion by-volume, ppbv. The cancer group included all patients with a biopsy-confirmed 
oesophago-gastric cancer. The positive control group included all patients diagnosed with non-
cancer diseases of the upper gastro-intestinal tract. The Normal Upper GI cohort did not have 
any diseases of the upper gastro-intestinal tract and were H.pylori negative). 
                                                          
 
 
  OG Cancer Normal Upper GI 
tract 
Positive controls1 
VOCs Precursor 
ion 
Median IQR Median IQR Median IQR 
Acetaldehyde H3O
+ 77 [52-141] 29 [21-55] 63 [27-136] 
Acetone H3O
+ 94 [28-253] 26 [12-67] 24 [16-75] 
Formaldehyde H3O
+ 45 [36-52] 52 [40-72] 49 [36-77] 
Acetic acid NO+ 43 [32-73] 20 [16-39] 30 [19-100] 
Hexanoic acid H3O
+ 36 [20-269] 13 [11-71] 13 [10-196] 
Hydrogen 
sulphide 
H3O
+ 2.3 [0.8-5.5] 0.9 [0.4-1.9] 1.7 [0.8-2.2] 
Hydrogen 
cyanide 
H3O
+ 15.1 [7.7-25] 6.1 [4-10.5] 7.2 [3.7-13] 
Methanol H3O
+ 74 [53-160] 48 [39-69] 51 [36-91] 
Acetone O2
+ 296 [154-525] 96 [63-128] 178 [86-229] 
Methyl phenol O2
+ 17 [11-22] 8 [5-15] 12 [8-31] 
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Figure 4.3: Box-Whisker plots of the headspace median concentrations and interquartile 
ranges (part-per-billion by-volume, ppbv) of (A) acetaldehyde, (B) formaldehyde, (C) acetone, 
(D) acetic acid, (E) hexanoic acid and (F) pH measurements of the gastric content of cancer, 
positive control and normal upper GI groups. Acetaldehyde and formaldehyde and hexanoic 
acid were analysed using H3O
+ precursor ions, acetone were analysed using O2
+ ions, acetic 
acid was analysed using NO+ precursor ions. 
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Figure 4.4: Box-Whisker plots of the headspace median concentrations and interquartile 
ranges (part-per-billion by volume, ppbv) of (A) methanol, (B) methyl phenol, (C) hydrogen 
sulphide and (D) hydrogen cyanide from the gastric content of cancer, positive control and 
normal upper GI groups. Methanol, hydrogen sulphide and hydrogen cyanide were analysed 
using H3O
+ ions and methyl phenol was analysed using O2
+ precursor ions and in the SIFT-
MS.  
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4.1.4.4 VOCs within gastric content headspace to differentiate cancer from healthy controls   
Mann-Whitney U test (p-values ≤ 0.05) was performed for all the volatile organic compounds 
(listed in Table 4.1) to assess for any differences in median concentrations between oesophago-
gastric patients and people with healthy upper gastro-intestinal tracts. Eight metabolites were 
found to be statistically significantly different across the two groups including: 
 acetaldehyde (p = 0.01) 
 formaldehyde (p = 0.046) 
 hexanoic acid (p = 0.036)  
 acetic acid (p = 0.016)  
 acetone (p = 0.007)  
 hydrogen sulphide (p = 0.015)  
 hydrogen cyanide (p = 0.016)  
 methyl phenol (p = 0.01)  
 
Their median concentrations and interquartile ranges from cancer, normal upper GI and 
positive control groups are given in Table 4.2.  
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Figure 4.5: Receiver operating characteristics (ROC) curve of discrimination result for the 
diagnosis of oesophago-gastric cancer from normal upper GI controls using the combined 
VOCs of acetaldehyde, formaldehyde, hydrogen sulphide and methyl phenol. The integrated 
area under ROC curve (AUC) is 0.90. 
Using the statistically significant VOCs identified in the Mann Whitney U test, binary logistic 
regression analysis was performed to construct a discrimination model. The combination of 
acetaldehyde, formaldehyde, hydrogen sulphide and methyl phenol demonstrated the highest 
area under curve (AUC) for diagnosing cancer with a value of 0.90. Figure 4.5 demonstrates a 
high degree of discrimination between oesophago-gastric cancer and healthy controls with 
reasonable sensitivity and specificity using the aforementioned compounds. The result raises 
the prospect that a VOC profile rather than a single biomarker may be a preferable in the 
molecular-orientated diagnosis of oesophago-gastric cancer.  
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4.1.5 Discussion 
4.1.5.1 Aldehydes and Ketones  
Three short-chain carbonyl compounds, i.e., acetaldehyde, formaldehyde and acetone present 
in the headspace of gastric content were quantified using SIFT-MS. There is a decreasing trend 
in the median concentrations of acetaldehyde when comparing cancer, positive control and 
normal upper GI cohorts (Figure 4.3). The acetaldehyde concentrations of the cancer and 
positive control patients have similar median values 77 ppbv and 63 ppbv, as shown in Table 
4.2 and Figure 4.3. In comparison, the median value from the normal upper GI cohort (29 ppbv) 
is much lower than the cancer group. Furthermore, the majority of acetaldehyde concentrations 
in the normal upper GI cohort are less than 55 ppbv, while in the cancer and positive control 
groups, the majority of observed values are above 55 ppbv. Acetaldehyde is a metabolite of 
ethanol oxidation, but in recent years it has been classified as a Class I carcinogen. Several 
studies has postulated that deficiencies in enzymes involved in aldehyde metabolism may 
contribute to upper gastro-intestinal carcinogenesis; Oikawa et al. demonstrated that those 
deficient in aldehyde dehydrogenase II (ALDH2) in the presence of gastric hypochlorhydria 
are at increased risk of oesophageal squamous cell carcinoma137. Linderborg et al. reported that 
reducing acetaldehyde exposure in those with an achlorhydric stomach may be an important 
factor in reducing the risk of gastric cancer138.  
For formaldehyde, a slight increasing trend in median value from the cancer, positive control 
and normal upper GI groups is apparent (Figure 4.3). Formaldehyde has been associated with 
cancer states to varying degrees in previously reported studies. Fuchs et al. studied breath gas 
aldehydes using GC-MS in patients with lung cancer, smokers and healthy volunteers and 
found that concentrations of exhaled formaldehyde were significantly lower in smokers when 
compared to healthy volunteers and lung cancer patients63; there was however no difference 
observed between lung cancer patients and healthy volunteers. Spanel et al. studied 
formaldehyde in the headspace of urine from bladder cancer, prostate cancer and healthy 
controls83. This study demonstrated that formaldehyde was clearly elevated in the headspace 
of urine from cancer patients when compared to healthy controls83. The varying findings 
associated with formaldehyde in different biofluids and exhaled breath studies are difficult to 
explain and further investigation of formaldehyde in cancer is necessary.  
Acetone, the simplest of the ketones, was measured using both H3O
+ and O2
+ by SIFT-MS. It 
is the most abundant ketone body (the other two being beta-hydroxybutyric acid and 
acetoacetic acid) and is a product of lipolysis139. Elevated acetone levels have been observed 
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in people in starving states and specifically in diabetic ketoacidosis140,141,142. There is a 
decreasing trend in the median acetone values from the cancer, positive control to the normal 
upper GI groups (Figure 4.3). Patients in the cancer cohort demonstrated the highest 
concentrations of acetone. As shown in Figure 4.3, acetone values in the cancer group also 
have a much wider interquartile range of 154-525 ppbv in contrast to the positive control and 
normal upper GI groups. This observed increase in acetone may be related to the patient’s 
cancer status or may reflect a change in their underlying metabolism in response to disease. 
Patients with oesophago-gastric cancer often have difficulty in maintaining an adequate oral 
intake due to dysphagia and given their increased energy requirements, this can induce a state 
of malabsorption and weight loss. There is subsequently a reliance on ketogenic metabolic 
processes leading to a reduction in hepatic glycogen stores. The body’s natural response to 
depleted glycogen stores is to cleave triacylglycerol to produce fatty acid chains and glycerol. 
Through beta-oxidation, these fatty acids are utilized an alternative source of energy and 
produce acetyl Co-A. The liver utilizes the excessive acetyl Co-A leading to generation of 
ketone bodies, acetoacetate, β-hydroxybutyrate and acetone. This mechanism may be partially 
responsible for the increased concentrations of acetone in these patients. 
 
4.1.5.2 Acids 
Two organic acids were measured in the headspace of gastric content using SIFT-MS. Acetic 
acid is a metabolic intermediate for the generation of the tioester acetyl-CoA. Its presence has 
been shown in the exhaled breath of lung cancer patients using SIFT-MS143. As shown in 
Figure 4.3, acetic acid in the headspace of gastric content from the cancer cohort has a higher 
median value and wider interquartile range compared to the other two groups. The median 
value in the cancer group is found to be higher than that in the normal upper GI group, i.e., 43 
and 20 ppbv. Hexanoic acid has been previously been muted as a potential biomarker for cancer 
in a study of urine from patients with leukaemia, lymphoma and colorectal cancer70. Hexanoic 
acid is found to be significantly different between cancer and the other two control groups 
(Figure 4.3). The normal upper GI group, in particular, has a lower median and narrower 
interquartile range. The median concentration of hexanoic acid in the cancer group is 36 ppbv, 
i.e., approximately 3 times greater than the both the positive and normal Upper GI groups. As 
shown in Figure 4.3, compared to the positive and normal Upper GI controls, a much wider 
distribution of hexanoic acid values in the cancer group are observed (interquartile range 20-
269 ppbv).  
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The observed differences in the headspace acid concentrations between the 3 groups prompted 
analysis of the pH of the gastric content samples, because it was hypothesised that the higher 
acid concentrations would correlate with a lower pH of the gastric content. Gastric content can 
have a variable pH range depending on the respective contribution from gastric acid and bile 
reflux. This variation in pH, and specifically the hypoacidity, is believed to contribute to the 
pathogenesis of upper gastro-intestinal diseases. Lu et al. investigated gastric content acidity 
and found that both gastric cancer and gastric ulcer patients had a higher pH (6.6 and 3.4 vs 
2.9) than healthy controls123. As shown in Figure 4.3, the gastric content from the normal upper 
GI group has a median pH value of 1.93. The median pH of gastric content from the positive 
group is 5.67 and the median value for the cancer group is 6.18. The cancer cohort also has the 
widest pH range amongst the three groups. There were no differences in proton pump inhibitor 
or H2 receptor antagonist use amongst the three groups; many of these patients are started on 
such medications (i.e. for acid suppression) by their general practitioners prior to being referred 
for an OGD. However, from an analytical chemistry perspective, it can be postulated that a low 
pH would facilitate the release of volatile organic acids into the headspace vapour. However, 
the results from this study do not support this theory. Figure 4.3 shows that both the cancer and 
positive control groups (with higher median pH values) have higher measured concentrations 
of acetic acid and hexanoic acid than the normal upper GI controls. The pH of a biofluid 
represents one variable that may contribute to the measured volatile organic acid 
concentrations; however, other factors such as bacteria (e.g. H.pylori) or cancer cells may have 
a greater overall influence within gastric content. The potential influence of pH on the release 
of VOCs from gastric content in cancer and non-cancer is further reported in this chapter.  
 
4.1.5.3 Alcohol and Phenol derivatives 
Methanol, ethanol, phenol and methyl phenol were detected in the headspace of the gastric 
content. Methanol is a low molecular mass highly volatile compound that can be difficult to 
detect by GC-MS but which is readily detected and quantified by SIFT-MS. The measured 
median values for methanol demonstrate a decreasing trend from the cancer cohort to the 
normal upper GI group and positive control cohort (Figure 4.4). The methanol concentration 
from the gastric content of the cancer cohort shows the widest distribution in contrast to the 
other two groups. Ethanol levels within the headspace of gastric content were also measured 
during this study; however these values are difficult to interpret given the potential effects of 
exogenous ethanol sources (e.g. disinfectant hand gel) within the hospital. Boshier et al. have 
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previously investigated the level of volatile trace gases within the Imperial College NHS Trust 
environments. Median ethanol levels of 2136 ppbv and 733 ppbv were observed within ambient 
air collected from hospital wards in the morning and evening, respectively144. Therefore, 
caution must be exercised when interpreting ethanol data from patients in the hospital 
environment.   
As shown in Figure 4.4, the distribution of methyl phenol concentrations is similar among 
the cancer and positive control groups. Methyl phenol concentration from gastric content in the 
cancer group is found to have the largest median value (17 ppbv), followed by positive control 
group (12 ppbv) and the normal upper GI group (8 ppbv).  
 
4.1.5.4 Sulphur and nitrogen-containing compounds 
H2S and HCN are highly volatile compounds with low molecular weights, for which SIFT-MS 
has an advantage in analysing compared to GC-MS. The measured H2S and HCN levels 
showed large variation between cancer, positive control and normal upper GI groups. As shown 
in Figure 4.4 and Table 4.2, the median concentrations and interquartile ranges of H2S showed 
a decreasing trend from the cancer cohort (2.3 ppbv) to the normal upper GI group (0.9 ppbv). 
The HCN median value is 15.1 ppbv for the cancer group which is significantly higher than the 
other two groups. The measured median concentrations for positive control and normal upper 
GI groups were found to be similar, i.e., 6.1 and 7.2 ppbv, respectively. The other volatile 
organic compounds shown in Table 4.1 did not show any significant differences between the 
groups. Therefore, no further evaluation of these compounds was conducted in this study.  
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4.1.6 Conclusions 
This is the first study of VOC analysis of gastric content from patients with oesophago-gastric 
cancer, non-cancer diseases of the upper gastro-intestinal tract and those with normal upper 
gastro-intestinal tracts. A total of 13 VOCs have been analysed in the headspace of gastric 
content samples. Of these compounds, the headspace concentrations of eight VOCs (acetone, 
formaldehyde, acetaldehyde, acetic acid, hexanoic acid, hydrogen suphide, hydrogen cyanide 
and methyl phenol) were statistically different between the oesophago-gastric cancer group and 
the healthy cohort. The study highlights that VOC differences exist within the stomach 
environment between those with cancer and those with normal upper gastro-intestinal tracts. 
Moreover, gastric content represents a good surrogate biofluid that may improve our 
understanding of the pathogenesis of upper gastro-intestinal diseases. The clear differences in 
pH were most interesting given there was no difference in proton pump inhibitor or H2-receptor 
antagonist use amongst the 3 groups. The influence of pH on the production of abundant VOCs 
within urine headspace has previously been investigated by Smith & Španěl145. Ammonia 
concentrations significantly increased by making urine alkaline; abnormally high levels of 
nitric oxide were also observed in the headspace above acidified bacterially infected urine145. 
Hence, the influence of pH on the release of VOCs from gastric content is further investigated. 
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4.2 The effect of pH on VOCs in gastric content headspace 
4.2.1 Objective  
To evaluate the influence of pH on the VOCs in gastric content headspace, focusing on those 
VOCs that discriminate patients with oesophago-gastric cancer to those with normal upper GI 
tracts.  
 
4.2.2 Methods 
4.2.2.1 Gastric content sampling and storage 
All gastric content samples for this study were taken from patients undergoing an OGD and 
retrieved using a disposable suction jar (procedure described in section 4.1.3.2). Gastric content 
samples were stored in a -80°C freezer within 1 hour of collection. Studies have shown there 
is no decline in the quality of biofluids when stored in this state for several weeks145.  
 
4.2.2.2 Gastric content sample preparation & SIFT-MS analysis 
Gastric content samples were thawed on the day of analysis. A total of 5mL gastric content 
from the original suction jar was aliquoted into a standard 60 mL specimen jar.  The natural 
pH of a gastric content sample was measured using a Hanna pH meter HI 9124 (Sigma-Aldrich, 
Missouri, USA). The specimen jar was sealed with parafilm and then placed in an incubator at 
37 ̊C for five minutes prior to SIFT-MS analysis of the headspace. The sterile needle placed 
within the headspace of the gastric content liquid was connected to the SIFT-MS sampling port 
via 200cmVygon extension tubing. The headspace vapour was analysed using the same method 
described in section 1 of this chapter with the specimen jar, needle and extension tubing all 
being kept within the incubator at 37 ̊C. All the VOCs in this study - acetaldehyde, 
formaldehyde, hexanoic acid, acetic acid, acetone, hydrogen sulphide, hydrogen cyanide, 
methyl phenol - were quantified using the MIM mode and analysed using the same reagent 
ions, as described in section 4.1.4.3. After completion of MIM analysis of the sample in its 
natural state, 5mL of the same gastric content sample was taken from its original suction jar 
for each pH measurement. The sample was aliquoted into a standard 60mL specimen jar and 
its pH was altered through the addition of appropriate amounts of 0.1M HCl and 0.1M NaOH. 
Samples were investigated over the expected pH range of gastric content and hence analysis 
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was conducted at pH 1, 2, 4, 6 & 8; the pH levels were measured to an accuracy of 0.01 using 
the Hanna pH meter HI 9124 (Sigma-Aldrich, Missouri, USA) 
 
4.2.3 Results 
Twenty gastric content samples were analysed at pH 1, 2, 4, 6 & 8. There were 10 samples 
from patients with oesophago-gastric cancer and 10 samples from non-cancer controls (i.e., 
those with benign upper GI diseases and normal upper GI tracts). Gastric content samples were 
retrieved from 8 males & 2 females in OG cancer group and 7 males & 3 females in the non-
cancer control group. The median pH in the OG cancer and non-cancer controls was 4.8 (IQR 
4.0-7.5) and 1.3 (IQR 1.0-2.0), respectively. Figures 4.7 and 4.8 demonstrate the comparative 
analysis of the investigated VOCs at pH 1, 2, 4, 6 & 8. 
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Figure 4.6: Bar graphs of acetaldehyde, formaldehyde, hexanoic acid (HA) and acetic acid (AA) concentrations from the headspace of gastric 
content from non-cancer controls and patients with oesophago-gastric cancer. Comparative analysis of the groups at pH 1, 2, 4, 6 & 8 is shown.  
 
57 
 
Figure 4.7: Bar graphs of acetone, hydrogen sulphide (H2S), hydrogen cyanide (HCN) and methyl phenol concentrations from the headspace of 
gastric content from non-cancer controls and patients with oesophago-gastric cancer. Comparative analysis of the groups at pH 1, 2, 4, 6 & 8 is 
shown. 
 
58 
 
4.2.4 Discussion 
4.2.4.1 Aldehydes 
Acetaldehyde and formaldehyde were significantly increased at all pH levels in the oesophago-
gastric cancer group compared to controls (Figure 4.6). The production of acetaldehyde within 
the headspace vapour of gastric content demonstrated a similar trend in both groups, peaking 
at pH 6; this may partly explain why increased concentrations of acetaldehyde are observed in 
the headspace of gastric content of OG cancer and positive controls. The median acetaldehyde 
concentrations in gastric content headspace were 77 ppbv and 63 ppbv in the OG cancer and 
positive control groups, respectively. The median pHs in the same study were 6.18 and 5.67 
for the aforementioned groups. Jokelainen et al. investigated in vitro acetaldehyde formation 
by human colonic bacteria. They reported maximal acetaldehyde production at pH 9.6 but 
significant concentrations were also observed at pH 7.4 and 6146. The risk of upper GI 
malignancy is known to be markedly increased in ALDH2-deficient alcohol users compared to 
those with the normal enzyme93,94. The reduced ability of ALDH2-deficient persons to process 
acetaldehyde within the stomach environment may be a contributory factor in the development 
of these cancers. It has also previously been reported that reducing acetaldehyde exposure may 
decrease the risk of gastric cancer in patients with chronic gastric acid hyposecrection138. Thus 
the role of acetaldehyde in upper GI disease must be explored further. There was little influence 
of pH on formaldehyde concentrations within the headspace vapour of gastric content in both 
OG cancer and non-cancer controls (Figure 4.6). 
 
4.2.4.2 Acids 
Hexanoic acid and acetic acid were increased at all pH levels in the oesophago-gastric cancer 
group compared to non-cancer controls (Figure 4.6). Hexanoic acid concentrations were similar 
at pHs 1, 2 & 4 in the non-cancer controls with a sudden increase at pH 6; this is followed by 
a significant decline at pH 8. However, in the cancer cohort, the higher hexanoic acid 
concentrations within the headspace vapour of gastric content were maintained at pH 8. Acetic 
acid demonstrated a decreasing trend from pH 1 to 8 in the non-cancer controls (Figure 4.6). 
In the cancer cohort, acetic acid concentrations were maintained until pH 6 and decreased 
slightly at pH 8. These phenomena remain difficult to fully explain as one would expect the 
acid concentrations to decrease at neutral and alkali pH. It is hypothesised that other influential 
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factors such as H.pylori or the cancer cells may be stimulating the production of these acids 
within gastric content. 
 
4.2.4.3 Acetone & Methyl Phenol 
Acetone and methyl phenol concentrations were increased across all pH levels in the OG cancer 
group compared to non-cancer controls (Figure 4.7). Acetone concentrations were reduced at 
pH 6 & 8 in both groups. Španěl et al. previously reported that pH variation (i.e. from 4 to 8) 
had no effect on acetone concentrations within the headspace of urine145. The reduced 
concentrations of acetone observed at neutral and alkali pH in this study are most likely due to 
the biochemical differences between gastric content and urine. In healthy individuals, urine is 
sterile whereas gastric content is a complex biofluid interacting with the gut microbiome. 
Further studies utilising multiple reagent ions are necessary to verify the influence of pH on 
acetone within gastric content. There was a negligible effect of pH on the production of methyl 
phenol in both groups.  
 
4.2.4.4 Sulphur and nitrogen-containing compounds 
Hydrogen sulphide and hydrogen cyanide concentrations were increased across all pH levels 
in the OG cancer group compared to non-cancer controls (Figure 4.7). Hydrogen sulphide 
demonstrated a varying trend at different pH levels. In both the cancer cohort and non-cancer 
controls, H2S demonstrates a decreasing trend from pH 1 towards pH 4, followed by increases 
at pH 6 & 8 (Figure 4.7). In both the OG cancer group and non-cancer controls, HCN 
production from the headspace of gastric content peaked at pH 4 followed by significant 
decreases at pH 6 & 8 (Figure 4.7). The weakly acidic nature of HCN is likely to contribute to 
this trend.  
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4.2.5 Conclusions 
The results of this study demonstrate a significant influence of pH on the measured headspace 
levels of VOCs that may be of importance in oesophago-gastric cancer. In particular, the pH 
changes affecting acetaldehyde production are noteworthy. Acetaldehyde derived from alcohol 
is a human carcinogen and the observed increased production at pH 6 in OG cancer patients 
warrants further investigation. Within the stomach environment, there are several variables that 
may interplay to affect VOC production including gastric content, presence/absence of 
H.pylori, cancer cell metabolism and intra-gastric pH. The higher pH observed in gastric 
content with patients with benign diseases of the upper GI tract suggests higher intra-gastric 
pH is likely to be a causative factor preceding cancer development. Future studies should focus 
on the effects of varying pH on the growth of oesophageal and gastric cancer cell lines; this 
could provide us with new insights in the oncological proliferation of oesophago-gastric cancer.    
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Chapter 5   
 
VOCs in the headspace of urine 
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5.1 Objective  
To evaluate whether VOCs within the headspace of urine from patients with oesophago-gastric 
cancer are present at different concentrations to those with benign upper gastro-intestinal 
conditions and healthy persons. 
 
5.2 Introduction  
In the previous chapter, eight VOCs (viz. acetone, formaldehyde, acetaldehyde, acetic acid, 
hexanoic acid, hydrogen sulphide, hydrogen cyanide and methyl phenol) within gastric content 
were identified that were significantly different between cancer patients and a normal upper GI 
group. The results highlighted potential VOCs that may be important in the molecular 
orientated diagnosis of oesophago-gastric cancer. However, the retrieval of gastric content as 
part of a diagnostic test is not straightforward. Gastric content can only be retrieved either 
during an OGD or via a nasogastric (NG) tube, both of which are invasive procedures. If one 
is performing an OGD, then a tissue biopsy would be the ‘gold standard’ method for diagnosis 
confirmation. Insertion of a NG tube also causes patient discomfort and still has a small but 
non-negligible risk of morbidity147. The analysis of gastric content remains important to 
develop our insights into the pathogenesis of upper gastrointestinal malignancy. However, in 
order to develop a VOC-based diagnostic test for oesophago-gastric cancer, it would be 
preferable to utilize bio-samples that can be obtained non-invasively.  
Urine is a biofluid that can provide good information regarding the physiological or patho-
physiological state of a person. Hippocrates (~400 BC), the father of Western Medicine, 
visually assessed urine to interpret human body functioning and wrote “no other organ system 
or organ of the human body provides so much information by its excretion as does the urinary 
system”148. In ~ 700 AD, Theophilus developed uroscopy (the visual examination of urine) into 
a diagnostic tool and established systematic methods for its analysis149. One of the most well-
known historical examples of uroscopy relate to King George III (1738-1820), whose attending 
physicians noted unusual colours in his urine. It is believed that the ‘bilious’ and ‘bluish’ 
colours observed in the King’s urine and his concurrent episodes of insanity were due to 
porphyria150. Since that time, urinalysis has become a quick, cost-effective, routinely employed 
diagnostic test in clinical medicine. Urinalysis for the assessment of infection, protein, blood 
and ketone content is well established and urine-based pregnancy testing kits can be purchased 
over the counter. However, urine vapour is chemically complex with over 280 VOCs present46. 
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Urine, in particular, is considered an ideal biofluid for VOC analysis, because it is obtained by 
non-invasive sampling and relatively large volumes can be retrieved.  
The contemporaneous technological advances in gas phase analytical techniques have 
allowed scientists to measure VOCs developed in the headspace of urine at concentrations 
down to parts-per-billion by volume (ppbv). Several mass spectrometric techniques have been 
employed to study metabolites present in urine from patients with specific cancer states. Hu et 
al. developed an experimental model using mice implanted with human gastric cancer SGC-
7901 cells to predict gastric cancer metastasis through urinary metabolonomic 
investigations151. They employed GC-MS and demonstrated that 10 metabolites differentiated 
cancer from controls. Smith & Španěl performed the first study on the analysis of formaldehyde 
in the headspace of urine samples from patients with bladder cancer and prostate cancer using 
SIFT-MS83. In this study, they observed elevated levels of formaldehyde in the headspace of 
urine samples from patients with bladder cancer (mean concentration 85 ppbv) and prostate 
cancer (mean concentration 25 ppbv) compared to healthy controls (mean concentration 11 
ppbv)83. Issaq et al. employed liquid chromatography-mass spectrometry (LC-MS) to 
discriminate between healthy urine specimens and bladder cancer urine samples152. By 
employing principal component analysis, PCA, they were able to correctly predict 46 of 48 
healthy and 40 of 41 bladder cancer urine samples152. Cheng et al. analysed urine samples from 
patients with colorectal cancer and healthy controls with time-of-flight mass spectrometry 
coupled with GC and LC (GC-TOF-MS and LC-TOF-MS)153. They observed a distinct urinary 
metabolic footprint for the colorectal cancer cohort - a panel of metabolite markers including 
citrate, hippurate, cresol, 2-aminobutyrate, myristate, putrescine, and kynurenate were able to 
discriminate colorectal cancer patients from controls153. Guadagni et al. developed a 
Headspace-SPME/GC-MS method for the analysis of hexanal and heptanal in urine69. In this 
study, higher urinary concentrations of hexanal were found in the lung cancer cohort compared 
with controls69. . Hanai et al. investigated urinary VOCs in patients with lung cancer using GC-
TOF-MS, identifying nine VOCs - tetrahydrofuran, 2-chloroethanol, 2-pentanone, 2-
methylpyrazine, cyclohexanone, 2-ethyl-1-hexanol, 2-phenyl-2-propanol, isohorone and 2,6-
diisopropylphenol - to be increased in the lung cancer cohort compared with controls154. They 
also reported that 2-pentanone may have utility in differentiating between adenocarcinoma and 
squamous cell carcinomas of the lung154. The above animal and human studies have all 
demonstrated promising early results through urine profiling in cancer disease states.  
Both GC-MS and LC-MS are offline mass spectrometric techniques requiring 
appropriate column selection155,156. It is also necessary to optimize storage of urine as well as 
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undertake pre-analysis preparation methods. Therefore, analytical processing times are lengthy 
and VOCs with low molecular weight can be difficult to accurately quantify with GC-MS or 
LC-MS157. In comparison to these techniques, SIFT-MS has the advantage of online, real-time 
VOC quantification without the need for any pre-concentration steps. The analysis of VOCs 
emitted from the headspace of urine using SIFT-MS has been reported in several 
studies83,158,159. 
As mentioned at the beginning of this Introduction, several VOCs that were 
significantly different between cancer and healthy controls were identified in the headspace 
vapour of gastric content. For this study, urine was selected as the biofluid of choice for 
investigation. It was hypothesized that the VOCs of the urine retrieved from patients with 
oesophago-gastric cancer would differ from non-cancer controls. It was also postulated that 
several of the VOCs identified in the headspace of the gastric content of oesophago-gastric 
cancer patients may be present in the headspace of the urine of cancer patients, reflecting a 
systemic signature of the disease. This study also constitutes the first investigation of VOCs 
using the SIFT-MS platform for the headspace analysis of urine of oesophago-gastric cancer 
patients.  
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5.3 Methods 
5.3.1 Patient selection  
Patients for this study were recruited through St. Mary’s Hospital, Paddington (Imperial 
College NHS Trust, London) and via the North West Thames regional oesophago-gastric 
cancer network (UK). As before, all patients provided a comprehensive medical history, 
including past medical history, medications as well as smoking status and alcohol intake. 
Demographic and clinical data for each patient were archived in a linked, anonymised database. 
The same exclusion criteria described in section 4.1.3.1 was exercised for this study. Patients 
with a current or past medical history of significant kidney/bladder disease were also excluded. 
The cancer and positive control groups were recruited following the same criteria in section 
4.1.3.1. The ‘healthy’ cohort in this study had no upper gastro-intestinal symptoms and no past 
medical history. Local ethics committee approval was obtained for this study. Patients eligible 
for the study were given information sheets pertaining to the study and written informed 
consent was obtained prior to enrolment in the study. The comparative analysis of urine vapour 
metabolites was conducted with an oesophago-gastric cancer cohort of 17 patients, a positive 
control group of 14 patients and a ‘healthy’ group of 13 patients.    
 
5.3.2 Urine sampling procedures 
All patients and healthy participants had fasted for a minimum of 6 hours with no oral intake 
prior to urine sampling. Urine samples were all retrieved from patients prior to undergoing 
their scheduled gastroscopies. Study participants were requested to pass urine into a 
standardized 60 mL urine specimen vial, which was immediately sealed. All samples were 
taken to the Surgical Sciences laboratory located within the hospital and analysed within 1 hour 
of collection. The pH of each urine sample was measured immediately after SIFT-MS analysis 
using a Hanna Piccolo® pH meter (Sigma-Aldrich, Missouri, USA). All urine samples also 
underwent urine dipstick analysis (Siemens Multistix 8G) to assess for any infection. Any 
samples with dipstick-proven evidence of infection were excluded from final analysis. 
 
 
 
 
66 
 
5.3.3 SIFT-MS analysis of urine headspace 
In this study, the full-scan mode (FS) of the SIFT-MS was initially employed to identify VOCs 
of interest in the headspace vapour of the urine samples. Using H3O
+ and NO+ precursor ions 
individually, the downstream analytical mass spectrometer system was scanned from m/z 10 to 
200 for 9 x 60 seconds period. H3O
+ and NO+ full scan spectra were produced that revealed the 
characteristic product ions, which allowed the identification and quantification of specific 
VOCs using the standardized kinetics library53. The O2
+ precursor ion is suitable for the 
detection and quantification of specific molecules (e.g. NH3). However, it was not used for FS 
analysis, as the majority of VOCs investigated in this study were best analysed by H3O
+ and 
NO+. The O2
+ reagent ion was only used in MIM mode for the detection and quantification of 
one VOC - methyl phenol.  
For the accurate quantification of selected VOCs of interest, multi-ion monitoring mode 
(MIM) was primarily employed in this study. Prior to MIM headspace analysis of a urine 
sample, the calibration procedure using the water content of the operator’s exhaled breath (6 
+/- 0.1%) was carried out to check the sample flow rate settings of the instrument. The absolute 
concentrations of the volatile compounds present in the headspace of the urine samples were 
obtained over a chosen period of analysis using the in-built SIFT-MS software that utilizes the 
known rate coefficients of the reactions between reagent ions and selected volatile organic 
compounds contained in the in-built kinetics library53. In the MIM mode, selected VOCs from 
the urine headspace were analysed for a total of 60 seconds and the measured concentrations 
were averaged over the analysis time for each VOC. For each measurement, a total of 10 mL 
urine was aliquoted into a standard 60 mL specimen vial. The specimen vial was sealed with 
parafilm and then placed in an incubator at 37 ̊C for five minutes prior to analysis. As before, 
a 21g Luer-lock sterile hypodermic needle was connected to a 200 cm Vygon extension tube 
that was directly connected to the inlet port of the SIFT-MS instrument. The sterile needle 
punctured the parafilm layer of the specimen vial to sample the headspace above the liquid. 
The headspace vapour automatically flowed into the helium carrier gas at a fixed rate through 
the sampling line that was held at a temperature of 80 ̊C. For the duration of the analysis, the 
specimen vial, needle and extension tubing were all kept within the incubator at 37 ̊C. 
Measurements of VOCs within the background laboratory room air were also recorded. 
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5.3.4 Statistical analysis  
Statistical analysis was performed using IBM SPSS statistics 20 (SPSS Inc., Chicago, IL). 
Kruskal-Wallis one-way analysis of variance was used to compare the measured concentrations 
of VOCs between cancer patients, positive controls and healthy controls. The Mann-Whitney 
U test was used to compare the measured concentrations of acetone between the cancer cohort 
and positive controls. Receiver operating characteristic (ROC) curves were used to determine 
the accuracy of a diagnostic test in classifying subjects into those with and without disease. 
The ROC curves were constructed using the same method described in section 4.1.3.4. In this 
study, the statistically significant VOCs identified by the Kruskal-Wallis test, which showed a 
difference between cancer and the non-cancer controls (including both positive and healthy 
controls), were included as variables for the ROC curve. To construct the ROC curve, the 
disease conditions were used as the dependent variable, and the sum concentration of selected 
VOCs was used as the independent variable. To select the VOCs, different combinations of the 
statistically significant ones were tested using a binary logistic regression analysis to obtain the 
discrimination model with the highest R2 and the AUC value for the ROC curve. A p-value ≤ 
0.05 was taken as the level to indicate statistical significance, in keeping with most clinical 
studies. 
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5.4 Results 
5.4.1 Analysis of full scan spectra using H3O
+ and NO+ 
Figure 5.1: Full scan spectra of the headspace of urine using (a) H3O
+ precursor ion (b) NO+ 
precursor ion. The individual characteristic product ions and their hydrates were assigned to 
the analyzed molecules. In (a), m/z 19, 37, 55, 73 are H3O
+(H2O)0,1,2,3; m/z 33, 51, 69, methanol; 
m/z 47, 65, 83, ethanol; m/z 43, propanol; m/z 45,81, acetaldehyde; m/z 35, hydrogen sulphide; 
m/z 117,135, hexanoic acid. In (b), m/z 19, 37, 55, 73 are H3O
+(H2O)0,1,2,3; m/z 30, 48, 66, 84 
are NO+(H2O)0,1,2,3; m/z 88 is acetone; m/z 90, 108 is acetic acid; m/z 94, 112 is phenol. 
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Full scan (FS) spectra were obtained when the headspace vapour of urine was introduced into 
the helium carrier gas. Several VOCs of interest were clearly identified. As shown in Figure 
5.1(a), the representative spectrum using H3O
+ clearly shows the presence of the precursor ion 
H3O
+ and its water hydrates (m/z 19, 37, 55 and 73), due to the humidity of the urine sample 
(typically 6% by volume of water vapour). Important VOCs, such as methanol, ethanol, 
propanol, acetaldehyde and hydrogen sulphide were unambiguously identified by their 
characteristic product ions. Similarly, Figure 5.1(b) shows the presence of NO+ precursor ions 
and its associated hydrates (m/z 30, 48, 66 and 84); acetone, acetic acid and phenol, which are 
detected using NO+ ion, are also clearly shown. Furthermore, full scan spectra were also used 
to identify those VOCs showing overlapped product ions and hence these were excluded from 
further MIM mode analysis.  
 
5.4.2 Reproducibility and validity of the sampling method  
Additional experiments were conducted to assess the inter-sample reproducibility of headspace 
analysis using the exact methods described above. Ten healthy volunteers (with no medical 
history) were recruited and requested to provide 2 urine samples each. A total of twenty urine 
samples were analysed using the MIM mode for selected VOCs. The inter-sample coefficient 
of variation (CV) was calculated for the measured concentration of several VOCs from the 
headspace vapour of the urine. These CV values obtained in percent are: acetaldehyde, 8.7%; 
acetone, 22.6%; acetic acid, 15.8%; hexanoic acid, 27.8%; methanol, 44.5%; ethanol, 9.9%; 
phenol, 19.3%; methyl phenol, 41.2%; ethyl phenol, 26.0%; hydrogen sulphide, 38.3%. These 
coefficients of variation demonstrate the reproducibility of the MIM measurement.  
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5.4.3 MIM analysis of selected VOCs in the headspace of urine 
Compounds Molecular 
formula 
Precursor 
ions 
m/z Characteristic product 
ions 
REF 
Methanol CH4O H3O
+ 33, 51, 
69 
CH5O
+, CH5O
+(H2O), 
CH5O
+(H2O)2 
129 
Ethanol 
 
C2H6O H3O
+ 47, 65, 
83 
C2H7O
+, C2H7O
+(H2O), 
C2H7O
+(H2O)2 
129 
Propanol C3H8O H3O
+ 43 C3H7
+ 129 
Hydrogen 
sulphide 
H2S H3O
+ 35, 53 H3S
+, H3S
+(H2O) 129 
Hexanoic acid C6H12O2 H3O
+ 117, 135 C6H12O2H
+, 
C6H12O2H
+(H2O) 
129 
Acetaldehyde C2H4O H3O
+ 45, 81 CH3CHOH
+, 
CH3CHOH
+(H2O)2 
134 
Acetone C3H6O NO
+ 88 NO+·C3H6O 
134 
Acetic acid C2H4O2 NO
+ 90, 108 NO+·CH3COOH, 
NO+·H2OCH3COOH 
129 
Phenol C6H6O NO
+ 94, 112 C6H6O
+, C6H6O
+(H2O) 135 
Ethyl phenol C8H10O NO
+ 122, 140 C8H10O
+, C8H10O
+(H2O) 135 
Methyl phenol C7H8O O2
+ 108, 126 C7H8O
+, C7H8O
+(H2O) 135 
Table 5.1: A summary of analytical information of 11 volatile organic compounds detected 
and quantified by the MIM mode of SIFT-MS using H3O
+, NO+ and O2
+ precursor ions.  
 
As shown in Table 5.1, a total of 11 volatile organic compounds released from the headspace 
of urine were analysed using the MIM mode of the SIFT-MS. The analytical information, 
including chemical formula, precursor ions, m/z values and characteristic product ions are 
given. H3O
+ is the most frequently used precursor ion as it reacts with more compounds than 
the other two precursor ions. However, NO+ has also been employed for specific molecules 
when it has an advantage in unambiguously detecting and quantifying these compounds over 
H3O
+ (i.e., when there are known overlaps with other product ions). 
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  Cancer cohort Positive controls Healthy controls Room air Kruskal-Wallis 
test 
VOCs Median IQR Median IQR Median IQR Median IQR p-value 
Acetaldehyde 140 [68-210] 92 [69-140] 58 [49-59] 7 [3-11] p < 0.001 
Acetone 1326 [646-
3281] 
882 [552-
1584] 
265 [206-357] 6 [3-10] p < 0.001 
Methanol 216 [172-
277] 
210 [159-276] 70 [56-102] 38 [30-50] p < 0.001 
Phenol 12 [9-29] 14 [11-35] 34 [28-50] 2 [1-3] p = 0.019 
Acetic acid 40 [27-90] 59 [46-103] 25 [20-36] 5 [3-5] p = 0.004 
Hexanoic acid 66 [27-263] 20 [11-41] 18 [11-32] 1 [0-3] p = 0.006 
Hydrogen 
sulphide 
11 [6-26] 8 [4-13] 3 [1-4] 0 0 p < 0.001 
 
Table 5.2: A summary of median concentrations and interquartile ranges (in ppbv) for the 7 VOCs that were significantly different between 
oesophago-gastric cancer and non-cancer controls. Results of Kruskal-Wallis one-way analysis of variance for the VOCs that are different between 
cancer, positive control and healthy samples are included. There are 17 patients in the cancer cohort, 14 patients in the positive control group and 
13 patients in the ‘healthy’ control group. Laboratory room air concentrations for each of the VOCs are also included.  
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Figure 5.2: Box-Whisker plots of the median concentrations and interquartile ranges (part-per-
billion by-volume, ppbv) of (a) acetaldehyde, (b) acetone measurement of the headspace 
vapour of urine of oesophago-gastric cancer patients, positive controls and healthy groups. 
Laboratory room air concentrations for each of the volatile organic compounds are also 
included for comparison. 
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Figure 5.3: Box-Whisker plots of the median concentrations and interquartile ranges (part-per-
billion by-volume, ppbv) of hydrogen sulphide measurement of the headspace vapour of urine 
of oesophago-gastric cancer patients, positive controls and healthy groups.  
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Figure 5.4: Box-Whisker plots of the median concentrations and interquartile ranges (part-per-
billion by-volume, ppbv) of (a) acetic acid (b) hexanoic acid measurement of the headspace 
vapour of urine of OG cancer patients, positive controls and healthy groups. Laboratory room 
air values for each of the volatile organic compounds are also included for comparison. 
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Figure 5.5: Box-Whisker plots of the median concentrations and interquartile ranges (part-per-
billion by-volume, ppbv) of (a) methanol, (b) phenol, measurement from the headspace vapour 
of urine of OG cancer, positive control and healthy groups. Laboratory room air concentrations 
for each of the VOCs are also included for comparison. 
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5.4.4 pH measurements of urine 
 
Figure 5.6: pH measurement of urine of oesophago-gastric cancer patients, positive controls 
and the healthy group.  
 
The normal pH of the urine is approximately 6.7. Španěl & Smith have reported that pH 
variations (from 4 to 8) do not influence the measured concentrations of several VOCs 
(including acetone, ethanol and methanol), which are released from urine to the headspace 
vapour145. As shown in Figure 5.6, the urine from the healthy group has a pH value of 6.0 ± 
0.6. The mean pH of urine from the positive group is 6.4 ± 1.2 and the mean value for the 
cancer group is 6.3 ± 1.2. The cancer cohort demonstrated the widest pH range amongst the 
three groups. However, there was no significant difference in pH across the three groups and 
therefore no further investigation of the influence of pH on VOC concentrations within urine 
was undertaken.   
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5.4.5 VOCs within urine headspace to differentiate OG cancer from non-cancer controls 
Kruskal-Wallis one-way analysis of variance (p-value ≤ 0.05) was performed for all the volatile 
organic compounds listed in Table 5.1, to assess any differences in median concentrations 
between the three groups. Seven metabolites were found to be statistically significant different 
across the three groups, including acetaldehyde (p < 0.001), acetone (p < 0.001), acetic acid (p 
= 0.004), hexanoic acid (p = 0.006), hydrogen sulphide (p < 0.001), methanol (p < 0.001) and 
phenol (p = 0.019), five of these compounds also being significant in the headspace analysis of 
gastric content. Their median concentrations and interquartile ranges from cancer, healthy and 
positive control groups are given in Table 5.2. 
Using the six statistically significant VOCs, which demonstrated an increased concentration in 
the cancer cohort, a binary logistical regression analysis was performed to construct a ROC 
model. The sum concentrations of acetaldehyde, acetone, acetic acid, hexanoic acid, hydrogen 
sulphide and methanol demonstrated the highest area under the curve, discriminating cancer 
from both control groups with a value of 0.904. Figure 5.7 below demonstrates a high degree 
of discrimination between oesophago-gastric cancer and non-cancer controls (both positive and 
healthy control groups) with a good sensitivity and specificity using the aforementioned 
compounds.  
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Figure 5.7: Receiver operating characteristics (ROC) curve of discrimination result for the 
diagnosis of oesophago-gastric cancer from non-cancer controls using the sum concentrations 
of acetaldehyde, acetone, acetic acid, hexanoic acid, hydrogen sulphide and methanol 
exhibited, respectively. The AUC is 0.904.  
Of note, is that both acetaldehyde and hydrogen sulphide were previously identified as VOCs 
in the ROC curve constructed in the study on headspace analysis of gastric content. Given these 
VOCs have been influential in separate ROC curves from 2 different biofluids in oesophago-
gastric cancer, further studies are necessary to establish whether certain VOCs are systemically 
raised in cancer states. Moreover, this result provides further evidence that a VOC profile may 
be most appropriate for molecular orientated diagnosis in OG Cancer; it could also have a 
potential therapeutic monitoring role in the surveillance of disease recurrence. 
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5.5 Discussion 
5.5.1 Aldehydes and Ketones  
Two short-chain carbonyl compounds, i.e., acetaldehyde, and acetone, were detected in the 
headspace of urine. There is a significant decreasing trend in the median concentrations of 
acetaldehyde when comparing cancer, positive control and healthy cohorts, which is the same 
trend that was observed in the analysis of the headspace of gastric content (Figure 5.2). The 
median acetaldehyde concentration of the cancer is 140 ppbv, and positive control patients have 
a median value of 92 ppbv.  In comparison, the median value from the healthy group is 58 
ppbv, which is much lower than that of the cancer group. Furthermore, the majority of 
acetaldehyde values in the healthy cohort are less than 60 ppbv, while in the cancer and positive 
control groups, the majority of observed values are above 60 ppbv. As shown in Table 5.2, in 
sampling our laboratory air, we observed a median acetaldehyde concentration of 7 ppbv; this 
value highlights the negligible contribution from the surrounding environment. There is 
significant evidence linking acetaldehyde and carcinogenesis. Fanelli et al. examined the 
effects of acetaldehyde accumulation in rat mammary tissue and concluded that this may be a 
critical event in the development of breast cancer96. Väkeväinen et al. reported that microbial 
ethanol metabolism in achlorhydric atrophic gastritis after alcohol ingestion leads to high intra-
gastric acetaldehyde levels160. The group postulates that the higher levels of intra-gastric 
acetaldehyde may be one of the factors contributing to the increased risk of gastric cancer in 
atrophic gastritis patients. The evidence from both headspace studies for acetaldehyde within 
biofluids in patients with oesophago-gastric cancer as well as significant animal model and 
epidemiological evidence indicate that the potential role of acetaldehyde should be further 
evaluated.  
Acetone is generally observed as the most abundant ketone body in urine (the other two 
being beta-hydroxybutyric acid and acetoacetic acid)161. As shown in Figure 5.2, the acetone 
values in the cancer group also have a much higher interquartile range of 646 to 3281 ppbv in 
comparison to the healthy cohort, 206 to 357 ppbv. There is a clear decreasing trend of acetone 
concentration in the headspace of urine in the cancer, positive control and healthy groups which 
is the same trend observed in the previous study on gastric content. In contrast to the cancer 
group, although the positive control group has a smaller median concentration of acetone (882 
ppbv vs 1326 ppbv), the interquartile range of acetone from positive control (552 to 1584 ppbv) 
falls within the range of the oesophago-gastric cancer group (646 to 3281 ppbv). A Mann-
Whitney U test was performed to compare the acetone concentrations between the cancer and 
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positive group and the difference was not found to be significant (p = 0.250). Several studies 
have also reported increased acetone concentrations in urine, blood and breath in various cancer 
states. Shariff et al. characterized urinary biomarkers in hepatocellular carcinoma (HCC) in 
patients of Nigerian descent using Nuclear Magnetic Resonance (NMR) spectroscopy162. In 
this study, acetone was identified as one of the most influential metabolites in multivariate 
models that distinguished HCC from patients with cirrhosis and healthy individuals162. Hasim 
et al. reported markedly increased blood plasma acetone concentrations in patients with poorly 
differentiated oesophageal cancer compared with patients with well differentiated oesophageal 
cancer163. Zhang et al. employed NMR spectroscopy to distinguish pancreatic cancer from 
chronic pancreatitis and healthy individuals164. Their group reported elevated levels of acetone 
in blood plasma of patients with pancreatic cancer compared with controls164. Ulanowska et al. 
observed an increased concentration of acetone in the exhaled breath of patients with lung 
cancer compared with controls (including active smoker, passive smoker and non-smokers)165. 
The observed increase in acetone in this study may be related to the patient’s underlying cancer 
status or may reflect a changed physiological state of the patient in response to disease. 
Furthermore, patients with oesophago-gastric cancer can often be malnourished due to 
dysphagia or the systemic effects of cancer, resulting in a dependence on ketogenic metabolic 
processes. 
 
 
5.5.2 Sulphur compounds 
Hydrogen sulphide (H2S) is produced by anaerobic bacteria in the colon or can be synthesized 
endogenously from L-cysteine166,167. Ramasamy et al. reported that increased levels of 
hydrogen sulphide in the human colon may be a contributory factor in the development of 
colorectal cancer168. Chávez-Piña et al. studied the effects of endogenous hydrogen sulphide 
in a rat model169. They demonstrated that inhibition of endogenous hydrogen sulphide protects 
against ethanol-induced gastric damage169. Yamagishi et al. reported the concentrations of 
sulphur-containing compounds (including hydrogen sulphide) in the flatus of colorectal cancer 
patients were significantly higher than in healthy individuals170. Their study also demonstrated 
that gaseous sulphur-containing compounds are generated in tumour tissues170. H2S is a highly 
volatile compound and has a low molecular weight; GC-MS is often not capable of detecting 
H2S. SIFT-MS has an advantage in analysing these types of compounds in comparison to GC-
MS techniques. The measured H2S concentrations of the cancer and positive control groups 
showed similar values, 11 and 8 ppbv respectively. However, only trace quantities of H2S were 
81 
 
detected in the headspace of the urine from healthy control group, i.e., 3 ppbv. There was a 
large variation in the measured H2S levels between oesophago-gastric cancer, positive control 
and healthy groups, with those from the cancer cohort having the widest interquartile range 
(Figure 5.3). The decreasing trend of H2S in the headspace of urine from the cancer cohort to 
the healthy control group was also observed in the study on the headspace of gastric content. It 
is postulated that the increased concentrations of hydrogen sulphide observed in both biofluids 
of the cancer patients may reflect H2S production by cancer cells (as observed by Yamagishi 
et al.170) or may be due to alterations in gut microbiota in response to cancer.  
 
5.5.3 Acids 
Acetic acid and hexanoic acid were detected in the headspace of the urine samples. Acetic acid 
can be quantified using both H3O
+ and NO+ using SIFT-MS. However, the true concentration 
of acetic acid can be lost among the interferences from the possible isobaric compounds such 
as methyl formate and propanol which also have a molecular weight of 60. This problem is 
increased when humid exhaled breath is analysed as these compounds can form hydrates of 
characteristic product analytical ions113. Pysanenko et al. studied the ion chemistry of acetic 
acid using SIFT-MS; they reported that the most reliable identification and quantification of 
acetic acid from methyl formate within a vapour is achieved using NO+ precursor ion158. Hence, 
the NO+ precursor ion was selected to analyse acetic acid in this study. As shown in Figure 5.4, 
acetic acid in the headspace of urine from the cancer cohort and positive controls has a higher 
median value and wider interquartile range, in contrast to the healthy group. The median 
concentration in the cancer group was ~ 40% higher than that in the healthy group, i.e., 40 and 
25 ppbv, a virtually identical trend to that observed in the headspace analysis of gastric content. 
Hasim et al. also reported elevated levels of acetate in the NMR profile of urine in patients 
with oesophageal cancer compared with healthy controls163. Urinary 5-hydroxyindole acetic 
acid (5-HIAA) is a metabolite that is routinely measured in the diagnosis and monitoring of 
carcinoid tumours171. However, it is evident that the increased acetic acid concentrations within 
urine are not oesophago-gastric cancer-specific, given the similar median values observed in 
both the cancer and positive control groups.  
Hexanoic acid is found to be significantly different between cancer and the other two control 
groups (Figure 5.4). Both positive and healthy control groups have similar medians and 
interquartile ranges. The median concentration of hexanoic acid in the cancer group is 66 ppbv, 
whilst the positive and healthy controls have median concentrations of 20 and 18 ppbv, 
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respectively. As shown in Figure 5.4, compared to the positive and healthy controls, a much 
wider distribution of hexanoic acid values is observed in the cancer cohort (interquartile range 
27-263 ppbv). This result again displays a similar trend to the hexanoic acid concentrations 
reported in the headspace of gastric content from patients with oesophago-gastric cancer. Silva 
et al. have reported lower levels of hexanoic acid in the urine of patients with colorectal cancer, 
leukaemia and lymphoma compared to normal controls70; however these samples were 
analysed with GC-MS and there were no patients with upper gastrointestinal malignancy 
included in this study70. Hexanoic acid is increased within the headspace of gastric content and 
urine of the cancer patients in these studies and hence this VOC may be specific to oesophago-
gastric cancer.  
 
5.5.4 Alcohols and Phenol derivatives 
Methanol, ethanol, propanol, phenol, methyl phenol and ethyl phenol were investigated in the 
headspace of the urine samples. Of these compounds, only methanol and phenol demonstrated 
a statistically significant difference across the three groups. The methanol concentration in the 
headspace of urine samples of the cancer cohort and positive control groups demonstrated a 
similar median concentration (216 ppbv and 210 ppbv respectively). The measured median 
values for methanol demonstrate a significant decreasing trend from the cancer cohort to the 
healthy group, as shown in Figure 5.5. A similar decreasing trend for methanol was also 
observed in the headspace analysis of gastric content in oesophago-gastric cancer patients, 
although this result was not statistically significant. In comparison to the other significant 
VOCs, a higher background laboratory room air value for methanol was observed. However, 
as shown in Table 5.2, this value is much lower than the median concentrations measured in 
both cancer and positive control groups. Garner et al. studied VOCs emitted from stool samples 
collected from asymptomatic donors and patients with infective diarrhoea and ulcerative 
colitis172. They investigated the headspace of the faeces samples using GC-MS and observed 
that methanol was present more frequently in patients with Campylobacter jejuni infection and 
ulcerative colitis compared to the asymptomatic donors172. Caldwell studied the effects of 
methanol on the growth of representative, anaerobic gut bacteria173. He demonstrated that the 
growth of many organisms was completely inhibited by higher concentrations of methanol. 
Many of these bacteria have a protective role in the human gut and the higher concentrations 
of methanol may have a role in the pathogenesis of gastro-intestinal diseases. 
In this study, phenol was measured with the NO+ precursor ion to avoid 
acetoneH+(H2O)2 at m/z 95 that occurs with the H3O
+ precursor ion. The measured phenol 
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concentrations in cancer and positive controls were similar (12 and 14 ppbv), while the healthy 
group has a higher phenol concentration in comparison (34 ppbv), as shown in Figure 5.5. In 
the previous study on the headspace analysis of gastric content, there was a significant 
difference in the concentration of methyl phenol between the cancer cohort and controls. 
Phenol is also the most frequently observed VOC in the gastric content of patients with 
oesophago-gastric cancer (Appendix B). Ling et al. have reported that urinary phenols can be 
up to 10-times higher than the concentrations of phenol found in the serum of the same 
individuals174. McDonald et al. hypothesized that the higher concentrations of phenol observed 
in the urine reflect efficient removal of phenol from the blood and subsequent excretion175. It 
is postulated that the lower concentrations and tight interquartile range of urinary phenols 
observed in the cancer group in this study may be due to impaired phenol excretion. 
Dysfunction of phenol or its derivatives may be due to alterations in tyrosine metabolism by 
gut bacteria or impairment in the mechanisms that remove these compounds from the blood.  
 
The other volatile organic compounds shown in Table 5.1 did not show any significant 
differences between the groups. Hence, no further consideration was given to these compounds 
in this study. Ten measurements of laboratory room air concentrations of acetaldehyde, 
acetone, acetic acid, hexanoic acid, hydrogen sulphide, methanol and phenol were also 
recorded. As shown in the figures above, the room air concentrations of all the VOCs are trace 
in comparison to the measured concentrations from the headspace of patients’ urine samples. 
Thus, the potential exogenous contribution of background laboratory room air to the measured 
concentrations of the VOCs in the headspace of the urine samples is deemed negligible.  
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5.6 Conclusions 
This is the first study of headspace analysis of urine from patients with oesophago-gastric 
cancer and non-cancer controls using the SIFT-MS platform. Real-time analysis of urine 
headspace without the need for pre-concentration treatment was conducted using this platform; 
this is particularly advantageous in a clinical environment setting whereby samples can be 
readily retrieved and processed within an hour. A total of 11 VOCs were analysed in the 
headspace of urine obtained from the above cohorts. Of these compounds, the concentrations 
of 7 VOCs (acetaldehyde, acetone, methanol, hexanoic acid, acetic acid, hydrogen sulphide 
and phenol) were statistically different between the oesophago-gastric cancer group and non-
cancer controls. Several VOCs which differentiated oesophago-gastric cancer from healthy 
controls from the headspace analysis of gastric content have also been identified. The increased 
concentrations of specific VOCs observed in two separate biofluids in patients with oesophago-
gastric cancer are noteworthy and may reflect the systemic effects of the disease. OG Cancer 
is known to have poor 5-year cancer survival outcomes18,19. One of the preferred approaches 
for improving oncological survival lies in the earlier diagnosis of these cancers through targeted 
screening. Urine is an ideal biofluid that would be suitable for development as a non-invasive 
diagnostic test in oesophago-gastric cancer. It can be retrieved without causing any patient 
discomfort and relatively large volumes are readily available. The rationale for developing a 
VOC-based urine screening test would be to identify patients at highest risk of OG cancer, who 
could subsequently be sent for further investigations.  
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Chapter 6 
 
VOCs and Exhaled Breath 
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6.1 Exhaled Breath VOCs in OG Cancer 
The analysis of exhaled breath through the identification and accurate quantification of volatile 
organic compounds (VOCs) is an evolving scientific field. It has great potential for both disease 
diagnosis and measuring physiological response to treatment. The major appeal of exhaled 
breath analysis for both the clinicians and patients is that the technique is both non-invasive 
and painless. The easy availability of exhaled breath as a bio-sample is also a plus point; it 
means that sampling and testing could eventually be conducted in a physician’s consultation 
room. The development of clinical breath tests for certain diseases could also potentially reduce 
the number of invasive procedures undertaken and decrease hospital visits. As well as the 
potential financial savings in a nationalised healthcare system, these indirect benefits are 
particularly advantageous in certain patients groups, including young children and the elderly. 
However, there remain limited medical applications of human breath analysis at present. 
Quantification of blood alcohol levels is the most widely employed breath test. The 13C urea 
breath testing for H. pylori bacterium, hydrogen breath test for small bowel bacterial 
overgrowth and the measurement of exhaled nitric oxide for airways inflammation in asthma 
represent the only mainstream medical breath tests48,49,50. However, there remains much 
scientific interest and research effort in developing exhaled breath analysis of VOCs for cancer.  
Human breath has been demonstrated to be a complex gaseous mixture containing hundreds of 
volatile organic compounds46. The systematic review (Section 2.4) highlighted the potential of 
exhaled breath analysis of VOCs in several cancer states, including lung, prostate, breast and 
colon cancers68,72. These studies have employed various chemical analytical techniques and 
have demonstrated some very promising VOC-disease associations. To date, GC-MS has been 
the most commonly employed analytical instrument for the detection of VOCs from exhaled 
breath. However, it remains an analytical technique which requires trace gas adsorption 
devices, column calibration for desired analytes as well as lengthy sample processing times. 
GC-MS is also less preferable to quantify important trace compounds that are present in 
exhaled breath. Bajtarevic et al. investigated VOCs within the exhaled breath of lung cancer 
patients and reported SPME GC-MS to be a relatively insensitive method for analysis of breath 
metabolites176. In recent years, mass spectrometry techniques such as proton transfer reaction 
mass spectrometry (PTR-MS) and selected ion flow tube mass spectrometry (SIFT-MS) have 
garnered more interest as they offer real time VOC quantifications of exhaled breath53,177. PTR-
MS most commonly utilises H3O
+ as the reagent ion for chemical ionisation and represents 
semi-quantitative analysis, but the most recent PTR-MS instruments can also utilize NO+ and 
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O2
+ reagent ions177. However, since its inception, SIFT-MS has employed three reagent ions, 
H3O
+, NO+ and O2
+ and offers absolute quantification of VOCs in exhaled breath. It allows the 
simultaneous quantification of several VOCs in air or exhaled breath without the need for 
sample pre-treatment53. The abundant volatile organic compounds within exhaled breath 
including acetone, methanol, ethanol, acetaldehyde, propanol and isoprene have been 
extensively investigated in healthy individuals using SIFT-MS114,115,116,117. It has also been 
employed for breath analysis in disease diagnosis and therapeutic monitoring. Hryniuk et al. 
measured the exhaled breath metabolites of patients with coeliac disease using SIFT-MS178. 
Endre et al. measured breath ammonia using SIFT-MS in patients with chronic kidney failure 
undergoing haemodialysis179. Boshier et al. have also employed a SIFT-MS instrument intra-
operatively in which they measured trace gases in the ventilated exhalations of anaesthetised 
patients during laparoscopic surgery180. These studies all highlight the capabilities and 
advantages of SIFT-MS as a chemical analytical tool in the field of breath analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
6.1.1 Objective  
To investigate whether VOCs within exhaled breath from patients with oesophago-gastric 
cancer differ from patients with benign upper gastro-intestinal conditions and those with 
healthy upper gastro-intestinal tracts using the SIFT-MS analytical method.  
 
6.1.2 Introduction 
The VOCs in the headspace vapour of biofluids retrieved from patients with oesophago-gastric 
cancer, positive controls (i.e., non-cancer diseases of the upper gastro-intestinal tract) and a 
‘healthy’ cohort (i.e., those with no diseases present within the upper gastro-intestinal tract) 
were previously investigated. In the study on the headspace of gastric content (section 4.1.4), 
the concentrations of eight VOCs - acetone, formaldehyde, acetaldehyde, hexanoic acid, acetic 
acid, hydrogen sulphide, hydrogen cyanide and methyl phenol were identified that were 
significantly different between the cancer patients and healthy control group. In the study on 
the headspace of urine (section 5.4), the concentrations of seven VOCs - acetaldehyde, acetone, 
acetic acid, hexanoic acid, hydrogen sulphide, methanol and phenol were found to be 
significantly different between cancer, positive control and healthy groups. The results of these 
studies on biofluids identified potential compounds that may be important in VOC profiling of 
oesophago-gastric cancer and thus warrant further investigation. In this study, exhaled breath 
has been selected as the bio-sample for investigation.  A breath sampling methodology has 
been developed and validated including assessment of Nalophan® bag contribution, water level 
degradation and presence of trace VOCs. It is postulated that the VOCs within exhaled breath 
obtained from patients with oesophago-gastric cancer will differ from controls. It is also 
hypothesised that several of the VOCs detected at increased concentrations in the headspace of 
biofluids from oesophago-gastric cancer patients may be present in the exhaled breath of these 
patients. The present study reports the first investigation of VOCs using the SIFT-MS platform 
of exhaled breath from patients with oesophageal and gastric cancer. VOCs were selected for 
analysis based on their presence in biofluids in the previous studies on oesophago-gastric 
cancer or if they have been detected in exhaled breath in other cancer states.  
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6.1.3 Methods 
6.1.3.1 Patient selection  
Patients were recruited through the endoscopy suite at St. Mary’s Hospital, Paddington 
(Imperial College NHS Trust, London) and via the North West Thames regional oesophago-
gastric cancer network (UK). OGD referral forms were screened to identify suitable patients 
for recruitment into this study. Patients were age-matched across the 3 groups and requested to 
provide a comprehensive medical history, smoking status and alcohol intake history. Patients 
with the following conditions were excluded from recruitment:   
 Barrett’s oesophagus  
 Liver disease/oesophageal varices/portal hypertension 
 Small bowel or colonic pathology 
 A history or presence of another type of cancer 
 Presence of acute infection 
All patients included in this study underwent their OGD on the day of breath collection. 
Patients with a biopsy-confirmed invasive gastric or oesophageal cancer were included in the 
cancer cohort. Patients with biopsy confirmed non-cancer conditions of the upper 
gastrointestinal tract (e.g., esophagitis, gastritis and peptic ulcer disease) were included in the 
positive control cohort. Patients who had a normal OGD test (as interpreted by the endoscopist) 
and a negative rapid urease test were included in the ‘healthy upper gastrointestinal tract’ 
cohort. Local ethics committee approval was granted for this study and written informed 
consent was obtained from all patients prior to enrolment in the study. Demographic and 
clinical data were archived in a linked, anonymized database. The comparative analysis of 
exhaled breath VOCs was conducted with an oesophago-gastric cancer cohort of 18 patients, a 
positive control group of 18 patients and a ‘healthy upper gastrointestinal tract’ cohort group 
of 17 patients.  
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6.1.3.2 Breath Sample Collection 
Exhaled breath samples were collected using a standardised method in the same room in the 
admissions area of the endoscopy suite. All study participants were fasted for a minimum of 6 
hours in keeping with the standard protocol for an OGD with no oral intake (including water) 
prior to their breath sample collection. All subjects had been rested in the same area for at least 
20 minutes prior to exhaled breath collection with all samples retrieved prior to OGD 
procedures. Samples of mixed alveolar breath were collected into secure double thickness (2x 
25µm) Nalophan® (Kalle UK Ltd., Witham, UK) bags via a 1mL Luer lok syringe (Terumo 
Europe, Leuven, Belgium). The syringe is made up of 2 parts: the first part is the syringe barrel, 
which is fixed to the inside of the Nalophan® bag with a pull tight security seal. The second 
part is the syringe plunger that when removed, allows one to breathe into the secure bag via the 
aperture of the syringe barrel. The sampling bags used in these experiments were constructed 
in the Surgical Sciences Laboratory and subject to strict quality control protocols; every breath 
bag had a fixed volume of 2 litres and had been washed with dry synthetic air (BOC Ltd, 
Guildford, UK) prior to its use (Figure 6.1A). All subjects were seated throughout the breath 
sampling process. All participants were requested to perform a single deep nasal inhalation (as 
close to total lung capacity as possible) followed by complete exhalation via their mouth. This 
exhaled breath was not collected for analysis and served the purpose of demonstrating the 
breath manoeuvre required for sampling to the subject. The syringe plunger was only then 
removed from the syringe barrel and subjects were requested to repeat this procedure using the 
same breath manoeuvre directly into the Nalophan® bag. Following complete exhalation, the 
syringe plunger was immediately re-inserted into the barrel and breath samples were taken 
directly to the Surgical Sciences laboratory located within the hospital (Figure 6.1B). All breath 
samples were analysed immediately after collection.   
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           A) Pre-sampling                                              B) Post-sampling 
          
Figure 6.1: Nalophan® bags employed for the collection of mixed alveolar breath samples. A) 
An example of a Nalophan® bag pre-sampling B) The same Nalophan® bag containing an 
exhaled breath sample 
 
The studies identified in the systematic review in chapter 2 predominantly employed off-line 
bag sampling methodologies (i.e, Nalophan® or Tedlar® bags) for the collection of exhaled 
breath. Although direct exhaled breath sampling (which is feasible with the SIFT-MS platform) 
would be preferable, there were several reasons that an off-line breath sampling method was 
employed: 
 Standardisation of the direct exhaled breath analytical method is difficult. Many 
patients can often find it difficult to maintain the continuous respiratory effort or 
requested breath manoeuvre needed to obtain accurate on-line measurements.  
 Direct breath sampling only provides a small window of opportunity to capture exhaled 
breath VOC data. Although multiple exhalations are possible, patients easily become 
tired with this approach. A far larger number of VOCs can be measured with off-line 
bag sampling rather than with direct exhalations.  
 Exhaled breath sample using off-line bag samples can be acquired from patient within 
one minute. This allowed a larger number of patients to be recruited. The minimal time 
required to collect an exhaled breath sample also gave the sampling method a good 
acceptability rating amongst patients; hence there was an extremely low drop-out rate 
for participation in the studies.  
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 The SIFT-MS instrument is located in the Surgical Sciences Laboratory within the 
hospital. Hence, Nalophan® bag samples were collected in the endoscopy suite and 
analysed within an hour, minimising potential VOC degradation. Gilchrist et al. have 
previously investigated the suitability of double thickness (2x 25µm) Nalophan® bags 
for the collection and storage of breath samples181. They reported that the correlation of 
on-line and off-line measurements at 37oC for trace compounds such as HCN was good 
up to 6 hours and for abundant compounds such as acetone was good up to 24 hours181.  
 
6.1.3.3 SIFT-MS analysis of exhaled breath samples 
A Profile-3 SIFT-MS instrument (Instrument Science, Crewe, UK) located in the Surgical 
Sciences laboratory at St. Mary’s Hospital, Paddington (Imperial College Healthcare NHS 
Trust, London) was employed to analyse all exhaled breath samples in this study. Identification 
of exhaled breath VOCs including acetone, methanol and isoprene have been extensively 
reported in the literature53,121. These studies employed the more accurate multiple ion 
monitoring (MIM) mode of SIFT-MS for targeted analysis of selected VOCs of interest in 
exhaled breath, and the MIM mode was also adopted in the current study. A full description of 
the MIM mode of analysis is given in asection 3.4. The majority of VOCs in this study were 
analysed using the H3O
+ and NO+ precursor ions. The O2
+ precursor ion was only used for the 
detection of methyl phenol and ammonia in the MIM mode, as this reagent ion provides more 
accurate quantification for these trace compounds than does the H3O
+ and NO+ ions53. For each 
measurement, the syringe plunger was removed from the 1 mL Luer lok syringe and the 
Nalophan® bag was directly connected via the syringe barrel to the sample inlet arm of the 
SIFT-MS instrument. The breath sample automatically flowed into the helium carrier gas at a 
fixed rate (0.2 TorrL/s) through the sampling line that was held at a temperature of 80 ̊C. For 
the duration of the analysis, breath sample bags were enclosed within an incubator held at 37 ̊C. 
For the MIM mode, selected VOCs from the breath samples were analysed for a total of 60 
seconds and the measured concentrations were averaged over this analysis time for each VOC.  
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6.1.3.4 Statistical analysis  
Statistical analysis was performed using IBM SPSS statistics 20 (SPSS Inc., Chicago, IL). A 
p-value ≤ 0.05 was taken as the level to indicate statistical significance. The Mann-Whitney U 
test was used to compare the measured concentrations of VOCs between the oesophago-gastric 
cancer cohort and control groups. The Mann-Whitney U test was also applied to compare the 
measured concentrations between positive control and healthy upper gastrointestinal tract 
control groups. The ROC curves were constructed using the same method described in section 
4.1.3.4. In the current study, the statistical significance of differences in VOC concentrations 
between the cancer and positive controls was determined and then only those with p < 0.05 
were included as variables for the proposed diagnostic test. The aim of comparing these groups 
was to assess the feasibility of VOC profiles within exhaled breath to differentiate between two 
distinct (biopsy confirmed) disease groups of the upper gastrointestinal tract.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
6.1.4 Results 
6.1.4.1 Water vapour level of breath samples 
Ten healthy volunteers (with no co-morbidities) were recruited to provide four breath samples 
for the purposes of assessing the water level degradation employing Nalophan® bag (2x 25µm) 
sampling. All four breath samples were collected consecutively with a standardized 1-minute 
interval between each sample and immediately stored in a sealed 9-litre Really Useful Box 
(395 x 255 x 155mm) at room temperature. Breath samples were analysed at 30, 60, 120 and 
240 minutes from the time of collection. Each sample bag was only removed from the storage 
container at their specific time point. All samples were analysed in the order that they were 
collected in (i.e., at the 30, 60, 120 and 240 minutes time points). Table 6.1 demonstrates the 
median water level of the exhaled breath samples at each of the designated time points. With 
appropriate storage, the water level within double thickness (2 x 25µm) Nalophan® bags is 
relatively stable with a median water level of 5.3% at 30 minutes and 4.6% at 240 minutes. 
This is an important consideration in terms of calibration of the SIFT-MS instrument and 
analysis of Nalophan® collected breath samples. Since the absolute humidity of exhaled breath 
is close to 6% (the saturation vapour pressure of water at body temperature) and so the 
measurement of the breath humidity acts as an internal check on the proper set up of the 
instrument53. Furthermore, the observed water levels within double thickness Nalophan® bags 
in this study are similar to those recorded in on-line studies. In a recent study by Gilchrist et 
al., median (IQR) on-line water vapour concentration was 5 (4.9-5.2)%181. The results in this 
study demonstrate that double thickness Nalophan® bags, that are appropriately stored, 
maintain a suitable water level up to 4 hours after collection.  
Analysis time (minutes) Median (%) Interquartile range (%) 
30 5.3 5.1-5.5 
60 5.1 4.2-5.7 
120 4.9 4.0-5.7 
240 4.6 3.8-5.0 
 
Table 6.1: Median water vapour level and interquartile range within Nalophan® bags at 30, 
60 120 and 240 minutes from the time of breath collection taken from 10 healthy volunteers.  
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6.1.4.2 Reproducibility and validity of the sampling method  
Experiments were also conducted to assess the inter-sample reliability and reproducibility of 
the aforementioned breath sampling methodology. Ten healthy volunteers (with no co-
morbidities) were recruited and requested to provide 2 breath samples obtained within a minute 
of each other. A total of 20 breath samples were analyzed using the MIM mode for the selected 
VOCs. The inter-sample coefficient of variation (CV) was calculated for the measured 
concentration of several VOCs within the exhaled breath samples. These CV values obtained 
in percentage are: acetone, 10.7%; isoprene, 11.5%; methanol, 7.2%; hexanoic acid, 15.7%; 
phenol 14.9%; ethyl phenol, 17.2%; methyl phenol, 14.6%. These coefficients of variation 
demonstrate the reproducibility of the MIM measurement for these VOCs within exhaled 
breath. 
 
6.1.4.3 Surgical Sciences Laboratory room air and Nalophan bag measurements 
Ten measurements of the Surgical Sciences laboratory room air concentrations for acetone, 
isoprene, methanol, hexanoic acid, phenol, methyl phenol and ethyl phenol were also recorded. 
As shown in Table 6.3 and the figures later in the ‘Discussion’, the room air concentrations of 
all the VOCs are at trace levels in comparison to the measured concentrations within exhaled 
breath. It was noted that methanol has a higher background laboratory room air value, but this 
is much lower compared to the median concentrations observed within exhaled breath. In a 
recent study by Španěl et al., it was reported that there is minimal retention of exogenous 
methanol in exhaled breath182. Hence, the potential exogenous contribution of background 
laboratory room air to the measured concentrations of the VOCs in exhaled breath samples in 
these experiments is deemed negligible. 
The potential contribution of the Nalophan® bag surface to exhaled breath samples has also 
been investigated. Ten Nalophan® bags were filled with dry synthetic air (BOC Ltd, Guildford, 
UK) and analysed using the MIM mode of the SIFT-MS. All the VOCs within the Nalophan® 
bags were present in trace quantities in comparison to the median concentrations within exhaled 
breath. Both these experiments highlight that the important trace VOCs identified in this study 
are not significantly influenced by exogenous sources or experimental methodology. 
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6.1.4.4 Analysis of selected VOCs in exhaled breath  
As shown in Table 6.2, a total of 17 VOCs present within exhaled breath were analysed using 
the MIM mode of the SIFT-MS. The analytical information, including chemical formula, 
precursor ions, m/z values and characteristic product ions are given. H3O
+ is the most frequently 
used precursor ion as it reacts with more compounds than the other 2 precursor ions. However, 
NO+ and O2
+ have also been employed for specific molecules when they have an advantage in 
unambiguously detecting and quantifying these compounds over H3O
+ (i.e., when there are 
known overlaps with other product ions). 
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Compounds Molecular 
formula 
Precursor 
ions 
m/z Characteristic product 
ions 
REF 
Methanol CH4O H3O
+ 33,51 CH5O
+, CH5O
+(H2O) 53 
Propanol C3H8O H3O
+ 43 C3H7
+ 53 
Butanol C4H10O H3O
+ 57 C4H9
+ 53 
Pentanol C5H12O H3O
+ 71 C5H11
+ 53 
Pentanoic 
acid 
C5H10O2 H3O
+ 103 C5H10O2H
+ 53 
Hexanoic acid C6H12O2 H3O
+ 117, 135 C6H12O2H
+, 
C6H12O2H
+(H2O) 
53 
Hydrogen 
sulphide 
H2S H3O
+ 35 H3S
+ 53 
Hydrogen 
cyanide 
HCN H3O
+ 28 H2CN
+ 136 
Acetaldehyde C2H4O H3O
+ 45, 81 CH3CHOH
+, 
CH3CHOH
+(H2O)2 
53 
Formaldehyde H2CO H3O
+ 31 H2COH
+ 53 
Acetone C3H6O NO
+ 88 NO+·C3H6O 53 
Acetic acid C2H4O2 NO
+ 90, 108 NO+·CH3COOH, 
NO+·(H2O)CH3COOH 
53 
Isoprene C5H8 NO
+ 68 C5H8
+ 53 
Phenol C6H6O NO
+ 94, 112 C6H6O
+, 
C6H6O
+(H2O) 
183 
Methyl 
phenol 
C7H8O O2
+ 108, 126 C7H8O
+, 
C7H8O
+(H2O) 
183 
Ethyl phenol C8H10O NO
+ 122, 140 C8H10O
+, 
C8H10O
+(H2O) 
183 
Ammonia NH3 O2
+ 17, 35 NH3
+,NH3
+(H2O) 53 
Table 6.2: A summary of the characteristic ions of the 17 VOCs analysed by the MIM mode 
of SIFT-MS using H3O
+, NO+ and O2
+ precursor ions.
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Table 6.3: Summary of median concentration and interquartile range (IQR) measured in parts-per-billion by volume (ppbv) for the most abundant 
VOCs present in exhaled breath and the 4 VOCs that were significantly different between the oesophago-gastric cancer cohort and controls as 
denoted by the asterix*. Room air and Nalophan® bags (inflated with dry synthetic air) measurements of each VOC are also included. (N.B. 
Throughout the ‘Results and Discussion’ Section, the Healthy Upper GI tract cohort is abbreviated to the ‘Healthy’ cohort) 
 
 Cancer cohort Positive controls Healthy controls  Room air Nalophan® bag  
VOCs Median IQR Median IQR Median IQR Media
n 
IQR Median IQR 
Acetone 307 [116-
1205] 
449 [261-
698] 
372 [164-
958] 
6 [3-10] 1 [0-2] 
Isoprene 71 [46-175] 72 [46-117] 52 [45-80] 3 [1-5] 2 [1-3] 
Methanol 235 [170-
328] 
210 [170-
304] 
159 [125-
195] 
38 [30-50] 29 [22-37] 
Hexanoic acid* 19 [12-37] 7 [4-13] 10 [8-18] 1 [0-3] 1 [1-2] 
Phenol* 17 [8-26] 7 [5-9] 6 [3-9] 2 [1-3] 1 [0.95-
1.35] 
Methyl phenol* 12 [9-19] 3 [2-6] 5 [3-10] 1 [0-2] 1 [1-3] 
Ethyl phenol* 9 [5-23] 5 [2-11] 6 [2-15] 0 [0-2] 2 [1-2] 
99 
 
 
 
 
 
 
Figure 6.2: Box-Whisker plots of the median concentrations and interquartile range (in ppbv) 
of (a) acetone, (b) methanol and (c) isoprene from the exhaled breath of oesophago-gastric 
cancer patients, positive controls and the healthy upper GI tract cohort. Room air 
concentrations from the Surgical Sciences laboratory for each VOC are also included. 
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Figure 6.3: Box-Whisker plots of the median concentrations and interquartile range (in ppbv) 
of (a) hexanoic acid, (b) phenol, (c) methyl phenol and (d) ethyl phenol from the exhaled breath 
of oesophago-gastric cancer patients, positive controls and healthy controls. Room air 
concentrations from the Surgical Sciences laboratory for each VOC are also included. 
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6.1.4.5 Exhaled Breath VOCs to discriminate cancer from non-cancer controls 
Mann-Whitney U test (p-value ≤ 0.05) was performed for all the volatile organic compounds 
listed in Table 6.2, to assess for any differences in median concentrations between the 
oesophago-gastric cancer cohort and positive control group. Additional tests were also 
performed between the cancer cohort and healthy control group as well as the positive control 
and healthy control groups. Between the cancer and positive control groups, four VOCs were 
found to be statistically significantly different, i.e. hexanoic acid (p=0.001), phenol (p=0.001), 
methyl phenol (p<0.001) and ethyl phenol (p=0.044). Similar results were obtained between 
the cancer and healthy control groups including methanol (p=0.007), hexanoic acid (p=0.006), 
phenol (p=0.006) methyl phenol (p=0.001). However, methanol (p=0.007) was the only VOC 
to be statistically significantly different in the exhaled breath of the positive control and healthy 
control groups. Using the four statistically significant VOCs identified in the Mann-Whitney 
U test, the binary logistical regression analysis resulted in a linear combination of 
concentrations of hexanoic acid (coefficient 0.134), phenol (0.176), methyl phenol (0.228) and 
ethyl phenol (-0.187). The AUC of the ROC using this model equation is 0.910, demonstrating 
a high discriminating power between the oesophago-gastric cancer and positive control groups 
with good sensitivity and specificity (Figure 6.4). This result is encouraging and further 
supports the theory that non-invasive VOC profiling may have a diagnostic role for risk 
stratification in oesophago-gastric cancer. 
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Figure 6.4: ROC curve of discrimination results for the diagnosis of oesophago-gastric cancer 
from positive controls using a combination of the following exhaled breath VOCs - hexanoic 
acid, phenol, methyl phenol and ethyl phenol exhibited, respectively. The AUC is 0.910. 
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6.1.5 Discussion 
6.1.5.1 Abundant breath VOCs 
Abundant breath VOCs are those compounds present at concentrations of several hundred ppbv 
in the exhaled breath of the majority of the general population. Acetone, isoprene and methanol 
are considered abundant metabolites within exhaled breath, all of systemic origin, that have 
been formerly investigated using SIFT-MS183,184. Acetone (2-propanone, β-ketopropane) is a 
product of mitochondrial β-oxidation and the most abundant ketone present in exhaled 
breath139. Endogenous production of acetone in humans occurs by two processes - the 
decarboxylation of acetoacetate and dehydrogenation of isopropanol185. In this study, the 
quantification of acetone was achieved using the NO+ precursor ion, which produces a single 
characteristic product ion (m/z of 88) and no further cluster ions. The accurate quantification 
of acetone in exhaled breath using the NO+ precursor ion of SIFT-MS has been previously 
reported186. In the previous studies on the headspace of gastric content and urine, higher 
concentrations of acetone were observed in both biofluids in the cancer cohort compared to 
non-cancer controls. Pabst et al. reported increased concentrations of exhaled breath acetone 
during cardiac surgery and proposed this may be related to the simultaneous increase in 
oxidative stress187. Marcondes-Braga et al. reported that exhaled breath acetone levels correlate 
with heart failure severity188. As shown in Figure 6.2, the measured exhaled acetone 
concentrations of the cancer cohort has a larger interquartile range in comparison to the non-
cancer controls. However, no significant differences in median concentrations were observed 
between the oesophago-gastric cancer cohort (307 ppbv), positive control (449 ppbv) and the 
healthy (372 ppbv) cohort. Turner et al. have previously studied acetone in single breath 
exhalations by healthy volunteers using SIFT-MS over a 6-month period114. In this on-line 
study, they reported a median acetone concentration of 462 ppbv with a range of 148-2744 
ppbv in 30 healthy volunteers114. The results are comparable with the exhaled breath acetone 
concentrations observed in this study and further validate the aforementioned off-line bag 
sampling method. 
The exhaled breath concentrations of methanol demonstrate a clear decreasing trend from the 
oesophago-gastric cancer group to the healthy cohort, a trend that was observed in both the 
studies on the headspace of gastric content and urine. The oesophago-gastric cancer cohort and 
positive control group have very close median concentrations of methanol, i.e., 235 ppbv and 
210 ppbv, respectively (Figure 6.2). The healthy control group has a lower median methanol 
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concentration of 159 ppbv, which falls within quoted ranges for online measurements of 
exhaled breath methanol117. There is no statistically significant difference in methanol 
concentration between the cancer cohort and positive control group by Mann-Whitney U test. 
However, methanol was found to be statistically significantly different between the cancer 
cohort and healthy control group (p=0.006). Of note, it is also the only VOC that demonstrated 
a statistically significant difference between the positive control and healthy control groups 
(p=0.007). Methanol has been observed at a consistently higher median concentration in the 
exhaled breath, urine and gastric content of subjects with upper gastrointestinal diseases 
compared to those with healthy upper gastrointestinal tracts. The majority of endogenous 
methanol is produced within the gastro-intestinal tract. Caldwell demonstrated higher 
concentrations of methanol completely inhibit predominant anaerobic gut bacteria; many of 
these bacteria are present in a protective role in the human gut and their inhibition can lead to 
gut dysfunction173. Garner et al. also observed that methanol was present more frequently in 
faeces samples of patients with Campylobacter jejuni infection and ulcerative colitis compared 
to the asymptomatic donors172. Although exhaled breath methanol is not a specific VOC to 
oesophago-gastric cancer, it is increased in both upper gastrointestinal disease groups. It 
therefore may represent a marker of gut dysfunction and thus warrants further investigation in 
this regard.  
Isoprene (2-methyl-1,3-butadiene) is an abundant hydrocarbon within human exhaled breath 
and known metabolite of cholesterol synthesis189. Spanel & Smith have investigated the 
accurate quantification of isoprene in exhaled breath using SIFT-MS190. They reported that all 
three precursor ions can react with isoprene. For H3O
+ precursor ions, the characteristic product 
ion C5H9
+ is formed by a protonation reaction with both H3O
+ and its monohydrate ion. C5H9
+ 
has a m/z value of 69, which is overlapped with the hydrate of protonated methanol, 
CH3OH.H
+(H2O)2, which is often observed in humid breath samples. In contrast to the reaction 
of O2
+ with isoprene, in which two dominant product ions are produced, NO+ precursor ion 
only ionises isoprene into C5H8
+ at m/z 68 by a simple non-dissociative charge transfer reaction 
and no other common breath metabolites will produce m/z 68 products using NO+. Therefore, 
exhaled breath isoprene was analysed using the NO+ precursor ion in this study. As shown in 
Figure 6.2 and table 6.3, the median concentration of isoprene within exhaled breath is 71, 72 
and 52 ppbv in the oesophago-gastric cancer cohort, positive control and healthy control 
groups, respectively. Turner et al. have previously studied breath isoprene through online 
SIFT-MS analysis in healthy volunteers115. In this study, they reported a mean breath isoprene 
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level of 118  68 ppbv with significant variation amongst apparently healthy individuals115. 
Boshier et al. reported significantly increased concentrations of exhaled isoprene in patients 
undergoing laparoscopic surgery and postulated that this may represent a stress response180. 
Xu et al. recently analysed exhaled breath samples from patients with gastric complaints using 
a nanomaterial-based gas sensor191. Complementary chemical analysis was performed on these 
breath samples using GC-MS and they observed significantly elevated levels of isoprene in 
patients with gastric cancer and/or peptic ulcer compared to those with less severe gastric 
conditions191. Higher median concentrations of isoprene were observed in both the cancer 
cohort and positive control group compared to healthy controls, however this result did not 
reach statistical significance (p=0.08)191. Given the abundance of acetone, methanol and 
isoprene within exhaled breath and the levels observed in this study, it is evident these VOCs 
are unlikely to be specific breath biomarkers for oesophago-gastric cancer. 
 
6.1.5.2 Hexanoic Acid 
Hexanoic acid was analyzed using the H3O
+ precursor ion with 2 characteristic product ions 
(m/z 117 and 135 at a typical ratio of 27/29 counts per second). The median concentration of 
hexanoic acid in the exhaled breath of the oesophago-gastric cancer cohort (19 ppbv) is 
significantly increased in comparison to the positive control (7 ppbv) and healthy control 
groups (10 ppbv). As shown in Figure 6.3, the cancer cohort also have a much wider 
interquartile range (12-37 ppbv) range in comparison to both control groups. As shown in Table 
6.3, there is also a negligible hexanoic acid contribution from both laboratory room air and the 
surface of Nalophan® sampling bags. In the previous studies on the headspace of gastric content 
and urine, the same trend of significantly increased concentrations of hexanoic acid in the 
cancer cohort in comparison to non-cancer controls was observed. Saturated fatty acid vapours 
(up to C14) have previously been observed in human breath using electrospray ionization and 
atmospheric pressure ionization-mass spectrometry192. However, there remains limited data 
published regarding concentrations of these compounds (including hexanoic acid) within 
exhaled breath. Silva et al. have previously analysed urine samples from patients with 
leukaemia, lymphoma and colorectal cancer using SPME GC-MS70. They observed hexanoic 
acid less frequently in urine samples from these cancer groups compared with the healthy 
controls70. Hexanoic acid has been consistently elevated in biological samples from patients 
with oesophago-gastric cancer when analysed with SIFT-MS using the H3O
+ precursor ion with 
2 characteristic product ions (m/z 117 and 135); this may reflect this VOC being systemically 
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increased in oesophago-gastric cancer. To further investigate this, experiments using standards 
of hexanoic acid isomers were conducted at the SIFT-MS laboratory in Keele University. 
Hexanoic acid standards gave the following % signals at the characteristic product ions and the 
associated dihydrate using SIFT-MS – m/z 117: 5-23%, m/z 135: 27-63% and at m/z 153: 31-
69% - (D.Smith, priv. comm.). Analysis of the signals within exhaled breath samples from OG 
cancer patients with increased concentrations of hexanoic acid gave the following median % 
signals – m/z 117: 16%, m/z 135: 45% and at m/z 153: 37% (Table 6.4). Though the count rates 
were lower in exhaled breath, which is to be expected, the median % signals all fall within the 
appropriate ranges for the hexanoic acid standards. Further research utilising multiple 
analytical platforms (e.g., GC-MS) is necessary to verify the compound responsible for these 
increased concentrations is only hexanoic acid and whether a specific isomer of this compound 
is also consistently increased in OG cancer.  
 
 
 
Exhaled breath sample Water level (%) m/z 117 m/z 135 m/z 153 
OG 1 4 18% 17% 66% 
OG 2 4.6 17% 39% 45% 
OG 3 3.79 7% 45% 48% 
OG 4 4.62 23% 35% 42% 
OG 5 5.75 25% 44% 31% 
OG 6 4.33 7% 56% 37% 
OG 7 4.49 18% 46% 36% 
OG8 4.48 6% 29% 26% 
OG 9 4.81 4% 59% 37% 
OG 10 4.56 15% 65% 20% 
     
Median 4.53 16% 45% 37% 
Table 6.4: The water level and individual % signals for m/z 117, m/z 135 & m/z 153 for the 
measurement of hexanoic acid in exhaled breath samples from patients with OG cancer  
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6.1.5.3 Phenol and phenol derivatives 
The phenol, methyl phenol and ethyl phenol measurements are statistically significantly 
different in the exhaled breath of the oesophago-gastric cancer cohort compared to non-cancer 
controls. The median concentration of phenol in the exhaled breath of the cancer cohort is 17 
ppbv compared to 7 ppbv in the positive control group and 6 ppbv in the healthy control group. 
As shown in Figure 6.3, the cancer cohort also demonstrate a much wider interquartile range 
(8-26 ppbv) in comparison to both control groups which have tighter interquartile ranges. Of 
note is the upper quartile value of 9 ppbv for phenol in the positive and healthy control groups. 
Turner et al. have previously demonstrated the presence of phenol in the exhaled breath of 
healthy volunteers using thermal desorption GC-MS193. In the study on gastric content 
headspace using SIFT-MS, phenol was increased in patients with OG cancer compared to 
controls but this did not reach statistical significance. In an analysis of gastric content 
headspace using SPME/GC-MS (Appendix B), phenol was the most frequently observed VOC 
in gastric content from patients with oesophago-gastric cancer. In the headspace of urine, 
significantly lower concentrations of phenol were observed in the cancer cohort compared with 
controls. McDonald et al. have previously hypothesised that higher concentrations of phenol 
observed in urine may reflect its efficient removal from the blood and subsequent excretion175. 
It is postulated that the variations observed in phenol concentrations in the OG cancer cohort 
when compared to controls may be due to dysfunctional phenol excretion secondary to 
alterations in tyrosine metabolism by gut bacteria or impairment in the removal mechanisms in 
blood. Phenol is a known breakdown product of tyrosine through the process of proteolytic 
fermentation194. Deng et al. studied aromatic amino acids in gastric juice samples from patients 
with early-stage gastric cancer, advanced gastric cancer and non-neoplastic gastric diseases 
using high performance liquid chromatography mass spectrometry (HPLC-MS)126. They found 
that high levels of aromatic amino acids including tyrosine and phenylalanine were present in 
gastric juice samples from patients with gastric cancer126. It is hypothesised that the 
significantly increased concentrations of phenol in the exhaled breath of the oesophago-gastric 
cancer cohort may be associated with increased protein catabolism, changes in gut micobiota, 
up-regulation of tyrosine metabolism or a combination of all three.  
As shown in Figure 6.3, the median concentrations and trends of methyl phenol and ethyl 
phenol across the three groups are very similar. Exhaled breath methyl phenol and ethyl phenol 
from the cancer cohort are at higher median concentrations and wider interquartile ranges in 
comparison to non-cancer controls. For instance, the measured methyl phenol concentration 
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from the cancer cohort at 12 ppbv is significantly increased compared to the positive control 
and healthy control groups which have similar median concentrations of 3 ppbv and 5 ppbv, 
respectively. Ethyl phenol has a median concentration of 9 ppbv in the cancer cohort whilst the 
positive control and healthy control groups have median concentrations of 5 ppbv and 6 ppbv, 
respectively. In the study on the headspace of urine, no significant differences were observed 
in the measured concentrations of methyl phenol or ethyl phenol between the groups. In the 
study on the headspace of gastric content, a significantly increased concentration of methyl 
phenol was observed in the oesophago-gastric cancer cohort compared with healthy controls 
(17 ppbv vs. 8 ppbv). Silva et al. reported increased levels of methyl phenol in urine samples 
from patients with cancer compared to controls195. Phenol, methyl phenol and ethyl phenol 
within exhaled breath did not demonstrate any significant differences between the positive 
control and healthy control groups. As shown in Table 6.3, there were negligible phenol, 
methyl phenol or ethyl phenol contributions from both laboratory room air and Nalophan® 
sampling bags. 
The other VOCs that were investigated in Table 6.2 did not show any significant differences 
between the groups in this study and hence no further analysis was conducted at this time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
6.1.6 Conclusions 
This is the first study of VOCs within exhaled breath of patients with oesophago-gastric cancer. 
Comparative analysis has been made with control groups, all of whom had their upper gastro-
intestinal tracts visualised on the day of breath sampling. A total of 17 VOCs were analysed in 
exhaled breath samples from patients with OG cancer, positive controls and a healthy control 
group. Of these compounds, the median concentrations of 4 VOCs (hexanoic acid, phenol, 
methyl phenol and ethyl phenol) were statistically different between the oesophago-gastric 
cancer patients and the positive control group. Several of the same VOCs that differentiated 
oesophago-gastric cancer from control groups in the previous work of headspace analysis of 
gastric content and urine have also been identified in this study (Chapters 4 and 5). Of note, 
hexanoic acid has been observed at increased concentrations in all biological samples from 
patients with oesophago-gastric cancer. In comparison to the abundant breath metabolites, it is 
evident from this study that trace compounds are more likely to be influential in VOC profiling 
in exhaled breath in OG cancer. The SIFT-MS technique allows real-time detection and 
quantification of trace volatile compounds in human biological samples. In the current study, 
the VOCs within exhaled breath have been readily analysed without any sample preparation 
and therefore minimal delay. This is particularly advantageous within the clinical environment 
where samples are retrieved and real-time VOC measurements can be made with minimal 
concern for potential sample degradation. Multiple chemical analytical platforms are necessary 
to identify other VOCs that may be important in differentiating oesophago-gastric cancer from 
other diseases. Most importantly, chemical analytical research could lead to the development 
of a non-invasive VOC-based breath (and/or urine) screening test.  
The differences in the concentrations of particular VOCs observed in the exhaled breath 
of the oesophago-gastric cancer cohort when compared with control groups in this pilot study 
are promising. The results of VOC levels within the environment and from the surfaces of 
Nalophan® bags also gave me confidence in analysing the trace compounds within exhaled 
breath. Acetaldehyde and formaldehyde did not demonstrate any significant statistically 
significant differences between the cancer cohort and controls in this study. Smith et al. have 
investigated acetaldehyde in patients with non-small cell lung cancer. They observed increased 
concentrations of acetaldehyde in these patients but quickly realised that the major fraction for 
this VOC was being emitted from the bag surface143. However, aldehydes remain important 
VOCs to investigate in OG cancer  
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6.2 Exhaled breath Aldehydes in a Healthy population 
 
6.2.1 Objective  
To investigate the concentrations of C3-C10 aldehydes in the exhaled breath of healthy persons 
and elucidate ‘normal values’ or reference ranges for these compounds.  
 
6.2.2 Introduction  
The results of the systematic review from Chapter 2 identified aldehydes as VOCs that were 
linked to several types of cancer. Aldehydes produced within the human body are most 
commonly oxidised to carboxylic acids by aldehyde dehydrogenase enzymes. The C3-C10 
aldehydes have previously been reported to be associated with lung and colorectal cancer. 
Fuchs et al. reported elevated pentanal, hexanal, octanal and nonanal concentrations in the 
exhaled breath of lung cancer patients compared to healthy volunteers; they postulated that the 
increases in these exhaled breath aldehydes reflected oxidative stress and tumour-specific 
tissue metabolism63. Using GC-Time Of Flight MS, Buszewski et al. reported a higher 
concentration of butanal in the exhaled breath of lung cancer patients compared with 
controls196. Altomare et al. employed an off-line breath collection method (employing Tedlar® 
bags) to investigate VOC patterns within the exhaled breath of patients with colorectal cancer. 
Using thermal desorption GC-MS and a probabilistic neural network (PNN) analysis, they 
identified nonanal and decanal as two of the discriminating variables to distinguish colorectal 
cancer patients from controls197. The aforementioned studies all employed GC-MS for the 
analysis of exhaled breath aldehydes. Apart from the studies described in Chapters 4 and 5, 
SIFT-MS has previously been employed to study aldehydes in bladder, prostate and lung 
cancer. Španěl et al. demonstrated elevated levels of formaldehyde in the headspace of urine 
samples from patients with bladder and prostate cancer83. Smith et al. also identified higher 
levels of acetaldehyde in the lung cancer cell line SK-MES and CALU-1 cell lines82. SIFT-MS 
has great potential in the targeted, real-time analysis of short chain aldehydes from exhaled 
breath. In order for exhaled breath analysis to play a more prominent role in clinical 
diagnostics, standardization of breath collection methodologies and establishment of ‘normal 
values’ for VOCs of interest in healthy persons are necessary. Given there was no published 
data for C3-C10 aldehydes within exhaled breath using the SIFT-MS platform, it was 
considered important to investigate levels of these compounds in healthy subjects. In this study, 
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the detection and quantification of C3-C10 saturated aldehydes (propanal, butanal, pentanal, 
heptanal, hexanal, heptanal, octanal, nonanal and decanal) in exhaled breath has been 
investigated using the SIFT-MS platform.  
 
6.2.3 Methods 
6.2.3.1 Subjects 
Twenty six healthy volunteers were enrolled in this study, including 11 male and 15 female 
participants. Their mean age was 45.8±16.7 years. All subjects had no significant past medical 
history. There were 4-smokers and 22 non-smokers amongst the study participants.   
 
6.2.3.2 Breath sample collection 
All subjects were fasted for a minimum of 8 hours with no oral intake (including water) prior 
to sample collection. They had been requested to refrain from alcohol 24 hours prior to exhaled 
breath sampling. Off-line mixed alveolar breath samples were collected from all participants 
in same location (i.e., the Surgical Sciences laboratory) between 8am and 10am. All subjects 
provided samples into secure double thickness (2 x 25µm) Nalophan® (Kalle UK Ltd., Witham, 
UK) bags via the same method described earlier in this chapter. 
 Ten of the healthy volunteers were selected at random to provide four breath samples for the 
purposes of assessing the repeatability and reproducibility of the Nalophan® bag sampling 
methodology for saturated aldehydes. All four breath samples were collected consecutively 
with a standardized 1-minute interval between each sample and immediately stored in a sealed 
9-litre Really Useful Box (395 x 255 x 155mm) at room temperature. Breath samples were 
analysed at 30, 60, 120 and 240 minutes from the time of collection. 
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6.2.3.3 SIFT-MS analysis 
In this study, the FS mode was initially employed to demonstrate that SIFT-MS could detect 
the C3-C10 aldehydes within off-line exhaled breath samples. However, the MIM mode was 
the main modus operandi for quantification of the selected aldehydes. Calibration check 
procedures of the instruments and SIFT-MS analysis of exhaled breath samples were conducted 
as previously described in Section 6.1.3. For the FS mode, 9 x 60 seconds repeated scans were 
performed using the NO+ precursor ion only. For the MIM mode, the selected aldehydes from 
the breath samples were analysed for a total of 60 seconds and the measured concentrations 
were averaged over the analysis time for each compound. In addition, exhaled breath VOCs, 
including acetone, acetic acid and isoprene were simultaneously analysed using NO+ precursor 
ions.  
 
6.2.3.4 Ion chemistry 
C3 to C10 aldehydes, including propanal, butanal, pentanal, hexanal, heptanal, octanal, nonanal 
and decanal from exhaled breath were analysed using the NO+ reagent ion only. Acetone, acetic 
acid and isoprene were also measured using NO+ reagent ions (Table 6.5).   
 
 
Aldehyde Formulae Precursor ions Characteristic ions m/z 
Acetone C3H6O NO
+ NO+·C3H6O 88 
Acetic acid C2H4O2 NO
+ NO+·CH3COOH, 
NO+·(H2O)CH3COOH 
90, 108 
Isoprene C5H8 NO
+ C5H8
+ 68 
Propanal C2H5CHO NO
+ C3H5O
+ 57 
Butanal C3H7CHO NO
+ C4H7O
+ 71 
Pentanal C4H9CHO NO
+ C5H9O
+ 85 
Hexanal C5H11CHO NO
+ C6H11O
+ 99 
Heptanal C6H13CHO NO
+ C7H13O
+ 113 
Octanal C7H15CHO NO
+ C8H15O
+ 127 
Nonanal C8H17CHO NO
+ C9H17O
+ 141 
Decanal C9H19CHO NO
+ C10H19O
+ 155 
Table 6.5: Characteristic analyte and m/z of acetic acid, acetone, isoprene and the C3-C10 
aldehydes analysed using SIFT-MS. 
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H3O
+ reagent ion can also be used to ionise C3-C10 aldehydes via proton transfer reaction116 
[Equation 1].  
 
H3O
+ + M → MH+ + H2O                  [1] 
 
However, the parent product ions (MH+) + often dissociate into fragments (M-H2O)
+ with loss 
of a water molecule. For instance, the ultimate product ions from hexanal and H3O
+ will be a 
mixture of C5H11CHOH
+ and C6H11
+ [Equation 2]: 
 
     H3O
+ + M C5H11CHO → C5H11CHOH+ + H2O (50%)               [2a] 
 
                                                          → C6H11+ + 2H2O (50%)                  [2b] 
Hence, NO+ precursor ion is used for their quantification as only a single product ion is 
produced (M-H)+ via hydride transfer reaction134 [Equation 3]. It is also found that the hydride 
transfer reaction is the only process that occurs between a saturated aldehyde and NO+.180. 
Španěl et al. also reported that the produced (M-H)+ shows very little degree of association 
with water and hence the water molecules from the sample have no influence on the 
quantification of these saturated aldehydes198. Therefore, NO+ remains the most suitable 
precursor ion to analyse the C3-C10 aldehydes. 
 
NO+ + M → (M-H)+ + HNO                  [3] 
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6.2.4 Results 
6.2.4.1 Aldehydes quantification and variations within healthy subjects 
For the accurate quantification of exhaled breath aldehydes using SIFT-MS, specific precursor 
ions and characteristic product ions must be carefully selected for analysis121. As mentioned 
above, all eight aldehydes (C3 to C10) in this study were analysed using NO+ reagent ions to 
give a single product ion, which does not overlap with any other ions (Table 6.5. Propanal was 
the most abundant and has the smallest molecular weight amongst these eight compounds. 
Conventional GC-MS techniques are not suitably sensitive for the detection and quantification 
of aldehydes with less than four carbon atoms. However, SIFT-MS has been demonstrated to 
have a good sensitivity for these compounds in headspace experiments of foodstuffs129,199. Both 
H3O
+ and NO+ reagent ions can react with propanal to produce a single parental product ion. 
However, when H3O
+ is used, the product ion of propanal is isobaric with acetone, which will 
have the same m/z value112. Therefore, the NO+ ion is used for the quantification of propanal 
as acetone reacts with NO+ to produce the m/z 88 product ion, whilst the product ion of propanal 
is 57129,134. Figure 6.5 below shows that propanal can be identified from m/z 57 when NO+ 
reagent ion is used in the FS mode of SIFT-MS.  
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Figure 6.5: Full scan spectrum of exhaled breath obtained using the NO+ reagent ion. m/z 30, 48 and 66 are the NO+ reagent ions and its associated 
hydrate ion. m/z 57 is propanal, m/z 71 is butanal, m/z 85 is pentanal, m/z 99 is hexanal, m/z 113 is heptanal, m/z 127 is octanal, m/z 141 is nonanal 
and m/z 155 is decanal.  
116 
 
Similarly, figure 6.5 also demonstrates the presence of butanal at m/z 71 (C4H7O
+), when the 
exhaled breath was analysed using NO+ in FS mode. All the other aldehydes were detected 
from their single product ion using the NO+. However, the ion count rate is relatively low (as 
expected) in comparison to the abundant VOCs (i.e., acetone, methanol, isoprene) within 
exhaled breath. Hence, the MIM mode remained the preferable method for the accurate 
quantification of C3-C10 aldehydes.  
 
6.2.4.2 C3 to C10 aldehyde concentrations in exhaled breath of healthy subjects 
The repeatability of the sampling method was assessed, through calculating the coefficient of 
variation (CV%) of the measured concentrations of C3-C10 aldehydes from the four exhaled 
breath samples collected from ten healthy volunteers. All four breath samples were collected 
consecutively and immediately stored in a sealed 9-litre Really Useful Box (395 x 255 x 
155mm) at room temperature. All breath samples were analysed in the order they had been 
collected in. Each sample was only removed from the storage container at the time of analysis. 
The eight aldehydes were observed at trace quantities in the exhaled breath of the 10 healthy 
persons, and hence their associated CV% values are, as expected, relatively larger in 
comparison to abundant breath VOCs. As shown in Table 6.6, propanal has the lowest CV of 
28.4%. Butanal, pentanal, hexanal, heptanal, octanal and decanal all have CV values in a range 
of 40% to 60%. Trace exhaled breath VOCs often have a higher coefficient of variation as the 
exhaled concentrations are also close to the instrument detection limit. For instance, the CV% 
of exhaled breath HCN has been reported to be around 50% with a maximum of 85%; HCN 
has been proposed as a potential biomarker for Pseudomonas aeruginosa bacterial infection in 
patients with cystic fibrosis181. However, if a trace VOC is to be considered a suitable volatile 
breath biomarker for a specific disease, its concentration would need to be sufficiently 
increased or decreased in comparison to background levels. At the same time, it must also 
overcome any variation resulting from the sampling process or analytical method employed.  
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Aldehyde Median (IQR) CV% 
Propanal 10.8(6.9-18.1) 28 
Butanal 2.5(1-3.9) 43 
Pentanal 1.9(0.8-2.5) 55 
Hexanal 2.3(1.5-4.4) 51 
Heptanal 1.5(0.6-3.6) 58 
Octanal 1.5(0-2.4) 63 
Nonanal 0.9(0.2-2.2) 34 
Decanal 0.9(0.3-2.7) 41 
 
Table 6.6: Median concentrations and interquartile range (IQR) (ppbv) of C3 to C10 aldehydes 
from 26 healthy volunteers. The intra-individual CV% values have been calculated from four 
exhaled breath samples taken from 10 of the healthy volunteers. 
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Figure 6.6: Box-Whisker plots of the median concentrations and IQR (ppbv) of C3 to C10 
aldehydes within exhaled breath samples from the 26 healthy volunteers. 
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Figure 6.7: Correlation of the measured concentrations of hexanal with heptanal, from the 
exhaled breath of 26 healthy volunteers. 
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Figure 6.8: Box-Whisker plots of isoprene, acetic acid and acetone from the exhaled breath 
of 26 healthy subjects. 
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6.2.5 Discussion 
In this study, it is observed that C4-C10 aldehydes are present at trace concentrations in the 
exhaled breath of healthy subjects using SIFT-MS. The concentrations of exhaled propanal to 
decanal from 26 healthy volunteers were measured using the MIM mode of SIFT-MS. Propanal 
was found to be the most abundant amongst the investigated aldehydes, with a median 
concentration of 10.8 ppbv (IQR 6.9-18.1). The kinetics library entry for propanal has 
accounted for the isotopologue of (H3O
+)2 at m/z 55. In contrast to propanal, saturated 
aldehydes from butanal to decanal were present at trace concentrations in the exhaled breath of 
healthy persons. Each of these aldehydes has a median concentration of less than 3 ppbv, with 
a narrow interquartile range, in the exhaled breath of all healthy volunteers. Several aldehydes 
had concentrations of < 1 ppbv recorded within exhaled breath; at these levels it is likely that 
the limit of detection for the instrument is being reached for these compounds. In contrast to 
abundant VOCs such as acetone, these aldehydes did not demonstrate a normal or log-normal 
distribution within a healthy cohort. The median concentration and interquartile range (IQR) 
for these aldehydes is shown in Table 6.6 & Figure 6.6. Amongst the investigated VOCs, the 
measured concentrations of hexanal and heptanal were the only aldehydes that demonstrated a 
reasonable correlation (Figure 6.7). The square correlation coefficient R2 is 0.67. There was no 
correlation of age or gender with any of the C3-C10 aldehydes, a finding that previously been 
reported63,200. There were 4 smokers in this study out of 26 healthy subjects. Using Mann-
Whitney U test, no aldehyde demonstrated a significant difference between smokers and non-
smokers, although it is noted that there were relatively few smokers in this study cohort. Jareno-
Esteban et al. have previously reported that nonanal is influenced by smoking status201.  Fuchs 
et al. reported that the exhaled of propanal, butanal, heptanal and decanal concentrations were 
not significantly different between smokers and healthy volunteers using GC-MS63.  
The Box-Whisker plot of the measured abundant VOCs from the exhaled breath of 26 
healthy volunteers is shown in Figure 6.8. The median and IQR concentrations of isoprene, 
acetic acid and acetone were 66 ppbv (IQR 45-97), 25 ppbv (IQR 12-33) and 315 ppbv (IQR 
175-398), respectively. Pysanenko et al. have previously reported a concentration range of 30 
to 60 ppbv for acetic acid, from the exhaled breath of five healthy volunteers analysed using 
SIFT-MS158. In a study on exhaled breath samples from 30 healthy volunteers, Turner et al 
reported a mean concentration of 462 ppbv with a range of 148-2744 ppbv and 118 ± 68 ppbv 
for acetone and isoprene, respectively114,115. The measured concentrations of acetic acid, 
acetone and isoprene in this study are in agreement with the previous exhaled breath studies on 
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healthy volunteers using SIFT-MS, further underlining the reliability of the Nalophan® 
sampling method employed.  
Ligor et al. have previously analysed the exhaled breath of healthy volunteers using 
SPME/GC-MS202. Their study demonstrated the presence of propanal, hexanal and heptanal in 
the exhaled breath of healthy volunteers202. Fuchs et al. have demonstrated that C1–C10 
aldehydes could be detected in the exhaled breath of all their study subjects which included 
healthy volunteers, smokers and lung cancer patients using SPME/GC-MS63. Using this 
method, they reported aldehyde concentrations ranging from 7 pmol/l (161 pptv) for butanal to 
71 nmol/l (1,582 ppbv) for formaldehyde. Aldehydes are known to have both mutagenic and 
carcinogenic potential and hence these compounds warrant further investigation in the exhaled 
breath of persons with underlying disease to assess their potential as volatile breath biomarkers. 
Several studies have already demonstrated higher concentrations of aldehydes in respiratory 
diseases. In the study by Fuchs et al., they found significantly higher concentrations of 
pentanal, hexanal, octanal and nonanal in the exhaled breath of lung cancer patients compared 
with smokers and healthy controls63. Corradi et al. investigated aldehydes in exhaled breath 
condensate from patients with chronic obstructive pulmonary disease using liquid 
chromatography tandem mass spectrometry203. They found increased levels of 
malondialdehyde, hexanal, and heptanal in patients as compared with non-smoking control 
subjects. Bartoli et al. also demonstrated significantly higher levels of malondialdehyde in the 
exhaled breath condensate of those with chronic airways diseases vs. control subjects204. 
Further studies with large patient numbers are necessary to assess whether the promising 
aldehyde associations observed in these studies could be applied in mainstream clinical 
practice. 
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6.2.6 Conclusions 
In this study, C3-C10 aldehydes have been quantified within the exhaled breath of healthy 
subjects using the SIFT-MS platform. Propanal is the most abundant aldehyde present within 
the exhaled breath of healthy volunteers. The C4-C10 aldehydes are present at trace quantities 
in the exhaled breath of healthy subjects at median concentrations of less than 3 ppbv. The 
concentrations of the C3-C10 aldehydes observed in this study provide some guidance with 
respect to ‘normal values’ or reference ranges in absolutely healthy subjects. Knowledge of 
such ‘baseline’ concentrations in healthy persons is important, particularly in the context of 
exhaled breath aldehydes being investigated in those with underlying disease.   
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6.3 Exhaled breath VOC risk prediction model in oesophageal and gastric 
adenocarcinoma 
 
6.3.1 Objective 
The aims of this study were 1) to validate the exhaled breath VOCs identified in the pilot study 
in Section 6.1 in a larger patient cohort 2) to identify and quantify C3-C10 aldehydes in patients 
with oesophageal and gastric adenocarcinoma 3) to develop a VOC-based risk prediction 
model to distinguish oesophageal and gastric adenocarcinoma from non-cancer controls.    
 
6.3.2 Introduction  
The lack of signs and symptoms in the early stages of upper gastrointestinal cancer lead to 
delays in diagnosis. The results of the National OG Cancer Audit demonstrated that 65% of 
patients with oesophago-gastric cancer were not eligible for curative treatment due to spread 
of their disease20. However, many of these patients have soft symptoms in the earliest stages 
of their cancer. It is very challenging for general practitioners to differentiate patients with 
early cancer from those with benign causes for their symptoms, without referring all patients 
for endoscopy. This would not represent a cost-effective strategy in the Western world and 
hence there remains a significant clinical need to develop novel techniques to identify patients 
with upper gastro-intestinal cancer.  
The results of the pilot study (in Section 6.1) on exhaled breath VOCs identified 
compounds of interest in OG cancer, following on from the studies on biofluids. A total of 29 
VOCs have been investigated in this study including the C3-C10 aldehydes in a large patient 
cohort. In the cancer group, patients with both oesophageal and gastric adenocarcinoma were 
recruited for investigation. All patients with gastro-oesophageal junctional tumours (i.e., 
Siewert Type I-III) were classified within the oesophageal cancer group205. Patients with 
Barrett’s metaplasia were an additional control group that were also recruited. Demographic 
and potential clinical confounding factors that may affect exhaled breath VOC profiles have 
also been evaluated.   
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6.3.3 Methods 
6.3.3.1 Study Population 
Eligible patients referred for upper gastrointestinal endoscopy were recruited through Imperial 
College NHS Trust between November 2011 and August 2013. Exhaled breath samples were 
collected when patients were attending for one of the following investigations - staging 
laparoscopy and Oesophago-Gastro-Duodenoscopy (OGD), Upper Gastro-intestinal 
Endoscopic Ultrasound (EUS) or OGD only. The OGD component of the investigations and 
histological confirmation formed the reference standard for classification of patients within the 
study groups. Patients with histologically confirmed invasive oesophageal or gastric 
adenocarcinoma (prior to the commencement of any treatment) and considered for an ‘intention 
to cure’ treatment pathway were included in the cancer groups The non-cancer controls were 
classified according to endoscopy findings and biopsy results into Barrett’s metaplasia, benign 
disease and a normal upper gastro-intestinal (UGI) tract with negative urease test. Exclusion 
criteria for this study included patients with squamous cell carcinoma (SCC) of the upper 
gastro-intestinal (UGI) tract, previously diagnosed liver disease, small bowel/colonic 
pathology, any non-UGI cancer; and those with any signs/symptoms of acute infection. SCCs 
of the UGI tract were excluded from this study due to the relatively few number of patients 
treated with this pathology in our centre. Approval for the study was obtained from the 
institutional ethics review committee. Fully informed, written consent was obtained from all 
participants prior to enrolment in the study. Demographic and clinical data were archived in a 
linked, anonymised database. 
 
 
6.3.3.2 Procedures 
Breath sampling and analysis procedures were conducted using the method described in 
Section 6.1.3.2.  All patients were fasted for a minimum of 6 hours in keeping with the standard 
protocol for an OGD with no oral intake (including water) prior to their breath sample 
collection. Mixed alveolar breath samples were collected in secure double thickness (2x25µm) 
Nalophan® (Kalle UK Ltd., Witham, UK) bags prior to the patients’ scheduled clinical 
investigations. Collected breath samples were taken directly to the Surgical Sciences laboratory 
and analysed within an hour of collection.  
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6.3.3.3 SIFT-MS Analysis 
The Multiple Ion Monitoring Mode (MIM) of the Profile-3 SIFT-MS instrument was employed 
to analyse all exhaled breath samples. The calibration check procedure using the water content 
of the operator’s exhaled breath (6 +/- 0.1%) was conducted prior to each analysis. In this study, 
an additional check procedure using a Red-y Compact Mass Flow Meter (GCM-A4SA-BN00, 
Icenta Controls Ltd, Salisbury, UK) was performed. This external flow meter was employed to 
check the flow rate at the sample inlet of the SIFT-MS instrument prior to each analysis. The 
Nalophan® bag containing the breath sample was directly connected to the sample inlet arm of 
the SIFT-MS instrument and enclosed within an incubator held at 37 ̊C for the duration of the 
analysis. The 29 selected VOCs from exhaled breath samples were analysed for a total of 60 
seconds and the measured concentrations were averaged over this analysis time for each VOC. 
The running order for the VOCs and the reagent ions chosen for analysis of the VOCs is given 
in Table 6.7. The running order was strictly adhered to for each breath sample analysis. 
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Sample 
Run 
Ion Volatile organic compounds 
1 H
3
O
+
 Methanol, Propanol 
2 H
3
O
+
 Butanol, Pentanol, Diethyl ether 
3 H
3
O
+
 Propanoic acid, Buytric acid 
4 H
3
O
+
 Pentanoic acid, Hexanoic acid, Dimethyl disulphide 
5 H
3
O
+
 Dimethyl sulphide, Hydrogen sulphide, Hydrogen cyanide 
6 NO
+
 Isoprene, Phenol, Acetic acid 
7 NO
+
 Acetone, Ethyl phenol 
9 O
2
+.
 Carbon disulphide, Ammonia, Methyl phenol 
10 NO
+
 Propanal, Butanal, Pentanal, Hexanal 
11 NO
+
 Heptanal, Octanal, Nonanal, Decanal 
Table 6.7: The running order for the analysis of the VOCs and the characteristic ions employed.  
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6.3.3.4 Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics 20 (Chicago, IL, USA). A P 
value < 0.05 was considered significant and all statistical tests were two-sided. Mann-Whitney 
U tests were used to compare the concentrations of the measured VOCs. The comparisons 
made were: gastric adenocarcinoma versus normal UGI tract, oesophageal adenocarcinoma 
versus normal UGI tract, gastric adenocarcinoma versus non-cancer controls (benign controls 
& normal UGI tract), oesophageal adenocarcinoma versus non-cancer controls (Barrett’s 
metaplasia & benign controls & normal UGI tract), gastric adenocarcinoma versus oesophageal 
adenocarcinoma and finally benign controls versus normal UGI tract. The significantly 
different VOCs between the aforementioned groups were included in a binary logistic 
regression model; the accuracies of the models were assessed using the area under the curve 
(AUC) of the Receiver Operating Characteristic (ROC) curves.  The VOCs that demonstrated 
a statistically significant difference (set at a level of P<0.05) between each cancer group and 
non-cancer controls were included as variables ROC analysis. The aim of comparing these 
groups was to assess the feasibility of VOC profiles within exhaled breath to differentiate:  
1) Gastric adenocarcinoma from those with a normal upper gastro-intestinal tract 
2) Oesophageal adenocarcinoma from normal upper gastro-intestinal tract 
3) Gastric adenocarcinoma from non-cancer controls (benign controls & normal upper 
gastro-intestinal tract) 
4) Oesophageal adenocarcinoma from non-cancer (Barrett’s metaplasia, benign controls 
& normal upper gastro-intestinal tract) 
 
The linear combination of their concentrations was then compared with a variable threshold in 
order to construct the ROC curve. Optimum weights of the concentrations of individual VOC 
providing the maximal area under the curve (AUC) value for the ROC curve were obtained by 
a binary logistical regression analysis in which the disease conditions were used as the 
dependent variable and the VOCs were used as the independent variable. Using the linear 
combination of significant VOCs, the predicted probability (p) obtained from the binary 
logistical regression analysis is:   
 
ln (p/1-p) = coefficientn x VOCn + constant. 
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Potential confounding factors across the study groups were also evaluated by employing the 
Kruskal-Wallis test for age and χ2 test to assess for differences in gender, ischaemic heart 
disease, diabetes mellitus, respiratory disorders, renal disease, medications, H. pylori status, 
smoking status and alcohol intake. Linear regression models to assess any influence of patient 
demographic factors, upper gastrointestinal factors and medications on VOC concentrations 
were also created. Each individual VOC was used as a dependent variable and the possible 
confounding factors and cancer disease status as the independent variables. Age was 
continuous, whilst the remaining independent variables were categorical; medications, H. 
pylori status and cancer disease status were binary, either present or absent, smoking status and 
alcohol intake were ternary (smoker, ex-smoker, non-smoker and no alcohol, within guidance, 
excess of guidance). 
 
6.3.3.5 Risk Prediction Model 
A diagnostic prediction model was created for OG adenocarcinoma versus non-cancer controls 
using binary logistic regression analysis based on subset of VOCs statistically relevant for 
discrimination. The cancer group included both oesophageal and gastric adenocarcinoma; this 
combined group was tested as these cancers are considered comparable subtypes which have 
frequently been grouped together in neo-adjuvant chemotherapy trials206. The non-cancer 
group included the Barrett’s metaplasia, benign disease and the normal UGI tract controls.  
Step 1: a 10-fold cross-validation procedure for all VOCs was performed. Using this analysis, 
10% of randomly selected patients are left out at a time and the model is constructed based on 
the remaining 90% of the data. As part of this model building process, we employed ANOVA 
analysis in order to select the VOCs relevant for discrimination between the 2 groups based on 
the P value threshold of 0.05. The same procedure is iteratively applied until the ‘cancer’ versus 
‘non-cancer’ status of each patient has been predicted. Using a 10-fold cross-validation analysis 
results in 10 separate models being constructed, and a frequency histogram demonstrating the 
number of times a given VOC has been selected for discrimination using ANOVA is produced.  
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Step 2: the data was then split through a random number generation process; 2/3 of data were 
used to create the prediction model (model subset) and 1/3 to test the model (validation subset). 
The statistically significant VOCs were entered into a logistic regression analysis in a stepwise 
fashion. The most significant predictors were used to create the diagnostic prediction model. 
The accuracy of the resultant models was assessed using the area under ROC curve, sensitivity 
and specificity measures. In order to estimate variability, we performed a Monte Carlo 
simulation by repeating the aforementioned procedure 10 times with the resultant AUC 
presented as a mean +/- standard deviation.   
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6.3.4 Results 
6.3.4.1 Patient Characteristics 
210 consecutive patients (81 cancer cases and 129 controls) were enrolled into the study during 
the recruitment period. There were 48 patients with oesophageal adenocarcinoma and 33 
patients in the gastric adenocarcinoma group. The control groups had 16 patients with Barrett’s 
metaplasia and, 62 patients classified as benign controls and 51 patients were included in the 
normal UGI tract group. Patients within the benign group had the following diagnoses: 
oesophagitis (N=15), oesophageal stricture (N=5), oesophageal candidiasis (N=2), gastritis 
(N=20), gastric ulcer (N=6), gastro-jejunostomy-induced gastritis (N=2), duodenitis (N=9), 
duodenal ulcer (N=3). Table 6.8 outlines the demographic and clinical data for the patient 
groups. Details of the clinical staging of the cancer groups are provided in Table 6.9. The 
groups were well balanced in terms of baseline characteristics, except for gender. There is a 
male preponderance in the cancer groups (though not statically significant), which is to be 
expected given the disease is more common in men. There were no statistically significant 
differences in potential confounding factors across the groups except for H.pylori status; which, 
as expected, was higher in gastric cancer and benign groups. With regards to medications, 
aspirin was the only drug that demonstrated a statistical difference across the groups (Table 
6.10). All medications which demonstrated a P value < 0.2 between the study groups (i.e., 
Proton Pump Inhibitors (PPI), aspirin, folic acid, salbutamol, salmeterol, Selective Serotonin 
Reuptake Inhibitors (SSRIs), iron supplements & senna) were further assessed by linear 
regression analysis. 
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 Normal 
upper 
Gastro-
intestinal  
tract 
(N = 51) 
Benign 
Controls 
(N = 62) 
Oesophageal 
Adenocarcinoma 
(N = 48) 
Gastric 
Adenocarcinoma 
(N = 33) 
Barrett’s 
metaplasia 
(N = 16) 
P value† 
Age (IQR)* 61 (50-73) 64.5 (50-72) 63.5 (55.3-72.8) 58 (50.5-70.5) 67 (58.8-
72.8) 
0.47‡ 
Gender (M:F) 30:21 38:24 40:8 24:9 11:5 0.07 
Smoking      0.31 
     Non Smoker 33 (64.7) 32 (51.6) 21 (43.8) 14 (42.4) 8 (50.0)  
     Ex-Smoker 11 (21.6) 17 (27.4) 17 (35.4) 15 (45.5) 4 (25.0)  
     Smoker 7 (13.7) 13 (21.0) 10 (20.8) 4 (12.1) 4 (25.0)  
Alcohol Intake      0.76 
     Within Guidance 48 (94.1) 58 (93.6) 43 (89.6) 32 (97.0) 15 (93.8)  
     Excess 3 (5.9) 4 (6.5) 5 (10.4) 1 (3.0) 1 (6.3)  
PPI/H2 Antagonist 26 (51.0) 35 (56.5) 20 (41.7) 18 (54.5) 12 (75.0) 0.20 
Diabetes 13 (25.5) 8 (12.9) 4 (8.3) 6 (18.2) 2 (12.5) 0.18 
Hypertension/IHD 23 (45.1) 22 (35.5) 23 (47.9) 13 (39.4) 7 (43.8) 0.72 
Respiratory disorder 5 (9.8) 8 (12.9) 5 (10.4) 4 (12.1) 2 (12.5) 0.99 
Renal Disease 0 (0.0) 2 (3.2) 2 (4.2) 2 (6.1) 1 (6.3) 0.55 
H. Pylori Status 0 (0.0) 4 (6.5) 0 (0.0) 4 (12.1) 0 (0.0) 0.07 
Table 6.8: Patient characteristics across study groups. *Values are median (IQR), otherwise n 
(%). †χ2 test, except ‡ Kruskal-Wallis Test. Percentages are given within the brackets.  
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Characteristics 
 
Oesophageal Adenocarcinoma 
(N = 48) 
 
Gastric Adenocarcinoma 
(N = 33) 
Site of tumour: 
          Lower Oesophagus 
          Gastro-oesophageal junction 
          Proximal Stomach 
          Distal Stomach 
 
23 (47.9%) 
25 (52.1%) 
N/A 
N/A 
 
 
N/A 
N/A 
17 (51.5%) 
16 (48.5%) 
T Stage: 
                T1 
                T2 
                T3 
                T4 
 
 
11 (22.9%) 
7 (14.6%) 
29 (60.4%) 
1 (2.1%) 
 
4 (12.1%) 
11 (33.3%) 
12 (36.4%) 
6 (18.2%) 
Lymph Node Status 
               N0 
               N1 
               N2 
               N3 
 
19 (40.0%) 
27 (56.3%) 
2 (41.7%) 
0 (0.0) 
 
10 (30.3%) 
11 (33.3%) 
12 (36.4%) 
0 (0.0) 
Table 6.9: Clinical staging of the oesophageal and gastric adenocarcinoma groups. 
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Medications Normal 
upper GI 
Tract 
Benign 
Controls 
 
Oesophageal 
cancer 
 
Gastric 
cancer 
 
Barrett’s 
metaplasia 
 
P values 
Proton Pump Inhibitors 
(Omeprazole/Lansoprazole/Pantoprazole) 
26 33 21 18 13 0.14 
H2 Receptor Antagonist (Ranitidine/Famotidine) 1 4 1 1 1 0.67 
Gaviscon 1 1 0 0 0 0.78 
Sulfonylurea 
(Gliclazide/Glibenclamide/Glimperide) 
3 4 3 1 1 0.97 
Metformin 9 5 4 5 1 0.41 
Repaglinide 1 0 0 0 0 0.54 
Sitagliptin 1 0 1 0 0 0.69 
Insulin 2 1 1 0 0 0.72 
Statin(Simvastatin/Atorvastatin/Pravastatin & 
Rosuvastatin) 
19 16 13 5 5 0.27 
Ezetimide 1 1 0 0 0 0.78 
ACE Inhibitors (Lisinopril, Perindopril, 
Ramipril, Enalapril) 
12 9 6 4 4 0.43 
Angiotension II Inhibitors (Irbesartan, Losartan, 
Candesartan) 
4 5 5 1 3 0.45 
β-Blocker (Atenolol, Bisoprolol, Metoprolol) 6 10 6 5 3 0.93 
Furosemide 3 3 0 0 0 0.25 
Dihydropyridine Calcium Channel Blocker 
(Amlodipine, Nifidepine, Felodipine) 
11 11 8 5 3 0.953 
Diltiazem 0 2 1 0 0 0.56 
Thiazide Diuretics (Bendroflumethiazide, 
Indapamide) 
6 8 2 1 1 0.32 
Isosorbide Mononitrate 1 0 0 0 0 0.54 
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Digoxin 0 1 1 0 0 0.75 
Amiodarone 1 0 0 0 0 0.54 
Spironolactone 1 1 0 0 1 0.42 
Aspirin 12 9 4 2 6 0.01 
Clopidogrel 2 1 2 2 2 0.41 
Dipyridamole 2 1 0 0 0 0.45 
Warfarin 1 1 2 1 0 0.86 
B12 Injections 0 2 1 1 0 0.72 
Thiamine 2 2 0 0 0 0.47 
Folic Acid 2 0 0 0 1 0.14 
Salbutamol 0 6 2 2 0 0.15 
Salmeterol 0 3 1 3 0 0.17 
Tiotropium 1 2 0 1 0 0.73 
Prednisolone 2 4 0 0 0 0.20 
Levothyroxine 2 2 3 0 1 0.66 
Carbimazole 0 1 0 0 0 0.66 
Bisphosphanates (Alendronic Acid, Risedronate) 4 3 0 0 1 0.21 
ADCAL D3 2 2 1 0 1 0.74 
Cholecalciferol 1 4 0 1 2 0.37 
Calchichew 3 1 0 0 1 0.21 
Allopurinol 1 0 0 0 0 0.54 
Latanoprost 2 1 0 0 0 0.45 
Tramadol 1 1 0 2 0 0.36 
Cocodamol/Co-dydramol 3 0 1 0 1 0.20 
Paracetamol 1 0 0 1 0 0.51 
NSAIDS (Diclofenac/Naproxen) 1 1 0 0 0 0.78 
Selective Serotonin Reuptake Inhibitors (SSRIs) 
(Citalopram/Fluoxetine/Paroxetine/Sertraline) 
3 3 3 0 3 0.13 
Tricyclic Antidepressants (Amitriptyline, 
Nortriptyline) 
3 1 2 0 0 0.44 
Gabapentin 1 2 0 0 0 0.57 
134 
 
Benzodiazepines 
(Lorazepam/Diazepam/Temazepam) 
2 1 2 1 0 0.86 
Iron Supplements (Ferrous Sulphate, Ferrous 
Fumurate) 
4 3 0 5 1 0.09 
Doxazosin 3 1 2 1 2 0.39 
Tamsulosin 0 2 0 0 0 0.31 
Mycophenolate 1 0 0 0 0 0.54 
Methotrexate 1 0 0 0 0 0.54 
Domperidone 1 4 2 0 0 0.41 
Metoclopramide 0 0 0 1 0 0.25 
Senna 1 0 0 0 1 0.15 
Baclofen 1 0 0 0 0 0.54 
Dilsufuriam 0 0 1 0 0 0.50 
Mebeverine 0 0 0 1 0 0.25 
Table 6.10: Assessment of medication use across the study groups 
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6.3.4.2 Volatile Organic Compound Analysis 
A total of 29 VOCs from 8 distinct chemical groups present within exhaled breath (including 
alcohols, phenols, ketones, fatty acids, aldehydes, sulphur-containing compounds, nitrogen 
compounds and ether) were detected and quantified. The VOCs and the characteristic ions used 
for their analysis in MIM mode by SIFT-MS are listed in Table 6.11. The heat map 
demonstrated higher concentrations in the region of the fatty acids, phenols and aldehydes 
within both cancer groups (Figure 6.9). Univariate Mann-Whitney U analysis revealed 12 
VOCs at significantly higher concentrations in both the gastric and oesophageal 
adenocarcinoma groups when compared to non-cancer controls. These were pentanoic acid, 
hexanoic acid, phenol, methyl phenol, ethyl phenol, butanal, pentanal, hexanal, heptanal, 
octanal, nonanal and decanal (Figures 6.10, 6.11 and 6.12). In addition to these VOCs, butyric 
acid was significantly higher in the oesophageal adenocarcinoma group when compared to the 
non-cancer controls. There was no significant difference in the abundant breath VOCs 
(methanol, acetone, isoprene) and ammonia across the study groups (Figure 6.13 & Table 
6.12). Mann-Whitney U tests of all VOCs of oesophageal adenocarcinoma compared with 
gastric adenocarcinoma did not demonstrate any significant differences. Between the benign 
controls and the normal UGI tract group, there was a significant difference in nonanal (P < 
0.001) and decanal (P = 0.013). Details of the concentrations of the significant VOCs from 
each specific group and abundant breath metabolites are given in Table 6.12.  
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 Molecular 
formula 
Precursor ion m/z Characteristic product ions Reference 
Acetic acid C2H4O2 NO+ 90, 108 NO+·CH3COOH, 
NO+·(H2O)CH3COOH 
53 
Propanoic acid C3H6O2 H3O+ 75, 93 C3H6O2H+, C3H6O2H+(H2O) 53 
Butyric acid C4H8O2 H3O+ 89, 107 C4H8O2H+, C4H8O2H+(H2O) 53 
Pentanoic acid C5H10O2 H3O+ 103 C5H10O2H+ 53 
Hexanoic acid C6H12O2 H3O+ 117, 135 C6H12O2H+, C6H12O2H+(H2O) 53 
Propanal C3H6O NO+ 57 C3H5O+ 53 
Butanal C4H8O NO+ 71 C4H7O+ 53 
Pentanal C5H10O NO+ 85 C5H9O+ 53 
Hexanal C6H12O NO+ 99 C6H11O+ 53 
Heptanal C7H14O NO+ 113 C7H13O+ 53 
Octanal C8H16O NO+ 127 C8H15O+ 53 
Nonanal C9H18O NO+ 141 C9H17O+ 53 
Decanal C10H20O NO+ 155 C10H19O+ 53 
Methanol CH4O H3O+ 33, 51 CH5O+, CH5O+(H2O) 53 
Propanol C3H8O H3O+ 43 C3H7+ 53 
Butanol C4H10O H3O+ 57 C4H9+ 53 
Pentanol C5H12O H3O+ 71 C5H11+ 53 
Phenol C6H6O NO+ 94, 112 C6H6O+, C6H6O+(H2O) 135 
Methyl phenol C7H8O O2+ 108, 126 C7H8O+, C7H8O+(H2O) 135 
Ethyl phenol C8H10O NO+ 122, 140 C8H10O+, C8H10O+(H2O) 135 
Acetone C3H6O NO+ 88 NO+·C3H6O 53 
Dimethyl sulphide C2H6S H3O+ 63 C2H6SH+ 53 
Dimethyl disulphide C2H6S2 H3O+ 95 C2H6S2H+ 53 
Hydrogen sulphide H2S H3O+ 35 H3S+ 53 
Carbon disulphide CS2 O2+ 76 CS2+ 53 
Ammonia NH3 O2+ 17, 35 NH3+, NH3+(H2O) 53 
Hydrogen cyanide HCN H3O+ 28 H2CN+ 53 
Isoprene C5H8 NO+ 68 C5H8+ 53 
Diethyl ether C4H10O H3O+ 75 C4H10OH+ 53 
Table 6.11: The analytical chemistry information of the 29 VOCs, including their molecular 
formula, mass to charge ratio, the precursor ions, and characteristic product ions used for their 
analysis by SIFT-MS.  
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Figure 6.9: Heat map of the discriminatory VOCs from all patients across the study groups. Each column represents one patient (N = 210). The 
study groups include the normal upper gastro-intestinal tract, the benign disease controls, Barrett’s metaplasia, oesophageal cancer and gastric 
cancer groups. Each value in the unit is the measured concentration (ppbv) of the specific VOC. Within the colour scheme the 25th lower quartile, 
median and the 75th upper quartile of the measured concentrations for specific VOC are defined as pure green, yellow and red, respectively.  
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Figure 6.10: Box-Whisker plots of the measured concentrations (ppbv) of (A) butyric, (B) 
pentanoic and (C) hexanoic acids. Normal represents the normal UGI tract group; benign 
represents the benign disease group; Barrett’s is the Barrett’s metaplasia group; OC is the 
oesophageal cancer group and GC is the gastric cancer group. 
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Figure 6.11: Box-Whisker plots of the measured concentrations (ppbv) of (A) phenol, (B) 
methyl phenol and (C) ethyl phenol. Normal represents the normal UGI tract group; benign 
represents the benign disease group; Barrett’s is the Barrett’s metaplasia group; OC is the 
oesophageal cancer group and GC is the gastric cancer group. 
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Figure 6.12: Box-Whisker plots of the measured concentrations (ppbv) of (A) heptanal, (B) 
nonanal and (C) decanal. Normal represents the normal UGI tract group; benign represents the 
benign disease group; Barrett’s is the Barrett’s metaplasia group; OC is the oesophageal cancer 
group and GC is the gastric cancer group. 
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Figure 6.13: Box-Whisker plots of the measured concentrations (ppbv) of the abundant breath 
metabolites - (A) methanol, (B) acetone, (C) isoprene and (D) ammonia. Normal represents the 
normal UGI tract group; benign represents the benign disease group; Barrett’s is the Barrett’s 
metaplasia group; OC is the oesophageal cancer group and GC is the gastric cancer group. 
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Gastric cancer 
 
Oesophageal cancer Barrett’s metaplasia 
 
Benign Controls Normal upper gastro-intestinal 
 tract 
 P - values (Mann-Whitney U test) 
 Median IQR Median IQR Median IQR Median IQR Median IQR Oesophageal 
cancer vs. non 
cancer1 
Gastric 
cancer vs. 
non-
cancer2 
Adenocarcinoma3 
versus non-
cancer1 
Butyric acid 36 23-61 40 29-55 40 24-43 33 23-43 31 22-43 0.007 0.10 0.005 
Pentanoic acid 12 9-18 12 8-19 9 6-14 9 6-17 10 8-15 0.02 0.03 0.004 
Hexanoic acid 14 10-22 13 9-30 6 5-11 7 5-10 7 3-10 <0.001 <0.001 <0.001 
Phenol 10 6-25 9 6-18 5 1-11 5 2-8 4 3-7 <0.001 <0.001 <0.001 
Methyl phenol 8 3-10 7 4-13 3 2-5 4 2-6 3 2-5 <0.001 <0.001 <0.001 
Ethyl phenol 12 7-21 8 4-14 4 2-7 5 2-8 4 2-6 <0.001 <0.001 <0.001 
Butanal 4 2-7 4 2-7 3 2-4 3 1-6 2 1-4 0.008 0.04 0.002 
Pentanal 2 2-7 3 2-7 2 1-4 2 0-3 2 0-3 <0.001 <0.001 <0.001 
Hexanal 5 3-10 6 3-11 5 1-6 4 2-7 3 2-5 <0.001 0.009 <0.001 
Heptanal 5 2-7 4 2-6 2 1-4 3 1-5 2 1-4 0.003 0.001 <0.001 
Octanal 5 3-9 3 1-7 2 1-5 2 1-3 1 1-2 0.001 <0.001 <0.001 
Nonanal 5 2-10 3 1-8 1 0-3 2 1-4 1 0-2 <0.001 <0.001 <0.001 
Decanal 10 5-17 8 5-15 2 0-5 3 2-5 2 1-3 <0.001 <0.001 <0.001 
 
Methanol 
 
233 
  
  157-333 
 
245 
 
180-344 
 
258 
 
171-317 
 
248 
 
187-291 
 
248 
 
204-315 
          
         0.87 
 
0.65 
 
0.89 
Acetone 262 146-573 305 133-588 389 157-674 341 233-596 338 190-789 0.17 0.17 0.09 
Isoprene 69 49-100 67 49-109 64 41-79 58 41-89 64 51-83 0.18 0.38 0.14 
Ammonia 452 275-687 478 266-635 549 346-705 367 190-570 330 277-575 0.21 0.11 0.11 
Table 6.12: The statistically significant VOCs and abundant breath metabolites across the study groups. Median and Interquartile range (IQR) are 
measured by parts-per-billion by volume (ppbv). 1: the non-cancer controls comprise of the normal upper gastro-intestinal tract, benign and 
Barrett’s metaplasia groups. 2: the non-cancer controls comprises of normal upper gastro-intestinal tract and benign groups. 3: the carcinoma group 
comprises gastric adenocarcinoma and oesophageal adenocarcinoma. 
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ROC analysis applying the significant VOCs identified in univariate analysis gave an area 
under the curve (AUC) for discriminating gastric cancer and oesophageal cancer from the 
normal UGI tract group of 0.98 and 0.97 respectively (Figure 6.14). The AUC for the ROC 
curves to discriminate gastric cancer and oesophageal cancer from non-cancer controls were 
0.92 and 0.90 respectively (Figure 6.15). A summary of the ROC analysis, sensitivity and 
specificity of discriminating cancer groups from controls is given in Table 6.13. Detailed 
information of the coefficients and constants derived from the binary logistic regression 
equation for the ROC analysis is given in Appendix C.  
 
 
Figure 6.14: ROC curves for (A) gastric and (B) oesophageal cancer versus normal upper GI 
tract 
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Figure 6.15: ROC curves for (A) gastric and (B) oesophageal cancer versus all non-cancer 
controls.  
 
 
 
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
A  Gastric cancer versus non-cancer
AUC = 0.92
 
 
S
en
si
ti
v
it
y
1-Specificity
0.0 0.2 0.4 0.6 0.8 1.0 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
B  Oesophageal cancer versus non-cancer 
AUC = 0.90 
  
  
Sensitivity 
1-Specificity 
145 
 
Table 6.13: Summary of ROC analysis, sensitivity and specificity of discriminating cancer groups from control groups. 
 Gastric 
Adenocarcinoma 
versus 
normal upper gastro-
intestinal tract 
Oesophageal 
Adenocarcinoma 
versus 
normal upper gastro-
intestinal tract 
Gastric 
Adenocarcinoma 
versus 
non-cancer control1 
Oesophageal 
Adenocarcinoma 
versus 
non-cancer control2 
Diagnostic prediction 
model 
Model subset 
Diagnostic prediction 
model 
Validation subset 
AUC 0.98 0.97 0.92 0.90 0.92 ± 0.01 0.87 ± 0.03 
95% CI 0.96-1.00 0.93-1.00 0.85-0.98 0.85-0.96 N/A N/A 
Optimum probability 0.35 0.55 0.20 0.21 N/A N/A 
Sensitivity (%) 100% 98% 87.9% 87.5% 89.3% 86.7% 
Specificity (%) 92.2% 91.7% 88.5% 82.9% 83.7% 81.2% 
1. Benign control and normal upper gastro-intestinal tract. 
2. Benign control, Barrett’s metaplasia and normal upper gastro-intestinal tract. 
3. Gastric adenocarcinoma and oesophageal adenocarcinoma 
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The linear regression model demonstrated cancer disease status to be the strongest predictor of 
high concentrations for all the significant VOCs; disease status did not correlate with known 
abundant exhaled breath VOCs except isoprene. None of the patient demographic factors, H. 
pylori status, alcohol intake, smoking status or medications were independent predictors for 
any significant VOC. H. pylori status and PPI use were independent predictors for breath 
ammonia concentrations, which further emphasises the reliability of the sampling methodology 
and sensitivity of the analytical technique employed in this study. Detailed information of the 
binary logistic regression analysis for the potential confounding factors is given in Appendix 
D. The potential exogenous VOC contamination within the experimental methodology has also 
been investigated; all potential VOC biomarkers were present at trace concentrations or at the 
detection limit of the instrument within laboratory room air and the synthetic air-filled 
Nalophan® bags in comparison to the concentrations observed within exhaled breath. These 
experiments confirmed that the ambient air trace compounds and the sampling bag surface 
emissions have negligible overall contributions to the measured VOCs (Table 6.14). 
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VOCs Room air Nalophan® Bag 
 Median IQR Median IQR 
Butyric acid 1.3 1-4.3 3.2 1.7-4.1 
Hexanoic acid 1 0-3 1 1-2 
Phenol 2 1-3 1 1-1.4 
Methyl phenol 1 0-2 1 1-3 
Ethyl phenol 0 0-2 2 1-2 
Butanal 1 0-1.3 0.5 0.2-0.6 
Pentanal 0.8 0-1.3 0.5 0.2-1.0 
Hexanal 0.8 0-1.3 0.9 0.6-1.4 
Heptanal 0 0-0.3 1.1 0.8-1.6 
Octanal 0.9 0-1.8 0.6 0.4-1.0 
Nonanal 0.7 0-1 0.5 0.2-0.9 
Decanal 0.5 0-1.3 0.7 0.7-1.0 
Methanol 38 30-50 29 22-37 
Acetone 6 3-10 1 0-2 
Ammonia 75 30-200 50.4 21.2-84.3 
Isoprene 3 1-5 2 1-3 
Table 6.14: Room air and Nalophan® bags (inflated with dry synthetic air) measurements of 
each VOC. Median and Interquartile range (IQR) concentrations in parts-per-billion by volume 
(ppbv) have been calculated from ten measurements of laboratory room air taken on ten 
separate days; the measurement for the Nalophan® bag contribution was also calculated by 
applying the same method.  
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6.3.4.3 Risk Prediction Model 
A diagnostic prediction model to discriminate OG adenocarcinoma (N = 81) from non-cancer 
controls (including Barrett’s metaplasia, benign group & normal UGI tract N = 129) was 
constructed. The frequency histogram of the VOCs identified as discriminators between cancer 
and non-cancer is provided (Figure 6.16). Noteworthy, is that the significant VOCs identified 
by both univariate and multivariate analysis all came from the same chemical groups - fatty 
acids, phenols and aldehydes. The eight most significant predictors for adenocarcinoma 
identified from stepwise logistic regression were: butyric acid, hexanoic acid, phenol, ethyl 
phenol, methyl phenol, heptanal, nonanal and decanal. After being subjected to Monte Carlo 
simulation, the AUC curve for the model subset was 0.92 ± 0.01 with a sensitivity of 89.3% 
(95% CI, 77.0 – 95.7) and specificity of 83.7% (95% CI, 74.5 – 90.9). The AUC for the 
validation subset was 0.87 ± 0.03, with a sensitivity of 86.7% (95% CI, 71.6 – 97.6) and 
specificity of 81.2% (95% CI, 64.0 – 90.0) (Table 6.13 and Figure 6.17). The model subset, on 
average, correctly classified 120 out of 139 patients (diagnostic accuracy 86.0% ± 0.02) with 
6 false negatives. The validation subset, on average, correctly classified 59 out of 71 patients 
(diagnostic accuracy 83.3% ± 0.04), with 3 false negatives. 
 
Figure 6.16: Frequency histogram of VOCs used in the diagnostic model to discriminate OG 
adenocarcinoma from non-cancer controls.  
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Figure 6.17: ROC curves for (A) Model subset and (B) Validation subset of the diagnostic 
prediction model to discriminate upper gastro-intestinal adenocarcinoma from non-cancer 
controls. 
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6.3.5 Discussion 
In this study, increased concentrations of fatty acid, phenol and aldehyde VOCs have been 
observed in patients with oesophageal and gastric adenocarcinoma. The diagnostic prediction 
model based on butyric acid, hexanoic acid, phenol, ethyl phenol, methyl phenol, heptanal, 
nonanal and decanal differentiated cancer from controls with good diagnostic accuracy and 
with relatively few false negatives. The significant VOCs (i.e., phenol, methyl phenol, ethyl, 
hexanoic acid) previously identified (Section 6.1) have all replicated the same trend in this 
larger study on patients with oesophageal and gastric adenocarcinoma. The control groups 
recruited are also representative of a typical upper GI patient population, many of whom 
present with non-specific upper gastro-intestinal symptoms; in this group, it is very difficult to 
reliably identify those at highest risk of an upper gastrointestinal malignancy without referring 
the majority of such patients for endoscopy. The results of this study demonstrate that 
quantification of exhaled breath VOCs has the potential for development as a diagnostic test 
for oesophageal and gastric adenocarcinoma.  
The most significant VOC predictors for oesophageal and gastric adenocarcinoma all came 
from the fatty acid, phenol and aldehyde groups. These compounds were all observed at 
varying concentrations in the earlier studies on the headspace of gastric content and urine of 
patients with oesophago-gastric cancer (Chapters 4 and 5). The upregulation of fatty acids has 
been reported in both oesophageal cancer tissue and in the serum of patients with colorectal 
cancer207,208. Proteolytic fermentation of tyrosine results in the production of phenols with 
dysfunction in these pathways being linked to carcinogenesis194; high levels of tyrosine have 
previously been reported in the gastric juice of patients with gastric cancer and in oesophageal 
cancer tissue126, 207. Increased concentrations of aldehydes have been reported in patients with 
lung and liver cancer within exhaled breath and blood, respectively63,74. Similarly, in this study, 
we have observed increased concentrations for aldehydes within exhaled breath in oesophageal 
and gastric cancer. Elevated aldehyde dehydrogenase activity has been demonstrated as a 
function of oesophageal cancer tumorispheres and aldehydes have also been shown to be 
metabolised by human hepatocellular carcinoma cells209,210. The majority of VOCs are thought 
to be of systemic origin; the concentrations of these VOCs in exhaled breath are most likely 
related to levels observed in blood183. The higher concentrations of specific VOCs in the cancer 
cohort may be a result of the underlying malignancy or the host response to the disease; future 
studies will need to explore the biochemical mechanisms responsible for this.   
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The confounding factors, co-existing illnesses and medications that may affect exhaled breath 
VOC profiles in this cancer patient population have been extensively evaluated. The exclusion 
criteria were adopted to eliminate any potential influence from other intra-abdominal 
conditions on the investigated exhaled breath VOCs. Linear regression analysis of upper 
gastrointestinal factors, smoking status, alcohol intake and medications did not demonstrate 
any influence on the significant volatile breath biomarkers. H. pylori status predicted for 
increased concentrations of breath ammonia, irrespective of disease status; this underlines the 
reliability of the breath sampling technique and sensitivity of the VOC analytical method 
employed. Ulanowska et al. have previously analysed exhaled breath samples from patients 
with H. pylori and healthy controls using SPME/GC-MS211. They observed isobutane, 2-
butanone and ethyl acetate in the exhaled breath of H-pylori-infected patients and from cultures 
of H.pylori strains; they did not observe the presence of any fatty acids, phenols or aldehydes, 
indicating that their increased concentrations in this study are a primarily cancer-related 
effect211. The concentrations of abundant breath metabolites (i.e., acetone, methanol, isoprene 
and ammonia) did not demonstrate any significant differences between the cancer patients and 
non-cancer controls. On regression analysis, isoprene though did correlate with cancer disease 
status. Isoprene is a known product of lipid peroxidation and hence a surrogate for oxidative 
stress, but it is observed in the exhaled breath of all healthy people except neonates187,212. 
Exhaled breath isoprene has previously been reported at increased concentrations in patients 
with gastric cancer and in head & neck squamous cell carcinomas191,213. Isoprene levels have 
also been observed at increased concentrations intra-operatively and to subsequently reduce 
significantly after surgical resection of lung cancer214. The elevated levels of isoprene represent 
are likely to be a systemic oxidative stress response and are not specific to oesophageal and 
gastric adenocarcinoma. Comparison of early (Stage I) and late stages (Stage II & III) within 
the cancer groups did not demonstrate any significant VOC differences. However, all the 
recruited cancer patients had localized disease with no evidence of distant or peritoneal spread; 
this may account for the minimal differences observed between cancer stages. Phillips et al. 
have previously reported no differences in VOC concentrations between cancer stages in their 
study investigating exhaled breath in lung cancer60.   
 
The key advantage of the breath collection method that has been employed for these studies is 
that samples are easily acquired using a non-invasive approach; this gives it a high acceptability 
rating amongst patients. Sample processing (without any need for pre-analysis preparation) and 
acquisition of results takes ~ 15 minutes, which is advantageous in the clinical setting. The 
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SIFT-MS technique has allowed accurate quantification of VOCs within human biological 
samples down to 1 part-per-billion by volume. In this study, the clinical classification of the 
patients is also rigorous given everyone underwent an OGD on the day of sampling with 
subsequent histological confirmation. All cancer patients recruited into this study were on an 
‘intention to cure’ pathway (prior to starting chemotherapy treatment) and hence the results are 
applicable to a patient population that would benefit from curative surgery. An important 
limitation of the study is that further studies are required to evaluate the potential influence of 
other gastro-intestinal diseases as well as non-GI cancers on the volatile breath biomarkers. 
Investigation of exhaled breath VOCs in squamous cell carcinoma will also be necessary to 
give global relevance for any potential diagnostic test.  
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6.3.6 Conclusions 
In conclusion, fatty acid, phenol and aldehyde VOCs have been identified as potential breath 
biomarkers in oesophageal and gastric adenocarcinoma. These VOCs represent suitable 
chemical targets that could be used in the development of a point-of-care sensor-based device 
following the same concept as breathalysers for blood alcohol quantification. Following this 
principle, a VOC-based breath test could be employed in the primary care setting to risk-stratify 
patients with non-specific upper gastro-intestinal symptoms, identifying those at highest risk 
of oesophageal and gastric cancer and hence in need of urgent endoscopy. OGD will remain 
the ‘gold standard’ procedure for diagnosis of upper gastro-intestinal malignancy given it 
allows both direct visualization and tissue biopsy. Any VOC-based test would be utilised as a 
diagnostic adjunct to endoscopic investigation, being employed in a screening capacity. 
However, development of VOCs for this purpose would also need to take account of the World 
Health Organisation’s guidelines on screening215:  
1. The condition should be an important health problem. 
2. There should be a treatment for the condition. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a latent stage of the disease. 
5. There should be a test or examination for the condition. 
6. The test should be acceptable to the population. 
7. The natural history of the disease should be adequately understood. 
8. There should be an agreed policy on whom to treat. 
9. The total cost of finding a case should be economically balanced in relation to 
medical expenditure as a whole. 
10. Case-finding should be a continuous process, not just a "once and for all" project 
 
If these criteria could be satisfied, this translational approach has the potential to improve the 
pick-up rate for oesophageal and gastric cancer. Moreover, if a higher proportion of ‘treatable’ 
cancer cases are identified, this would lead to an increased number of patients being managed 
on an intention to cure basis and potentially improve oncological survival rates in the long 
term. A secondary benefit could also be a resultant decrease in the negative OGD rate and a 
reduction in the number of patients undergoing unnecessary invasive procedures. Thus, more 
studies with large patient cohorts will be necessary to evaluate exhaled breath VOCs for their 
applicability as potential cancer diagnostic tools.  
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6.4 The effect of acute infection on cancer-related VOCs 
 
6.4.1 Objective  
To investigate whether the significant exhaled breath VOCs in oesophageal and gastric cancer 
are elevated in the presence of acute infection.  
 
6.4.2 Introduction 
Community acquired pneumonia and urinary tract infections (UTI) are medical conditions that 
frequently necessitate hospital admission. The incidence of both infections continues to rise in 
line with increases in our aging population. The most common organisms responsible for 
community acquired bacteraemias include E.coli, Staphylococcus aureus and Streptococcus 
Pneumoniae216. Kunze et al. investigated E.coli cultures using multi-capillary column-ion 
mobility spectrometry (MCC-IMS); they reported that decan-1-ol, ethanol, indole and octan-
1-ol signals were important in differentiating E.coli from the Lysogeny Broth growth medium 
in which the bacterium was grown217. Filipiak et al. investigated VOC release from the 
headspace of Staphylococcus aureus and Pseudomonas aeruginosa cultures218. They observed 
increased concentrations of acetic acid, 3-methylbutanal, 2-methylpropanal, acetaldehyde and 
methyl-2-butenal in the headspace of Staph. aureus cultures218. It was also reported that 
propanal, butanal, octanal and nonanal were taken up by Pseudomonas aeruginosa cultures218. 
Julák et al. analysed bronchoalveolar lavage samples from patients with bacterial pneumonia 
using SIFT-MS and GC-MS219. They reported acetone and methanol levels of 1800-7200 ppbv 
and 170-1000 ppbv, respectively219. The above studies identified potential VOCs that may be 
of importance in the non-invasive diagnosis of infectious pathogens. The main aim of this study 
was to assess the concentrations of fatty acids, phenols and aldehydes within the exhaled breath 
of persons admitted to hospital with community acquired infections and UTIs.  
 
 
 
155 
 
6.4.3 Methods 
Patients were recruited for the study through Imperial College Healthcare NHS Trust, London 
after a diagnosis of community acquired pneumonia or urinary tract infection (UTI) was 
reported by an independent physician. Fully informed, written consent was obtained from all 
participants prior to enrolment in the study. Exhaled breath samples were collected from every 
patient within the first 24 hours of their admission to hospital. Samples of mixed alveolar breath 
were collected into Nalophan® bags employing the exact method described in section 6.1.3.2. 
All breath samples were analysed within 60 minutes of collection. SIFT-MS analysis of the 
exhaled breath samples was conducted using the MIM mode. The twelve VOCs present at 
significantly higher concentrations in patients with gastric and oesophageal adenocarcinoma 
(i.e., pentanoic acid, hexanoic acid, phenol, methyl phenol, ethyl phenol, butanal, pentanal, 
hexanal, heptanal, octanal, nonanal and decanal) were analysed in this study. In addition to 
these VOCs, concentrations of the abundant breath metabolites (i.e., methanol, acetone, 
isoprene and ammonia) were also recorded. Comparative analysis is made with the OG cancer 
cohorts and the upper gastro-intestinal control groups from section 6.3.3.1.  
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6.4.4 Results 
Ten patients with community acquired pneumonia (7 male: 3 female) and 10 patients with UTI 
(2 male: 8 female) were recruited for this pilot study. The mean ages were 63.8±22.4 years and 
52.1±19.6 years in the pneumonia and UTI groups, respectively. The median admission day C-
reactive protein (CRP) levels were 217 (IQR103-273) and 157 (IQR 119-274) in the pneumonia 
and UTI groups, respectively. Streptococcus pneumoniae growth was confirmed on blood 
culture in 3 of the pneumonia patients. E.coli was the most frequently cultured organism in the 
UTI group (3 out of 10 patients). Sputum, urine and blood cultures from patients admitted with 
pneumonia or UTI do not always confirm growth of a specific organism. Huijskens et al. 
reported that sampling strategy may influence diagnostic yield of bacterial pathogens in 
community acquired pneumonia220. They reported detection of a pathogen in 49.6% cases of 
pneumonia when employing conventional culture techniques220.  
Off-line bag sampling was observed as an important methodology in patients with pneumonia, 
as many of them would have been unable to achieve the necessary Forced Expiratory Volume 
(FEV1) required to record accurate on-line measurements. The median concentrations and 
interquartile ranges of the same compounds in the community acquired pneumonia and UTI 
groups are shown in Table 6.15. Box and Whisker plots of the median concentrations and 
interquartile range (in ppbv) of the 12 VOCs are shown in Figures 6.18, 6.19, 6.20 and 6.21. 
Comparison of the pneumonia & UTI cohorts is made with the groups from the previous study. 
In the Box and Whisker plots, the x-axis labels refer to the following - Normal represents the 
normal UGI tract group; benign represents the benign Upper GI disease group; Barrett’s is the 
Barrett’s metaplasia group; OC is the oesophageal cancer group and GC is the gastric cancer 
group. 
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Gastric cancer 
 
Oesophageal cancer Community Acquired 
Pneumonia 
Urinary Tract Infection 
 Median IQR Median IQR Median IQR Median IQR 
Pentanoic acid 12 9-18 12 8-19 9 6-13 10 7-12 
Hexanoic acid 14 10-22 13 9-30 8 6-11 8 7-9 
Phenol 10 6-25 9 6-18 6 3-9 5 2-8 
Methyl phenol 8 3-10 7 4-13 6 4-7 3 1-7 
Ethyl phenol 12 7-21 8 4-14 6 4-8 3 2-8 
Butanal 4 2-7 4 2-7 5 3-6 2 2-5 
Pentanal 2 2-7 3 2-7 3 2-4 2 1-4 
Hexanal 5 3-10 6 3-11 4 2-6 3 1-5 
Heptanal 5 2-7 4 2-6 3 1-5 3 2-3 
Octanal 5 3-9 3 1-7 2 1-4 2 1-3 
Nonanal 5 2-10 3 1-8 2 1-3 3 2-5 
Decanal 10 5-17 8 5-15 4 3-5 2 1-2 
Methanol 233 157-333 245 180-344 176 154-289 296 226-397 
Acetone 262 146-573 305 133-588 373 190-570 534 401-1246 
Ammonia 452 275-687 478 266-635 437 308-477 277 236-402 
Isoprene 69 49-100 67 49-109 84 70-110 129 92-163 
Table 6.15: Concentrations of fatty acids, phenols, aldehydes and abundant breath VOCs 
comparing oesophageal and gastric cancer with levels observed in the community acquired 
pneumonia and urinary tract infection groups. 
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Figure 6.18: Box-Whisker plots of the measured concentrations (ppbv) of the fatty acids  
A) Pentanoic acid and B) Hexanoic acid.  
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Figure 6.19: Box-Whisker plots of the measured concentrations (ppbv) of A) Phenol B) Methyl 
Phenol and C) Ethyl phenol.  
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Figure 6.20: Box-Whisker plots of the measured concentrations (ppbv) of the aldehydes  
A) Butanal, B) Pentanal, C) Hexanal and D) Heptanal.  
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Figure 6.21: Box-Whisker plots of the measured concentrations (ppbv) of the aldehydes  
A) Octanal, B) Nonanal and C) Decanal.  
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6.4.5 Discussion 
The majority of the fatty acid, phenol and aldehyde compounds in pneumonia and urinary tract 
infection cohorts demonstrated median concentrations in the same range as the upper gastro-
intestinal control groups. All the VOCs of interest, except for butanal, were significantly 
different (p < 0.05) between the cancer groups and both infection cohorts. Butanal 
demonstrated an increased median concentration in the pneumonia group of 5 ppbv compared 
with 4 ppbv in the cancer cohorts and 2 ppbv in the UTI group. This isolated increase of butanal 
in the pneumonia group is notable given that none of the other investigated aldehydes 
demonstrated higher concentrations than the cancer cohorts. Filipiak et al. investigated 
Streptococcus pneumoniae and Haemophilus influenza cultures using GC-MS221. Both bacteria 
demonstrated significantly increased concentrations of butanal in their headspace. The 
concentration of butanal was 18 ppbv in the medium (blood agar plates and in tryptic soy broth) 
used to grow Streptococcus pneumoniae; after 7.5 hrs of growth, the butanal concentration 
within the headspace was 33 ppbv221. Staphylococcus aureus cultures have been reported to 
produce 3-methylbutanal218. Buszewski et al. also reported a higher concentration of butanal 
in the exhaled breath of lung cancer patients compared with controls196. Given the bacteria 
would have a local effect on VOC concentrations within the lungs in pneumonia, this may 
account for the increased concentrations of butanal within exhaled breath in the community 
acquired pneumonia group. Alternatively, given the increased concentrations of butanal have 
also been observed in lung cancer, this may represent a physiological response of diseased lung 
parenchyma. With regards to the abundant breath metabolites, lower concentrations of 
ammonia (277 ppbv) and higher concentrations of acetone (534 ppbv) and isoprene (129 ppbv) 
were observed in the UTI group when compared to the other study groups. However, a 
limitation of this study is that there were relatively fewer patients in the pneumonia and UTI 
cohorts in comparison to the other study groups.  
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6.4.6 Conclusions 
The results of this pilot study demonstrate minimal influence of acute infection on the 
significant VOCs in oesophageal and gastric adenocarcinoma, except for butanal. The potential 
effects of individual pathogens on VOCs must be further evaluated as these could be 
confounding factors in the application of these metabolites as potential cancer screening tools. 
The identification of VOCs that are produced by specific bacteria also raises the prospect that 
such compounds could have a non-invasive diagnostic or therapeutic monitoring role in 
community acquired infections. This could have significant clinical impact particularly if these 
VOCs are able to discriminate bacterial infection from viral aetiologies.   
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Chapter 7  
 
Summary, Conclusions and Future work 
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The present mass spectrometric interrogation of multiple bio-samples from patients with 
oesophageal and gastric cancer has identified several trace VOCs including fatty acids, phenols 
and aldehydes. The analysis of gastric content, urine and exhaled breath have clearly 
demonstrated that such trace compounds are more influential than abundant metabolites (i.e., 
acetone, isoprene, methanol) in upper gastro-intestinal malignancy. The results of this wide 
ranging study also highlighted that VOC profiles rather than individual compounds are likely 
to be more accurate for the molecular-orientated diagnosis of oesophageal and gastric cancer. 
The investigation of VOCs within gastric content has been described for the first time; this has 
included development of the headspace sampling and analysis, assessment of reproducibility 
and validation of measured VOC concentrations. Gastric content represents an important bio-
fluid to investigate so that we can improve our understanding of the pathogenesis of upper 
gastro-intestinal disease. Significant differences in VOCs within the stomach environment 
have been observed between patients with upper gastro-intestinal malignancy and those with 
normal upper GI tracts. Analysis of gastric content samples has also indicated hypoacidity to 
be a feature of upper gastro-intestinal disease. The influence of varying pH of this bio-fluid 
demonstrated a significantly increased production of (known carcinogen) acetaldehyde at pH 
6 within gastric content. Further investigation of the potentiating effects of H.pylori and cancer 
cells on intra-gastric pH is necessary to establish which of these factors may be predominantly 
responsible for the production of specific VOCs in oesophago-gastric cancer.  
In the headspace analysis of urine, increased concentrations of acetaldehyde, acetone, 
hexanoic acid and hydrogen sulphide in OG cancer were observed. These VOCs were also 
observed at higher concentrations in gastric content from patients with OG cancer and may 
reflect the systemic effects of the cancer state. The markedly lower concentrations of phenol 
within the urine of OG cancer patients were also noteworthy. Future studies on the headspace 
of urine in OG cancer should also investigate short chain aldehydes as potential VOCs of 
interest. With regards to exhaled breath analysis, a reproducible and reliable off-line bag 
sampling method for trace VOCs was validated and tested in a clinical setting. The C4-C10 
aldehydes were all shown to be present at < 3 ppbv within the exhaled breath of healthy 
volunteers; this study was particularly important given the minimal published literature 
available on quantifying aldehydes within exhaled breath. The study on exhaled breath in 210 
patients considered a representative upper gastro-intestinal population, all of whom were 
classified according to endoscopy and histology. An extensive analysis of confounding factors 
including co-morbidities and medications revealed that the increased concentrations of specific 
fatty acids, phenols and aldehydes are related primarily to cancer status. Future studies will 
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need to explore whether these increased concentrations arise from the cancer cells themselves, 
the surrounding micro-environment, the patient’s physiological response to malignancy or a 
combination of these. There will also need to be investigation of patients with metastatic or 
peritoneal disease secondary to oesophageal or gastric cancer and how cancer spread can affect 
these VOCs. The preliminary study on the effect of acute infection on fatty acids, phenols and 
aldehydes demonstrated that butanal is increased in community acquired pneumonia and hence 
is not a cancer-specific VOC. This research has highlighted the significant capabilities of on-
line mass spectrometry in the clinical environment, however there remain certain questions to 
be answered before VOCs can fulfil their translational potential.  
In all the studies, bio-samples were analysed within 1 hour of collection in the same 
hospital. This protocol was adopted to allow for standardization in experimental methodology 
and prevent any significant VOC degradation. In the next phase of this research, external 
validation studies in different hospitals are necessary to verify the promising findings. In the 
first instance, this will require transport of samples to the location of the SIFT-MS instrument 
laboratory. Hence, temporal assessment of VOC decay/stability of fatty acids, phenols and 
aldehydes will be necessary; this will be particularly important for exhaled breath samples. As 
part of the same experiments, an investigation of the suitability of different sampling bag 
materials (i.e., (2 x 70µm) Nalophan® and/or Tedlar®) could also be undertaken to check their 
retention efficiency to the different VOCs. Gilchrist et al. have previously investigated HCN 
concentrations within different bag materials; they reported Tedlar®-based bags provide 
optimal storage for exhaled breath HCN at 37oC at 24hrs181. Similar experiments should be 
conducted for the fatty acids, phenols and aldehydes to evaluate optimal storage conditions for 
these compounds.  
In the present research, patients with non-upper GI disease were excluded from 
recruitment at the outset. This exclusion criteria was adopted to allow investigation of VOCs 
in only one clinically relevant patient population. However, in order to develop non-invasive 
VOC profiling as potential cancer-screening tools, there will need to be systematic assessment 
of other diseases that may influence the same VOCs. Several of the detected short chain 
aldehydes have previously been observed at higher concentrations in the exhaled breath of 
patients with lung cancer and there remains the possibility the identified VOCs may be 
increased in different cancer states63. The next organ system to be investigated should be the 
lower gastro-intestinal tract to allow direct comparison with the results of the present research. 
Previous studies have investigated exhaled breath VOC patterns in colorectal cancer and 
exhaled breath pentane in inflammatory bowel disease197,222. Both studies were entirely novel 
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in their approach but the findings have not been investigated in a large patient cohort or in 
heterogenous clinical groups. In patients with diseases of the colon, there will also be 
methodological issues to overcome with regards to sample retrieval. For example, VOC 
analysis should not be conducted on the day of a colonoscopy in the manner of this research. 
Patients undergoing a complete colonic camera evaluation are required to take bowel 
preparation 24 hours prior to the procedure to clear the colon of faeces. This creates an artificial 
environment within the colon and affects the natural flora, which may impact on VOC 
concentrations within exhaled breath and urine. However, sampling could be conducted in 
patients undergoing a flexible sigmoidoscopy (prior to phosphate enema) and hence diseases 
of the left colon may represent an appropriate starting point for comparative analysis. Liver 
diseases will also warrant investigation given gastro-intestinal cancers metastasize to the liver 
and its significant role in metabolic activities within the human body. Twelve significant VOCs 
having previously been reported in the exhaled breath of patients with cirrhosis - four ketones 
(2-butanone, 2- or 3-pentanone, C8-ketone, C9-ketone), two terpenes (monoterpene, 
monoterpene), four organosulphur & organonitrogen compounds  and two alcohols 
(heptadienol, methanol)223. Three significant VOCs have also been reported in blood from 
patients with liver cancer - hexanal, 1-octen-3-ol and octane74. In addition to these two organ 
systems, there will also need to be separate studies of other potential confounding factors for 
VOC profiles in oesophageal and gastric cancer including chronic diseases (i.e., hypertension, 
diabetes mellitus), nutrition/diet and exercise.  
Potential VOC biomarkers have been identified in this research for upper GI cancer and 
across several gastro-intestinal conditions224. It is hypothesized that there are likely to be organ-
generated VOCs, disease-specific VOCs and certain compounds that are systemically elevated. 
In order to answer these questions, tracing the source of the VOCs and identifying potential 
mechanisms responsible for their production will also be necessary. The efforts of developing 
non-invasive VOCs as diagnostic tools in cancer should ideally be for exhaled breath and urine 
given the significant translational potential and numerous clinical applications. However, 
correlation of VOCs within blood and biofluids from the target organs should also be evaluated 
to improve our understanding of the origins of these compounds. Moreover, there is also a need 
to explore the underlying pathways that may be contributing to increased concentrations of 
specific VOCs. The lower concentrations of phenol in urine coupled with the significantly 
increased concentrations of phenol, methyl phenol and ethyl phenol in exhaled breath led to a 
consideration of the following mechanisms that may account for phenol dysfunction. Phenol 
production is linked to aromatic amino acid metabolism and several studies have reported 
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increased phenylalanine and tyrosine in oesophageal and gastric cancer states194,225. 
Phenylalanine is converted to tyrosine by phenylalanine hydroxylase and tyrosine is 
subsequently converted to phenol through the action of the bacterial enzyme tyrosine phenol-
lyase. In a study of gastric content using NMR and LC-MS, median concentrations of 
phenylalanine and tyrosine were significantly higher in the gastric cancer group compared to 
controls126. Investigation of matched cancer and healthy mucosa tissue samples from patients 
with oesophageal cancer demonstrated significantly increased levels of tyrosine in cancer tissue 
compared to normal mucosa207. Significantly higher levels of phenylalanine and tyrosine have 
also been reported in gastric cancer tissue when compared to controls226. This possible 
relationship between increased phenol production and aromatic amino acid dysfunction in 
oesophageal and gastric cancer warrants further investigation. Assessment of these pathways 
will require employing multiple analytical platforms and investigation of the enzymatic 
intermediates.  
Further consideration must also be given to the roles of fatty acids and aldehydes in 
oesophageal and gastric cancer. Lipid peroxidation pathways activated by reactive oxygen 
species dysfunction in the Barrett’s metaplastic-dysplastic cascade have previously been 
reported, indicating that numerous fatty acids and aldehydes are produced227,228. Targeting of 
these compounds at a cellular level and understanding their potential contributions to VOC 
production should be considered. Evaluation of the key enzymes involved in their biological 
pathways is also necessary. Fatty acid synthase (FASN) generates medium chain fatty acid 
compounds from acetyl-CoA subunits under hypoxic conditions in the early stages of cancer 
growth229. FASN is upregulated by hypoxic-inducible factor-1 and over-expression of 
cytosolic FASN has also been reported in oesophageal adenocarcinoma230,231. Similarly, the 
aldehyde dehydrogenase superfamily of enzymes should also be investigated. Upregulation of 
aldehyde dehydrogenases have previously been reported in oesophageal cancer209: further 
studies should focus on ALDH1, ALDH2 & ALDH5 subtypes in oesophageal and gastric 
cancer. Through understanding the mechanisms that lead to VOC production, it will be possible 
to improve our insights of tumour biology as well as developing more robust diagnostic tools. 
 
There also remain technological issues to address to improve VOC analysis for clinical 
diagnostics. The sub-ppbv concentrations of specific VOCs observed in healthy study 
participants represent the current limit of detection for the SIFT-MS technology, but there are 
prospects of lowering this towards 0.1 ppbv. Lower sensitivities can be achieved using sample 
pre-concentration techniques such as SPME/GC-MS methods, but longer analysis times and 
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compromised accuracy of quantification are inevitable. However, SIFT-MS allows on-line, 
real-time detection and quantification of VOCs without the need for bio-sample modification 
in both headspace and exhaled breath analysis, thus providing immediate analyses. Though 
GC-MS and LC-MS will remain important techniques for VOC analysis, they both require the 
use of solvents and extensive sample preparation. This limits their potential applications within 
a clinical setting and prevents a biological sample being analysed in its natural state. At the 
present time, the limitations for the SIFT-MS technique are the relatively fewer number of 
VOCs that can be targeted and measured in real time; isomeric differentiation is also not 
feasible with the relatively low resolution analytical quadrupole mass spectrometers currently 
used in SIFT-MS instruments.  
The online analytical capabilities of the SIFT-MS for breath analysis have also not been 
exploited in this research given the number of VOCs being investigated and the inability to 
standardize direct breath manoeuvres in patients. If cross-platform validation of the highly 
significant VOCs in OG cancer occurs, then a direct exhaled breath method could be developed 
targeting only a few VOCs. At the same time, improvements in SIFT-MS technology will result 
in lighter, more readily portable instruments potentially with internal calibration mechanisms. 
Much smaller SIFT-MS instruments could be moved from the laboratory to the clinical 
consultation room and potentially be utilised by non-specialists. However, a second strategy 
for the clinical setting could be to develop electrochemical sensor-based devices targeting 
specific VOCs. Following a similar strategic approach to this research, mass spectrometry 
could be employed initially to detect and quantify VOCs in a particular cancer type. After 
validation on another analytical platform, these VOCs could then be targeted in a point-of-care 
hand-held type sensor device. ‘E-noses’ have previously demonstrated significant promise in 
the analysis of exhaled breath and in the diagnosis of bladder cancer from urine samples232,233. 
A significant advantage of sensor devices is that they can be designed to provide simple read-
outs of the outcome for the clinician/health care professional obviating the need for interpreting 
complex mass spectral data.  
Development of a non-invasive VOC-based screening tool to identify or at least risk-
stratify patients with suspected oesophageal and gastric cancer could have significant clinical 
impact. The potential benefits of undertaking such a strategy include: 
 
 Improving early diagnosis of oesophageal and gastric cancer.  
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 Reducing the number of patients referred for OGD and increasing the pick-up rate of 
oesophageal and gastric cancer. This could also result in cost-savings for the NHS. 
 Improving quality of life and patient experience for those diagnosed with oesophageal 
or gastric cancer. 
 
However, there is also a need to consider Barrett’s oesophagus and squamous cell carcinoma 
of the oesophagus for VOC analysis in upper gastro-intestinal malignancy. The frequency of 
assessment of Barrett’s oesophagus with endoscopy remains a much discussed subject. In a 
case-control study of 8272 patients with Barrett’s oesophagus, surveillance (within 3 years) of 
the Barrett’s oesophagus was not associated with a significant decrease in death from 
oesophageal adenocarcinoma234. In the study of exhaled breath, patients with Barrett’s 
metaplasia demonstrated VOC profiles more in the range of the control groups rather than 
cancer. However, investigation of Barrett’s dysplasia is also essential as a significant 
proportion of these patients will progress and develop oesophageal adenocarcinoma. 
Identifying VOC profiles specifically for early oesophageal cancer could provide another tool 
in the surveillance of patients with Barrett’s dysplasia and in terms of monitoring cancer 
recurrence. There are also potential roles for non-invasive VOC analysis beyond diagnostics. 
With the establishment of ‘normal values’ for increasing numbers of compounds, there is the 
possibility that VOCs could be employed as therapeutic monitoring tools to measure response 
to treatment.  
In conclusion, this research has identified VOCs that are elevated in concentration in 
biogenic fluids (i.e., fatty acids, phenol and aldehydes) in oesophageal and gastric cancer. 
There are several avenues of research discussed above that warrant investigation and there 
remains much promise for VOCs as non-invasive markers of disease. By employing a multi-
platform approach to VOC analysis, biomarker and technological break-throughs are more 
likely to happen resulting in clinically applicable tests that could help save the lives of patients 
with cancer.  
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APPENDICES 
 
Appendix A 
Exhaled Breath Studies 
 
Study 
(Author & 
Year) 
Number and 
Types of Patients 
Analytical 
Technique 
Sampling Technique REF 
Mazzone 
et al. 
(2012) 
N=92 lung cancer 
N=137 controls 
Colometric 
Sensor Array 
All subjects performed tidal breathing, inhaling unfiltered air through their nose and 
exhaling through their mouth into disposable corrugated tubing for a total of 5 
minutes. The exhaled breath was drawn across the sensor array at 200mL/min. 
235 
Darwiche 
et al. 
(2011) 
N=19 lung cancer Ion Mobility 
Spectrometry 
Samples were collected during bronchoscopy with the patient under conscious 
sedation with midazolam and topical administration of xylocaine. Excess fluid or 
mucus was removed. Air from the non-tumour side was aspirated for 20 seconds 
followed by aspiration of air from the tumour side. 
236 
Patterson 
et al. 
(2011) 
N= 20 breast 
cancer 
N=20 healthy 
controls 
Thermal 
desorption 
GC-MS 
Exhaled breath was collected in a commercially available Teflon/valved sampler 
equipped with a rapid passive diffusive sampler five times at 5-minute intervals, 
trapping alveolar breath VOCs. Patients were fasted for 2 hours prior to collection of 
a single breath sample.   
237 
Rudnicka 
et al. 
(2011) 
N=23 lung cancer 
N=31 controls 
SPME 
GC-TOF/MS 
Breath samples were collected in a 1L Tedlar® bag using a breath sampler. After 
collection, a 10mL sample was transferred into a glass vial. Ambient air samples were 
taken for blank measurements. 
 
238 
184 
 
 
Shuster et 
al. (2011) 
N=7 women with 
negative 
mammography 
N=16 benign 
breast conditions 
N=13 breast 
cancers  
Nanoscale 
artificial 
NOSE 
 
The dead space air was collected into a separate bag prior to the collection of 
alveolar air. 
Samples were collected on 2 separate visits to the hospital. 
239 
D’amico 
et al. 
(2010) 
N=56 lung cancer 
N=36 healthy 
control 
Electronic 
Nose 
Patients were requested to breathe into 2 Tedlar® bags through a mouthpiece. By 
controlling a valve, the first volume of air fills the smaller bag. As the bag is filled, 
the increased air resistance opens the valve and so the larger bag is filled. The VOCs 
in the second, larger bag were subsequently analysed. No food/drink the night before 
sampling. 
240 
 
 
Peng et al. 
(2010) 
N=30 lung cancer 
N=26 colon 
cancer 
N=22 breast 
cancer 
N=18 prostate 
cancer 
N=22 healthy 
controls 
 
Gold 
nanoparticles 
 
GC-MS 
 
3-5 mins repeatedly inhaling to lung capacity through a mouthpiece fitted with a 
cartridge that removes >99.99% exogenous VOCs from air. Exhalation was through a 
separate port against 10-15cm of water to ensure closure of vellum and hence no nasal 
entrainment was included. Alveolar breath was collected in a 750mL bag. Patients 
were requested to refrain from coffee and alcohol for at least 12 hours prior to 
collection. 2 samples were collected from each patient and all samples were analysed 
within 4 days. 
72 
185 
 
Poli et al. 
(2010) 
N= 40 lung cancer 
(NSCLC) 
N=38 healthy, 
asymptomatic 
controls 
SPME 
GC-MS 
Single, slow vital capacity breath collected into a Bio-Vac tube trap. At least 150mL 
of breath was collected stored at 4oC and analysed within 2 hours. 
 
62 
 
 
Phillips et 
al. (2010) 
 
N=54 breast 
cancer (pre-
treatment) 
N=204 cancer-free 
controls 
 
 
GC-MS 
Subjects wore noseclips and breathed normally for 2 mins through a mouth piece 
connected to a portable breath collection apparatus. VOCs in 1L breath and 1L room 
air collected on separate sorbent traps. All breath VOC samples were collected at the 
Royal Perth Hospital Breast Clinic and sent by express mail for analysis to the Breath 
Research Laboratory of Menssana Research Inc., Newark, NJ. 
 
(N.B. Pilot studies performed in normal volunteers prior to the clinical study 
demonstrated that breath VOC samples remained stable with no detectable loss or 
contamination for up to 4 weeks at room temperature and were not affected by 
international express shipping.) 
241 
 
De 
Gennaro 
et al. 
(2010) 
N=13 malignant 
pleural 
mesothelioma 
N=13 long term 
exposure to 
asbestos 
N=13 No asbestos 
exposure 
 
Thermal 
desorption 
GC-MS 
 
Patients were requested not to eat or drink for at least 3 hours prior to breath collection. 
Patients breathed tidally through a mouthpiece, connected to a three-way non-
rebreathing valve and an inspiratory VOC-filter (A2, North Safety, NL) for 5 mins. 
After a single deep inspiration, the patient exhaled a single vital capacity volume into 
a Tedlar® bag connected to the expiratory port. Two samples of exhaled breath were 
collected. The second sample was retrieved 2 mins after the 1st. 
65 
 
Qin et al. 
(2010) 
N=30 
hepatocellular 
carcinoma 
N=27 cirrhosis 
 
GC-MS 
All patients were fasted overnight prior to sampling. There was a 3 step process for 
breathing into the Tedlar® bags (4L-T2PV/L, Delin Company): take a deep breath; 
hold it for 4 seconds; then exhale smoothly into the bag. Simultaneously, the samples 
of ambient air were collected for reference. The samples were taken to the laboratory 
and analysed immediately after collection. 
68 
186 
 
N=36 healthy 
volunteers 
Song et al. 
(2010) 
N=43 lung cancer 
(NSCLC) 
N=41 controls 
 
SPME 
GC-MS 
All patients were fasted overnight prior to sampling. The patients were requested to 
deeply breathe in Tedlar® gas bags which trapped 4L breath gas through a disposable 
mouthpiece. Mixed expiratory samples were collected. All samples were analysed 
within 6 hours of collection.  
64 
 
Fuchs et 
al. (2010) 
N=12 lung cancer 
N=12 healthy 
smokers 
N=12 healthy 
volunteers 
 
SPME 
GC-MS 
 
10mL of exhaled air was drawn into a gastight syringe under visual control of expired 
PCO2 and immediately transferred into an evacuated sealed 20mL headspace vial. All 
measurements were repeated once and breath gas samples were processed within 6 
hrs of collection. 
63 
 
 
Bajtarevic 
et al. 
(2009) 
2 separate cohorts 
for each technique 
N=220 lung 
cancer 
N=441 healthy 
volunteers  
N=65 lung cancer 
N=31 healthy 
volunteers 
 
PTR-MS 
 
GC-MS 
 
Samples of mixed alveolar breath were collected in Tedlar® bags (SKC Inc, Eighty 
Four, PA) with parallel collection of ambient air (also in Tedlar® bags). Breath gas 
samples were obtained after a volunteer has been seated for ~5 minutes. Each subject 
provided 1 or 2 breath samples by use of a straw, all of which were processed within 
3-6 hours. Mixed alveolar breath (instead of only alveolar breath) was collected. 
Before collection of exhaled breath, all bags were thoroughly cleaned to remove any 
residual contaminants by flushing with nitrogen gas (purity of 99.9999%), and then 
finally filled with nitrogen and heated at 85°C for more than 8 hours. The bags were 
completely evacuated at the end of this process. 
 
 
176 
Dragonieri 
et al. 
(2009) 
N=10 lung cancer 
(NSCLC) 
Electronic 
Nose 
 
Patients were requested to refrain from food and drink for 2 hours prior to breath 
sample collection. Patients breathed tidally through a mouthpiece connected to a 3-
way non-breathing valve and inspiratory VOC filter for 5 mins. Patient were asked to 
deeply inspire and then exhale a single vial capacity volume into a Tedlar® bag 
71 
187 
 
N=10 COPD 
N=10 healthy 
controls 
connected to expiratory port, followed by a 1 min sampling of exhaled air through a 
silica filled drying chamber. 2 samples were collected per patient excluding the COPD 
group. The 2nd sample was collected 2-5 mins after the 1st sample. 
 
Westhoff 
et al. 
(2009) 
N=32 lung cancer 
N=54 controls 
Ion Mobility 
Spectrometry 
Subjects exhaled through a mouthpiece connected to a Teflon bulb. The breath was 
passed through an unheated sampling loop connected to a miniaturised suction pump 
to ensure homogeneous breath sample flow. 10mL of exhaled breath was analysed. 
242 
 
Barash et 
al. (2009) 
 
N=40 lung cancer 
N=56 healthy 
subjects 
 
Gold 
nanoparticles 
All participants were requested to abstain from alcohol for 12 hrs and coffee for 1 
hour prior to sampling. A subject was asked to inhale through a mouth piece 
containing a cleaning cartridge on the inspiration port, which removed more than 
99.99% of VOCs from the air during inspiration. Participants were asked to exhale 
against 10cm of H2O to ensure closure of the vellum and so exclude nasal entrainment 
of gas. Exhaled gas was collected through a separate exhalation port into 750mL 
Tedlar® gas-sampling bag  and a minimum of 5 bags were collected for each 
participant.  
243 
Ligor et 
al. (2009) 
N=65 lung cancer 
N= 31 healthy 
controls 
SPME 
GC-MS 
 Mixed expiratory and indoor air samples were collected. 87 
 
Wehinger 
et al. 
(2007) 
 
N=12 lung cancer 
N=170 controls 
 
PTR-MS 
The patients were requested to provide at least two breath samples that were collected 
the same day into 3L Tedlar® (polyvinylfluoride) bags. All patients provided their 
samples prior to the first chemotherapy cycle. Mixed expiratory breath samples were 
taken, with no restriction on a particular part of breath. While donating breath, all 
patients and controls were sitting at rest, inflating a bag through a disposable 
mouthpiece. To obtain reasonably constant fractions of alveolar and dead space breath 
in one bag, all individuals were advised to breathe normally during sample collection. 
84 
Mazzone 
et al. 
(2007) 
N=49 lung cancer 
(NSCLC) 
N=18 COPD 
Colometric 
Sensor Array 
Each participant performed tidal breathing of unfiltered room air for a total of 12 mins. 
During this time, they inhaled through their nose and exhaled through their mouth into 
the breath collection device. The exhaled breath was drawn over the sensor array by a 
pump at ~ 250 mL/min. The sensor array was held in place on a flat-bed scanner. The 
system was contained in an incubator set to 37oC. At the end of the 12 mins breath 
73 
188 
 
N=15 idiopathic 
pulmonary fibrosis 
N=20 pulmonary 
arterial 
hypertension 
N=20 sarcoidosis 
N=21 controls 
collection, all tubing and the sensor array were changed and a sample of room air was 
drawn across the system for a further 12 mins. 
Phillips et 
al. (2007) 
N=193 primary 
lung cancer 
N=211 controls 
Thermal 
desorption 
GC-MS 
All patients were fasted overnight. Patients were requested to breathe normally 
through the disposable mouthpiece of a portable breath collection apparatus for 2 
mins. VOCs within 1L alveolar breath and 1L room air were captured onto separate 
sorbent traps. 
67 
 
Chen et al. 
(2007) 
N=29 lung cancer 
N=7 chronic 
bronchitis 
N=13 healthy 
controls 
 
SPME 
GC-MS 
 
No food intake was allowed for 2 hours prior to breath collection. Patients were 
requested to take a deep breath, followed by holding their breath for 1s and exhaling 
directly into the sample bag.  
244 
 
Phillips et 
al.  (2006) 
N=51 histological 
evidence of breast 
cancer 
N=50 abnormal 
mammogram  
N=42 age matched 
controls 
 
Thermal 
desorption 
GC-MS 
 
Patients were requested to breathe normally through the disposable mouthpiece of a 
portable breath collection apparatus for 2 mins. VOCs within 1L alveolar breath and 
1L room air were captured onto separate sorbent traps. 
 
66 
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Yu et al. 
(2005) 
N = 15 lung 
cancer 
N= 15 healthy 
controls 
 
SPME GC 
 
Patient were requested not to smoke for one month prior to exhaled breath sample 
donation. 5L Tedlar® bags were used to collect the exhaled breath. These were cleaned 
with acetone, rinsed with dionised water, filled with nitrogen and dried at 80oC for 12 
hours prior to use. Subjects wore a nose clip and exhaled deeply into the bag. The 
environmental air was collected in a separate sampling bag for assessment of 
background VOCs.  
245 
 
Poli et al. 
(2005) 
N=36 lung cancer 
(NSCLC) 
N=25 COPD 
N=35 smokers 
N=50 non-
smokers 
 
SPME 
GC-MS 
 
 
After 60 mins rest, the participants were requested to perform a single slow vital 
capacity breath into a one-way valve connected to a Teflon-bulb, which traps the last 
portion of exhaled air (150 mL). 20 environmental samples were taken from the rooms 
in which the subjects performed the test in order to compare breath and ambient air 
VOC levels.  
Twenty-six of the NSCLC patients agreed to repeat the breath collection during a 
follow-up visit 15–30 days after surgery; the other 10 patients were excluded from the 
follow- up study due to significant deterioration in their clinical conditions.  
61 
 
Machado 
et al. 
(2005) 
 
2 separate cohorts 
for each phase 
N=14 lung cancer 
N=45 healthy 
controls for 
training phase 
N=14 lung cancer 
N=62 healthy 
controls 
 
Electronic 
nose, 
containing 32 
polymer 
composite 
sensors 
 
The subject inhaled through a mouth piece containing a cartridge on the inspiration 
port which removes more than 99.99% of VOCs from the air during inspiration, 
clearing the air of any ambient contaminants. Exhaled against 10cm of H2O to ensure 
closure of the vellum and so exclude nasal entrainment of gas. Exhaled gas was 
collected through a separate exhalation port into a non-reactive Mylar gas-sampling 
bags. Each sample was analysed a minimum of 5 times. 
 
 
 
 
246 
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Deng et 
al. (2004) 
N=10 lung cancer 
(NSCLC) 
N=10 healthy 
controls 
 
SPME 
GC-MS 
 
 
Minimal details specified.  
59 
 
Phillips et 
al. (2003) 
N=87 lung cancer 
N=91 non-cancer 
patients  
N=41 healthy 
volunteers 
 
Thermal 
desorption 
GC-MS 
 
Patients were requested to breathe normally through the disposable mouthpiece of a 
portable breath collection apparatus for 2 mins.  VOCs within 1L alveolar breath were 
captured onto a sorbent trap. 
 
247 
Reider et 
al. (2001) 
N=16 various 
cancers 
N=100 healthy 
volunteers 
PTR-MS All subject were fasted overnight. Smoking and chewing of gum was prohibited 2 
hour before exhaled breath sampling. Subjects were asked to take 2 deep breaths prior 
to exhaling into the sample bags. 
 
248 
Phillips et 
al. (1999) 
N=60 lung cancer 
N=48 controls 
 
GC-MS 
 
All participants were fasted overnight. Alveolar breath samples were collected from 
patients 24 hours prior to bronchoscopy. Participants wore a nose clip while breathing 
in and out of the portable electrical device, via a disposable mouthpiece for 5 mins. A 
10L sample was pumped through a sorbent trap, which contained activated carbon and 
trapped the VOCs for analysis. Ambient room air was also collected.  
60 
 
 
 
 
191 
 
Tissue Studies 
Study 
(Author & Year) 
Number of samples Analytical 
Technique 
Sampling techniques REF 
Abaffy et al. 
(2010) 
N= 5 naevi (skin) 
N= 3 melanoma (skin) 
HS-SPME GC-MS Specimens large enough to obtain two parallel 3-mm samples were used for 
both histology (H&E staining) and volatiles collection. Analysis for volatile 
compounds was completed within 3 hours of excision. 
249 
Buszewski et al. 
(2008) 
N= 5 gastric cancer (3 
male, 2 female) 
Normal gastric tissue 
was taken from same 
patients 
 
SPME GC-MS 
 
The presence of cancerous cells in tissues was confirmed or excluded by 
histopathological examination. The stomach tissues were collected in 20 mL 
vials after surgical resection then transported to laboratory and analysed. 
Vials were tightly crimped. Before analysis the vials were weighed (~2 
grams). The chromatographic analysis was done no longer than 25 mins after 
surgical resection. 
250 
Poli et al. 
(2008) 
N= 27 lung cancer 
(NSCLC) patients 
 
SPME GC-MS 
 
During surgical resection, 50-100 mg of cancerous and macroscopically 
unaffected lung tissue samples were collected and stored until analysis at -
20°C in RNA-laterTM solution (Ambion, USA). Before analysis, each 
sample was weighed and placed in a 4mL SPME-vial containing 0.5 g of 
NaCl and buffer solution.  
214 
Chen et al. 
(2007) 
N = 10 lung cancer 
patients (16 samples 
retrieved from 4 cell 
types (NSCLC, 
squamous cell, 
adenocarcinoma, 
broncho-alveolar) 
 
SPME GC-MS 
 
Excised tissue was rinsed in phosphate-buffered saline (PBS) several times 
and cut into ~ 1mm pieces. The PBS contained 8.0g/L of NaCl, 0.20g/L KCl, 
1.38g/L Na2HPO4 and 0.20g/L KH2PO4. After rinsing with PBS, the cells 
were digested with 0.25% trypsin for 45 minutes at 37oC. The cells were 
freed with gentle agitation, then 10% bovine serum was added to neutralise 
the trypsin. The solution was filtered and the collected cells were washed 
with PBS, suspended and counted. The cells were then added to 10% foetal 
calf serum, 100U/mL penicillin and 100 U/mL streptomycin. The cells were 
then plated and cultivated at 37oC in 5% CO2. 
244 
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Blood Studies 
Study 
(Author & Year) 
Number of blood 
samples 
Analytical Technique Sampling techniques REF 
Xue et al. (2008) N= 19 liver cancer 
N= 18 controls 
SPME GC-MS The blood samples were immediately frozen at -80oC after sampling 
and thawed at room temperature before analysis. They were all 
collected within 1 week and analysed in one batch within one day. The 
time between sampling and analysis was less than 2 weeks. 
74 
Deng et al. 
(2004) 
N= 10 lung cancer 
N= 10 controls 
SPME GC-MS 
 
5mL of blood from lung cancer patients and controls was introduced 
into different headspace glass bottles (15mL). A CAR-PDMS fibre was 
used for extraction of the volatile compounds from the blood. 
Extraction was carried out at 60 oC for 15mins, with a stirring ratio of 
1100rpm. 
59 
 
 
 
 
 
 
 
 
193 
 
Urine Studies 
Study 
(Author & 
Year) 
Number of 
samples 
Analytical 
Technique 
Sampling techniques REF 
 
 
Silva et al. 
(2011) 
N=14 
leukaemia 
N=12 
colorectal 
N=7 
lymphoma 
N=12 
cancer free 
 
Dynamic solid-
phase 
microextraction 
in headspace 
mode (dHS-
SPME) GC-MS 
 
Each participant provided a sample of morning urine (after overnight fasting) in a 20 mL sterile 
PVC container. The samples were frozen at -80oC and retained until needed for the experiments. 
Before extraction, the pH values of the 25mL urine samples were adjusted to 1–2. Three dHS-
SPME experimental parameters that influence extraction efficiency (fibre coating, extraction 
time and temperature of sampling) were optimised using a univariate optimisation design. The 
highest extraction efficiency was obtained when sampling was performed at 50oC for 60 min 
using samples with high ionic strengths and under agitation. 
70 
 
Guadagni 
et al. 
(2011) 
 
N = 10 
lung cancer 
N= 25 
healthy 
subjects 
 
SPME GC-MS 
Spot urine specimens were collected in 100mL sterile containers and immediately stored at -
20oC. Samples were analysed within a week of collection. After thawing, 3 mL of urine was 
transferred into sealed vials previously added with 1g NaCl, then 30 µL of the 1 ng µL−1 IS 
solution was added and the sample was analyzed by HS-SPME/GC/MS. Hexanal and heptanal 
were extracted from aqueous or urinary samples by SPME, as follows: 10mL sealed vials 
containing 1g NaCl, 3 mL of sample and 30 µL of the 1 ng µL−1 IS solution were kept in an 
ultrasonic bath at 60◦C. PDMS/DVB fibres were directly exposed on the head space above the 
sample for 20 min. At the end of the sampling time, the fibres was immediately inserted into the 
GC injector (at 200oC).  
69 
 
Spanel et 
al. (1999) 
 
N= 14 
bladder 
Cancer 
 
SIFT-MS 
Samples were immediately frozen at -70C prior to analysis. Tests showed that there was no 
apparent deterioration of these urine samples even when stored for several weeks. In these 
experiments, 10 mL aliquots of urine were introduced into glass bottles of volume approximately 
200 mL closed with a septum and, by the addition of appropriate amounts of 0.1MHCl and 0.1 
M NaOH, urine samples at pH values of 4 and 8 (in addition to samples at their unchanged pH) 
were prepared. The bottles with the samples were then placed in a thermostatically controlled 
83 
194 
 
N= 24 
prostate 
Cancer 
N= 14 
healthy 
volunteers 
oven to raise their temperature to 40C. The headspace above each urine sample was then 
sampled by puncturing the septum with a needle connected directly to the inlet port of the SIFT 
mass spectrometer. The mass spectra were then acquired using H3O
+ precursor ions over 50s 
integration periods. 
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Cell line Studies 
Study 
(Author & 
Year) 
Number and 
type of cell 
lines 
Analytical 
Technique 
Sampling techniques REF 
 
Brunner et 
al. (2010) 
 
N = 2  lung 
cancer cell 
lines (A549 
& EPLC)N= 
2 controls 
 
 
PTR-MS 
The 2 controls for this study were human bronchial epithelial cells (BEAS2B) and 
immortalized retinal pigment epithelium cells (RPE). The human A-549 lung epithelial cell 
line was propagated in DMEM (high-glucose) medium containing 10% heat-inactivated foetal 
bovine serum, 2 mmol L−1 L-glutamine (PAA Laboratories), 40 UmL−1 penicillin G, and 40 
μg mL−1 streptomycin (Invitrogen). RPE and A-549 were grown in culture flasks with a 
breeding area of 175cm² and a volume of 640cm3 until 70–80% confluence, which 
corresponds to approximately 2 million cells per flask. Both EPLC & BEAS2B cell lines were 
seeded on to 75-mL flasks RPMI 1640 culture medium (Seromed, Heidelberg, Germany) 
supplemented with 10% new foetal bovine serum, 2 mmolL−1 L-glutamine, 24 UmL−1 
penicillin, and 24 μg mL−1 streptomycin. The cells were grown until semiconfluent to avoid 
growth arrest because of cell–cell contact during overnight sampling.  
85 
Filipiak et 
al. (2010) 
N= 1 lung 
cancer cell 
line (A549) 
N= 2 
controls  
Thermal 
desorption 
GC-MS 
The 2 controls for this study were human bronchial epithelial cells (HBEpC) and human 
fibroblast cells (hFB). Both samples had approximately 50 million cells. Samples methods 
were as described below by Filipiak et al (2008) (Ref 75). The only difference was that the 
fermenters were sealed for 21 hrs in this study.  
77 
 
Bartolazzi 
et al. 
(2010) 
N=5 cancer 
(3 
melanoma, 1 
sarcoma and 
1 thyroid 
cancer) 
 
GC-MS 
 
Cells were derived from the respective primary human tumours and cultured in standard 
conditions in petri dishes with RPMI 1640 medium supplemented with 2mM glutamine, 10% 
foetal calf serum, penicillin and streptomycin at 37oC and 5% CO2 atmosphere. 
251 
Hu et al. 
(2010) 
N=3 lung 
cancer cell 
lines (A549, 
SPME  
GC-MS 
The cells were grown at 37oC in an atmosphere of 5% CO2 for 7 days. The culture medium 
was changed for a final time 24 hours before the VOCs were analysed. 
252 
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SK-MEM-1, 
NCIH446)  
N=1 control 
(BEAS-2B) 
Sponring et 
al. (2010) 
N=1 (Non-
small cell 
lung cancer 
cell line NCI 
–H1666) 
Thermal 
desorption 
GC-MS 
The cells were derived from bronchoalveolar adenocarcinoma. The cells were cultivated in 
RPMI-1640 culture medium supplemented with 10% foetal calf serum (FCS), penicillin 
(100,000units/L), streptomycin (100 mg/L) and L-glutamine (293mg/L). Cells were cultivated 
under standard conditions in a conventional incubator at 37˚C in a humidified atmosphere 
with 92.5% air/7.5% CO2. Prior to VOC measurements 25, 50 and 75 million trypsinized cells 
were inoculated in 100mL phenol red-free RPMI 1640 medium with 5% FCD, 100000 units/L 
penicillin, 100mg/ml streptomycin, 293 mg/L L-glutamine in a cell culture fermenter, which 
was flushed with clean, synthetic air taken from a gas cylinder containing 5% CO2 for 10 mins 
and then sealed for 21 hrs. At the end of the incubation time, 200mL of air from the headspace 
was retrieved for analysis.  
78 
 
Sponring et 
al. (2009) 
 
N= 1 (Lung 
cancer cell 
line (NCI-
H2087)) 
 
Thermal 
desorption 
GC-MS 
The lung tumour cell line NCI-H2087 was grown in RPMI-1640 culture medium 
supplemented with 5% foetal calf serum (FCS), penicillin (100,000units/L), streptomycin 
(100 mg/L) and L-glutamine (293 mg/l). Cells were cultivated under standard conditions in a 
conventional incubator at 37˚C in a humidified atmosphere with 92.5% air/7.5% CO2. For 
VOC measurements, 100×106 trypsinized cells were inoculated in 200mL phenol red-free 
medium in a cell culture fermenter, which was flushed with clean, synthetic air taken from a 
gas cylinder (50L defined gas mixture) containing 5% CO2 for at least 90 min and then sealed 
for 16 hrs. At the end of the incubation time, 200mL of air from the headspace was used for 
GC-MS analyses. 
76 
 
 
Barash et 
al. (2009) 
N=7 lung 
cancer cell 
lines 
(CALU3; 
H1650; 
H4006; 
H1435; 
H820; 
 
 
SPME  
GC-MS 
 
 
 
Grown in 100mm cell culture dish to 95% confluency (7x106 cells) using a medium under 
standard conditions (RPMI 1640 medium + 10% foetal bovine serum; 5% CO2 environment). 
A medium with the same incubation time and conditions but without cells served as the control 
(in duplicate). 
243 
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H1975; 
A549)  
N=2 
controls 
 
Filipiak et 
al. (2008) 
 
N= 1 
(CALU-1) 
 
 
Thermal 
desorption 
GC-MS 
 
The cells were grown in DMEM high glucose (4.5 g/L) culture medium containing pyruvate 
(PAA) and supplemented with 10% FCS, penicillin (100,000 units/L), streptomycin (100 
mg/L) and L-glutamine (293mg/L). Cells were cultivated under standard conditions in a 
conventional incubator at 37°C in a humidified atmosphere with 92.5% air/7.5% CO2. For 
VOC measurements, 50 million trypsinized cells were inoculated in 100 mL phenol red free 
medium (DMEM high glucose) in a cell culture fermenter, flushed with clean, synthetic air 
taken from a gas cylinder (50L defined gas mixture) containing 5% CO2 for at least 10 min at 
a flow rate of 100mL/min and sealed for 4 to 18 hrs. At the end of the incubation time, 200mL 
of air from the headspace was retrieved for analysis. 
75 
 
 
Smith et al. 
(2003) 
 
 
N= 2 
(CALU-1 
and SK-
MES) 
 
 
 
SIFT-MS 
Cell lines were grown in complete media (DMEM, Dulbecco/Vogt modified Eagle’s minimal 
essential medium, supplemented with 10% foetal calf serum, 1% glutamine and 
antibiotic/antimycotic). Cell growth was conducted in tissue culture flasks (Sarstedt, UK) at 
37°C in a 5% CO2 incubator. The culture medium was changed every 3–4 days. The cells 
were detached from the tissue culture flasks before reaching confluence using trypsin/EDTA. 
Complete medium was then added and the cells/medium were spun in a centrifuge at 1200rpm 
for 7 mins. The supernatant was removed and complete medium was again added. The cell 
numbers were counted, and the total was apportioned into four 150mL glass bottles, each 
sealed with a septum. The sealed bottles/cell cultures were placed in an incubator at 37oC 
overnight together with a 5th bottle that contained the same volume of media only (no cells). 
The headspaces above the medium-only and the cell/medium cultures were allowed to develop 
overnight, and were then sampled directly into the SIFT-MS system.  
82 
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Appendix B 
 
Objective  
This pilot study was conducted to identify VOCs of interest within the gastric content from patients with oesophago-gastric cancer using a 
secondary analytical platform, SPME/GC-MS.  
 
Methods 
The following experiments were conducted in the laboratory of Professor Patrik Španěl at the J. Heyrovsky Institute of Physical Chemistry 
(Academy of Sciences of the Czech Republic). I am indebted to Dr. Kristýna Sovová and Professor Patrik Španěl for their method development 
of SPME GC-MS analysis for gastric content. 
 
Gastric content sampling 
Ten gastric content samples from patients with oesophago-gastric cancer were retrieved from storage in a -80°C freezer. These samples were 
transported by a professional courier company on dry ice from the Surgical Sciences Laboratory at Imperial College, London to the Academy of 
Sciences of the Czech Republic. Prospective approval for this project was given by the Imperial College Tissue Bank Committee (Project R13057).  
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SP-ME GC-MS Analysis of gastric content 
Solid phase microextraction, SPME, was used in combination with gas chromatography mass spectrometry, GC/MS, for qualitative analyses of 
the headspace of gastric content samples from patients with oesophago-gastric cancer. A SPME fibre coated by carboxen/polydimethylsiloxane 
(CAR/PDMS) purchased from Supelco (Bellafonte, PA, USA) was exposed to the headspace of gastric content for 45 minutes at 40°C. Extracted 
trace compounds were then analysed by inserting the SPME fibre into the injector of the Focus GC with ITQ 700 ion trap mass spectrometer 
(Thermo Electron Corporation) and heated to 200°C. A TR-1 column (30 m length, 0.25 mm internal diameter, 1 µm film of dimethyl polysiloxane) 
was used for separation using the following temperature programme: 13 min fixed at 38°C, 3°C/min ramp reaching 100°C, 5 min at 100°C, 
4°C/min ramp to 150°C, 10°C/min to 200°C finished by a hold of 5 min at 200°C. The ion source was operated in the electron ionisation mode 
(70 eV, 20 µA) and the mass spectra were obtained using the ion trap operating in a scan mode (scan range from m/z 15-400 at a scan rate of 1 
scan/s).  
 
Results & Discussion 
Gastric content headspace analysis using a SPME GC-MS method for VOC analysis has not previously been reported. Hence, method development 
experiments were conducted to optimise adsorption of analytes from the headspace of gastric content. An exposure time of 45 minutes at a 
temperature of 40oC was the optimal conditions for headspace analysis of (unmodified) gastric content in this study. The VOC that appeared most 
frequently in the gastric content samples from oesophago-gastric cancer patients was phenol. In Figure B1 below, the phenol reference and 2 
representative GC-MS spectra from gastric content samples are shown. Both spectra are from patients who underwent surgical resection of their 
oesophago-gastric cancer after completing 3 cycles of ECX neoadjuvant chemotherapy treatment (a standard management regimen). Figure B1b 
demonstrates a strong phenol peak in the patient with a T3 N1 adenocarcinoma. The patient in Figure B1c responded well to his chemotherapy 
treatment such that there was no residual tumour in the post-operative histology; in this case, there is a much weaker phenol signal. This study was 
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conducted in a small sample size but clearly identified phenol as a potentially important VOC in patients with OG cancer. In the study on gastric 
content using SIFT-MS (Section 4.1), phenol was increased in patients with OG cancer compared to controls but this did not reach statistical 
significance; the lack of statistical validation may be due to a higher proportion of the OG cancer patients in that study having early stage tumours. 
Alternatively, quantification of phenol using SIFT-MS may have been improved if the NO+ precursor ion rather than H3O
+ ion had been employed. 
Although these are both factors were accounted for in subsequent studies, this pilot study provided further evidence that phenol and its derivatives 
were likely to be influential VOCs in oesophago-gastric cancer.       
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Figure B1: GC-MS spectra demonstrating the phenol reference and analysis of the headspace of gastric content from two patients with OG 
adenocarcinoma  
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Appendix C 
Summary of coefficients and constants derived from the binary logistic regression equation 
 Gastric 
Adenocarcinoma 
versus 
normal upper 
gastro-intestinal 
tract 
Oesophageal 
Adenocarcinoma 
versus 
normal upper 
gastro-intestinal tract 
Gastric Adenocarcinoma 
versus 
non cancer controls1 
Oesophageal 
Adenocarcinoma 
versus 
non-cancer control2 
Regression equation 
ln(p/(1-p)) = coefficients x VOCs + constant 
Butyric acid n/a 0.03 n/a 0.02 
Pentanoic acid n/a n/a -0.06 -0.07 
Hexanoic acid -0.01 0.14 0.10 0.13 
Phenol -0.22 -0.23 -0.05 -0.06 
Methyl phenol -0.41 0.26 -0.14 0.07 
Ethyl phenol 0.37 0.20 0.12 0.04 
Butanal 0.06 -0.16 -0.38 -0.29 
Pentanal -0.57 -0.11 -0.06 0.08 
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Hexanal 0.26 0.26 -0.06 -0.03 
Heptanal -0.17 -0.51 -0.06 -0.13 
Octanal -0.31 -0.76 0.11 -0.15 
Nonanal 0.92 0.51 -0.002 0.10 
Decanal 1.25 0.97 0.49 0.39 
Constant -5.95 -5.87 -2.70 -3.20 
R2 0.85 0.80 0.63 0.59 
 
1. Benign controls and normal upper gastro-intestinal tract. 
2. Benign controls, Barrett’s metaplasia and normal upper gastro-intestinal tract. 
3. Gastric adenocarcinoma and oesophageal adenocarcinoma 
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Appendix D 
Linear regression analysis of the influence of patient demographic and upper gastro-intestinal factors on the concentrations of VOCs: 
A Butanal Pentanal Hexanal Heptanal Octanal Nonanal Decanal 
 Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value 
Status 2.94 0.002 4.57 P<0.0001 4.14 0.002 4.43 P<0.0001 6.90 P<0.0001 8.82 P<0.0001 12.99 P<0.0001 
H.Pylori 0.43 0.85 -0.36 0.90 -1.87 0.57 -0.34 0.91 -1.57 0.70 -0.91 0.85 -1.97 0.73 
PPI -0.59 0.50 -1.55 0.17 -0.57 0.64 -0.78 0.49 -0.88 0.57 -1.12 0.54 -1.44 0.50 
Age 0.01 0.68 0.001 0.98 0.02 0.74 0.04 0.39 0.01 0.84 0.05 0.48 0.02 0.77 
Sex -1.29 0.17 -1.00 0.41 -1.02 0.45 0.15 0.90 -1.19 0.48 -0.72 0.72 -1.95 0.40 
Smoking 0.23 0.69 -1.32 0.08 -0.51 0.54 -0.18 0.82 -0.52 0.62 -1.13 0.35 -0.50 0.97 
Alcohol -0.46 0.53 -0.50 0.60 -0.03 0.98 -0.61 0.53 -1.40 0.28 -1.53 0.32 -3.10 0.09 
  
B Butyric acid Pentanoic acid Hexanoic acid Phenol Methyl phenol Ethyl phenol 
 Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value 
Status 19.57 0.001 5.31 0.04 22.89 P<0.0001 11.99 P<0.0001 8.61 P <0.0001 16.04 P<0.0001 
H.Pylori 4.55 0.74 -2.35 0.72 13.84 0.19 0.35 0.95 -0.21 0.96 -0.74 0.94 
PPI -4.49 0.39 0.29 0.91 -1.08 0.79 -0.78 0.73 -0.64 0.68 -3.32 0.34 
Age 0.15 0.46 0.01 0.94 0.10 0.54 0.04 0.67 0.02 0.77 0.08 0.57 
Sex -4.03 0.48 -2.75 0.30 -3.62 0.41 -4.65 0.06 -2.16 0.21 -5.02 0.18 
Smoking -3.02 0.39 1.52 0.36 -1.71 0.53 -1.26 0.40 -0.27 0.78 -2.61 0.26 
Alcohol -5.98 0.18 -1.86 0.37 0.18 0.96 -1.18 0.54 -0.50 0.71 -1.46 0.62 
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C Methanol Acetone Ammonia Isoprene 
 Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value 
Status -2.83 0.89 -61.34 0.64 90.17 0.17 18.13 0.04 
H.Pylori -9.92 0.84 167.12 0.61 335.48 0.04 6.58 0.76 
PPI 9.47 0.61 -101.67 0.41 119.56 0.06 -9.55 0.24 
Age 0.01 0.99 2.77 0.56 1.55 0.52 0.13 0.67 
Sex -5.33 0.79 -123.57 0.36 -148.05 0.03 -2.56 0.78 
Smoking -18.63 0.14 -141.22 0.09 -70.61 0.09 -2.46 0.65 
Alcohol 22.91 0.15 176.55 0.09 46.48 0.38 -3.55 0.61 
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Appendix E - Publications 
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